[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 6991
1. Hsu SC, Lee YY, Wang MC, Liu HL, Cheng MF, Huang JJ: Diffuse calcinosis and intradermal tophi in a uremic pateint: effect of low-calcium hemodialysis and mechanism of hypercalcemia. Blood Purif; 2004;22(2):224-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Soft tissue calcification is a frequent complication in end-stage renal disease (ESRD) patients with a high serum calcium-phosphate product, but systemic involvement of both the visceral organs and skin is rarely seen.
  • He received maintenance hemodialysis (HD) with low-calcium dialysate (1.25 mEq/l) for 11 months.
  • Serum calcium levels normalized only after anti-TB treatment for 2 months.
  • We thought that this patient might have had occult TB infection before the start of HD, which resulted in calcitriol production and hypercalcemia.
  • After the initiation of HD therapy, both the elevated serum calcitriol levels and accelerated resolution and mobilization of diffuse calcinosis from low-calcium HD contributed to persistent hypercalcemia.
  • [MeSH-minor] Adult. Calcium / administration & dosage. Calcium / blood. Dialysis Solutions / chemistry. Humans. Kidney Failure, Chronic / blood. Kidney Failure, Chronic / complications. Kidney Failure, Chronic / therapy. Male. Mycobacterium tuberculosis. Tuberculosis, Lymph Node / complications. Tuberculosis, Lymph Node / drug therapy

  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 S. Karger AG, Basel
  • (PMID = 15044822.001).
  • [ISSN] 0253-5068
  • [Journal-full-title] Blood purification
  • [ISO-abbreviation] Blood Purif.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Dialysis Solutions; SY7Q814VUP / Calcium
  •  go-up   go-down


2. Rademaker J: Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin North Am; 2007 Jan;45(1):69-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's and non-Hodgkin's lymphomas.
  • The diagnosis and management of lymphoma have undergone significant changes in the past 20 years.
  • For example, new immunophenotypic and molecular methods have replaced traditional histology-based classification schemes for lymphoma.
  • Fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) has evolved into a potent staging tool and prognostic indicator in many kinds of lymphoma.
  • The role of radiation therapy, especially in patients who have early-stage Hodgkin's disease, has changed substantially.
  • The introduction of anti-CD 20 antibody therapy (Rituximab) has improved the treatment of B-cell lymphoma.
  • These changes are linked with higher expectations for imaging, such as detection of more subtle lymphoma manifestations, evaluation of residual changes, and better assessment of early response.
  • This article reviews clinical and radiologic features of both Hodgkin's disease and non-Hodgkin's lymphoma.
  • It also describes the radiologic staging of lymphoma and the emerging role of FDG-PET for assessing lymphoma.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Magnetic Resonance Imaging. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Age Factors. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Child. Fluorodeoxyglucose F18. Humans. Lymphoma, B-Cell / drug therapy. Neoplasm Staging. Prognosis. Radiopharmaceuticals. Remission Induction. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17157624.001).
  • [ISSN] 0033-8389
  • [Journal-full-title] Radiologic clinics of North America
  • [ISO-abbreviation] Radiol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


3. Diamond C, Taylor TH, Im T, Anton-Culver H: Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leuk Lymphoma; 2006 Sep;47(9):1822-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS.
  • We used the San Diego/Orange County cancer registry to identify 64 cases of systemic non-Hodgkin's lymphoma (NHL) with AIDS who received highly active antiretroviral therapy (HAART) at the time of NHL diagnosis or thereafter and 64 NHL controls without AIDS, matched on age, sex, race, time of NHL diagnosis (1994-1995 and 1996-1999), and hospital type (academic, large community, and small community).
  • Among 40 matched pairs of cases and controls who received chemotherapy, 32% of cases received reduced-dose chemotherapy versus 5% of controls (p < 0.01) and median survival was 33 months for cases and 99 months for controls (p < 0.44).
  • Patients with AIDS-related NHL who received HAART had high grade histology and baseline cytopenia and received reduced-dose chemotherapy more often than patients without AIDS.
  • However, AIDS patients who received HAART and chemotherapy had survival similar to NHL patients without AIDS, an improvement from the pre-HAART era.
  • Appropriate hematologic support, through growth factors, transfusions, and avoidance of drugs with hematologic toxicity, might allow full dosing of chemotherapy, and perhaps would further improve outcomes among patients with AIDS and NHL.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. CD4 Lymphocyte Count. Case-Control Studies. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome


Advertisement
4. Medina-Sanson A, Chico-Ponce de León F, Cabrera-Muñoz Mde L, Gallegos-Castorena S, Caltenco-Serrano R, Barragán-Pérez E: Primary central nervous system non-Hodgkin lymphoma in childhood presenting as bilateral optic neuritis. Childs Nerv Syst; 2006 Oct;22(10):1364-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system non-Hodgkin lymphoma in childhood presenting as bilateral optic neuritis.
  • INTRODUCTION: Primary central nervous system lymphoma is a very rare condition in pediatric patients.
  • CASE REPORT: We describe the case of a 10-year old girl who presented with acute bilateral vision impairment.
  • At the time of presentation, the only positive finding was optic disk swelling, and the brain MRI scan was normal.
  • Seventeen months later, she developed a large-cell non-Hodgkin lymphoma in the brain, with no evidence of neoplasia elsewhere.
  • The patient was successfully treated with a combination of cyclophosphamide, etoposide, vincristine, methotrexate, and cytarabine, plus intrathecal chemotherapy.
  • OUTCOME: The patient's condition is still in remission 68 months after completing the treatment.
  • CONCLUSION: This case is the only non-Hodgkin lymphoma with primary central nervous system location treated in our institution in the last 10 years and represents less than 0.5% of our non-Hodgkin lymphoma series.
  • Due to its rare occurrence, not much is known about the clinical features and treatment outcome of primary central nervous system lymphoma in pediatric patients.
  • [MeSH-major] Central Nervous System Neoplasms / complications. Lymphoma, Non-Hodgkin / complications. Optic Neuritis / etiology


5. Unal A, Sari I, Deniz K, Ozkan M, Kontas O, Eser B, Cetin M: Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab. Leuk Lymphoma; 2005 Nov;46(11):1613-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab.
  • Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare tumor type distinct from classical Hodgkin lymphoma and its familial form is unusual.
  • The two cases (mother at age 48 and son at age 30 years) of NLPHL in advanced clinical stage are described.
  • This chemotherapy was well tolerated and the patients reached complete remission.
  • In patients with NLPHL, CHOP-R regimen should be used as an alternative treatment regimen to obtain a good long-lasting response without any adverse events.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / pathology. Lymphocytes / pathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Family Health. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Prednisolone / therapeutic use. Remission Induction / methods. Rituximab. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236615.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


6. Johnson TA, Press OW: Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas. Int J Cancer; 2000 Jan 1;85(1):104-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas.
  • Preliminary clinical trials suggest that iodine-131 ((131)I)-labeled anti-CD20 monoclonal antibodies (MAbs) are effective single agents for the treatment of relapsed non-Hodgkin's B-cell lymphomas.
  • We hypothesized that regimens combining (131)I-anti-CD20 antibodies with standard chemotherapeutic agents may provide synergistic anti-tumor effects, and may improve the durability of responses in patients with lymphoma.
  • To identify promising agents for clinical testing, we assessed the in vitro cytotoxicity of combinations of (131)I-anti-B1 (anti-CD20) antibody and 8 chemotherapeutic agents using 2 human CD20-expressing lymphoma cell lines and 2 corroborative assays, the thiazolyl tetrazolium bromide (MTT) and the Trypan blue dye exclusion assays.
  • ID(50) isobolographic and dose modification factor (DMF) analyses were used to classify interactions between the (131)I-anti-B1 antibody and the chemotherapeutic agents as supra-additive (synergistic), additive or sub-additive.
  • Thus, combination regimens containing (131)I-labeled anti-CD20 antibodies and nucleoside analogs or topoisomerase inhibitors appear particularly attractive for future clinical trials.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / radiotherapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy
  • [MeSH-minor] Antigens, CD20 / immunology. Cell Survival / drug effects. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Drug Synergism. Humans. Iodine Radioisotopes / therapeutic use. Radioimmunotherapy. Tetrazolium Salts. Thiazoles. Trypan Blue. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • Hazardous Substances Data Bank. Trypan blue .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10585592.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01CA44991; United States / NCI NIH HHS / CA / R01CA76287
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / Iodine Radioisotopes; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / iodine-131 anti-B1 antibody; 298-93-1 / thiazolyl blue; I2ZWO3LS3M / Trypan Blue
  •  go-up   go-down


7. Kluin-Nelemans HC: Therapy for stage I aggressive non-Hodgkin's lymphoma. Croat Med J; 2002 Oct;43(5):546-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy for stage I aggressive non-Hodgkin's lymphoma.
  • Although radiotherapy was considered sufficient for stage I and limited stage II aggressive non-Hodgkin s lymphoma in the past, new data from randomized studies have shown that intensified chemotherapy or combined modality therapy (multiagent chemotherapy followed by involved field radiotherapy) can result in complete remission in 75-90% of the cases, with 5-year overall survival ranging between 82% and 89%.
  • Patients above 60 years of age, with high lactate dehydrogenase concentration, poor performance, or extranodal disease localized in the testis or central nervous system have a much worse outcome.
  • Therefore, typical extranodal character of this disease (40-57% of the patients show a primary extranodal localization) needs to be recognized and therapy adapted to these subcategories.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12402393.001).
  • [ISSN] 0353-9504
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 15
  •  go-up   go-down


8. Bahl A, Chakrabarty B, Gulati S, Raju KN, Raja A, Bakhshi S: Acute onset flaccid quadriparesis in pediatric non-Hodgkin lymphoma: vincristine induced or Guillain-Barré syndrome? Pediatr Blood Cancer; 2010 Dec 1;55(6):1234-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute onset flaccid quadriparesis in pediatric non-Hodgkin lymphoma: vincristine induced or Guillain-Barré syndrome?
  • Immunological involvement of peripheral nervous system in non-Hodgkin lymphoma (NHL) is very rare and it may be difficult to differentiate it from vincristine-induced neuropathy.
  • We report clinical and electrophysiological findings of an 8-year-old male with NHL who developed acute onset fulminant motor sensory autonomic neuropathy during induction chemotherapy which included vincristine.
  • Characteristic clinical picture and nerve conduction studies favored Guillain-Barré syndrome.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Guillain-Barre Syndrome / complications. Lymphoma, Non-Hodgkin / drug therapy. Quadriplegia / etiology. Vincristine / adverse effects
  • [MeSH-minor] Child. Humans. Immunoglobulins, Intravenous / therapeutic use. Male. Palliative Care. Treatment Outcome


9. Vose JM, Sharp G, Chan WC, Nichols C, Loh K, Inwards D, Rifkin R, Bierman PJ, Lynch JC, Weisenburger DD, Kessinger A, Armitage JO: Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol; 2002 May 1;20(9):2344-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
  • PURPOSE: To determine whether the source of autologous hematopoietic stem cells altered the clinical outcomes of patients undergoing high-dose chemotherapy and hematopoietic stem-cell transplantation (HSCT) for aggressive non-Hodgkin's lymphoma (NHL).
  • RESULTS: PBSCT patients had significantly faster engraftment of all cell lineages: median time to absolute neutrophil count > or = 500/microL, 10 days versus 13 days on the ABMT arm; median time to platelet count greater than 20,000/microL untransfused, 11 days versus 15 days on the ABMT arm; and median time to RBC transfusion independence, 8 days versus 16 days on the ABMT arm.
  • Patients whose harvests were positive for minimal residual disease by molecular analysis had poorer EFS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Carmustine / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Graft Survival. Humans. Male. Middle Aged. Neoplasm, Residual. Proportional Hazards Models. Transplantation Conditioning / methods. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11981006.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA61453; United States / NCI NIH HHS / CA / CA61488
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; U68WG3173Y / Carmustine
  •  go-up   go-down


10. Maloney E, Ociepa T, Kamieńska E, Zielezińska K, Richter B, Urasiński T: [Venous sinus thrombosis which occurred during treatment of a 15-years old girl with t cell non-Hodgkin lymphoma - case report]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1082-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Venous sinus thrombosis which occurred during treatment of a 15-years old girl with t cell non-Hodgkin lymphoma - case report].
  • The highest incidence is among children with acute lymphoblastic leukaemia, followed by those with lymphoma and solid tumours.
  • Malignancy and/or chemotherapy complications are considered as triggering factors.
  • We report a case of a 15-year-old girl with non-Hodgkin lymphoma who developed generalized seizures during chemotherapy.
  • Head computed tomography revealed right transverse and sagittal sinus thrombosis.
  • Anticoagulation treatment using heparin as well as thrombolytic treatment with recombinant human tissue plasminogen activator (rhtPA) were introduced.
  • The reported case of severe venous thrombosis suggests that systemic treatment with rhtPA is effective and safe in children with cerebral venous sinus thrombosis.
  • [MeSH-major] Lymphoma, Non-Hodgkin / complications. Sinus Thrombosis, Intracranial / etiology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Female. Fibrinolytic Agents / therapeutic use. Heparin / therapeutic use. Humans. Tissue Plasminogen Activator / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Thrombosis.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. HEPARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531830.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Fibrinolytic Agents; 9005-49-6 / Heparin; EC 3.4.21.68 / Tissue Plasminogen Activator
  •  go-up   go-down


11. Ohno S, Rai Y, Iwata H, Yamamoto N, Yoshida M, Iwase H, Masuda N, Nakamura S, Taniguchi H, Kamigaki S, Noguchi S: Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol; 2010 Dec;21(12):2342-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1).
  • BACKGROUND: FINDER1 compared efficacy, tolerability and pharmacokinetics (PK) of three fulvestrant dose regimens in postmenopausal Japanese women with estrogen receptor (ER)-positive locally advanced/metastatic breast cancer recurring or progressing after prior endocrine therapy.
  • PATIENTS AND METHODS: The primary end point of this randomised, multicentre, phase II study was objective response rate (ORR) and the secondary end points included time to progression (TTP), clinical benefit rate (CBR), PK profiles and tolerability.
  • Postmenopausal women with ER-positive advanced breast cancer were randomised to 28-day cycles of fulvestrant approved dose (AD), loading dose (LD) or high dose (HD) until disease progression.
  • RESULTS: Hundred and forty-three patients (median age 61 years) received fulvestrant AD (n = 45), LD (n = 51) or HD (n = 47).
  • ORR was similar across dose regimens: 11.1%, 17.6% and 10.6% for AD, LD and HD, respectively, with overlapping confidence intervals.
  • TTP and CBR were also similar between groups (median TTP: 6.0, 7.5 and 6.0 months, respectively; CBR: 42.2%, 54.9% and 46.8% for AD, LD and HD, respectively).
  • C(max) and area under the plasma concentration-time curve were dose proportional and PK steady state was reached earlier with LD and HD than with AD.
  • All three doses were well tolerated, with a similar adverse-event profile and no emerging safety concerns.
  • CONCLUSION: Fulvestrant AD, LD and HD had similar efficacy and tolerability profiles in postmenopausal Japanese women with ER-positive advanced breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. FULVESTRANT .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20494961.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 22X328QOC4 / fulvestrant; 4TI98Z838E / Estradiol
  •  go-up   go-down


12. Fadiora SO, Mabayoje VO, Oboro VO, Ojemakinde KA, Bello TO, Adeniji AA: Ovarian non-Hodgkin's lymphoma presenting as obstructive jaundice - a case report. Niger Postgrad Med J; 2008 Dec;15(4):267-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian non-Hodgkin's lymphoma presenting as obstructive jaundice - a case report.
  • OBJECTIVE: To highlight the importance of considering abdominal Lymphoma as a differential diagnosis in the management of obstructive jaundice.
  • Following surgery allowing for adequate wound healing, the patient was placed on appropriate chemotherapy.
  • INVESTIGATION/DIAGNOSIS: Histology of excision biopsy revealed high grade Non-Hodgkins's Lymphoma.
  • The patient was placed on CHOP combination therapy.
  • She attained remission after four cycles of chemotherapy and was discharged home.
  • CONCLUSION: Abdominal Non-Hodgkin's Lymphoma should be a strong consideration in the management of obstructive jaundice.
  • [MeSH-major] Jaundice, Obstructive / drug therapy. Jaundice, Obstructive / etiology. Lymphoma, Non-Hodgkin / complications. Ovarian Neoplasms / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood Sedimentation. Diagnosis, Differential. Female. Humans. Laparotomy. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169347.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


13. Akhtar S, El Weshi A, Abdelsalam M, Hussaini H, Janabi I, Rahal M, Maghfoor I: Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients. Bone Marrow Transplant; 2007 Oct;40(7):651-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.
  • We report our experience with high-dose chemotherapy (HDC) and autologous SCT (ASCT) in 66 patients with primary refractory Hodgkin's lymphoma (PR-HL) who received salvage chemotherapy followed by BEAM as HDC.
  • Before salvage chemotherapy, stages I:II:III:IV were 2:21:14:29, bulky disease 27%, involvement of mediastinum 79%, spleen 26% and extranodal site 47%, 92% had ESHAP as salvage.
  • Post-ASCT evaluation showed response in 50 patients (76%); complete response (CR) 37 (56%), partial response 14 (21%), no response or stable disease 3 (5%) and progressive disease in 10 (15%).
  • Another five patients achieved CR after radiation therapy and one after surgery, making total CR 43 (65%).
  • From diagnosis and HDC, median follow-up is 38.5 and 22.8 months and median overall survival (OS) 78 and 57 months, respectively.
  • Twenty-two patients (33%) died due to disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Carmustine / administration & dosage. Child. Cohort Studies. Combined Modality Therapy. Cytarabine / administration & dosage. Disease-Free Survival. Female. Humans. Male. Melphalan / administration & dosage. Middle Aged. Multivariate Analysis. Neoplasm Staging. Podophyllotoxin / administration & dosage. Prognosis. Retrospective Studies. Salvage Therapy. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. PODOFILOX .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660837.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; L36H50F353 / Podophyllotoxin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM protocol
  •  go-up   go-down


14. Uppin MS, Paul TR, Rajappa S, Gayathri K, Jacob R, Uppin SG: Leukemia as a second malignancy. Indian J Pathol Microbiol; 2007 Jul;50(3):644-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary malignancies included carcinoma breast (4), multiple myeloma (3) and one each of Hodgkin's lymphoma, mediastinal germ cell tumor, papillary carcinoma thyroid and myxopapillary ependymoma.
  • Ten patients had received chemotherapy with combination radiotherapy in six patients.
  • The commonest type of leukemia was AML-M2.
  • The risk benefit ratio of chemotherapy and radiotherapy should be considered before starting the patients on treatment.
  • A high degree of suspicion and follow up with hematological parameters is required for therapy related complications.
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883171.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


15. Stanojević GZ, Stojanović MP, Stojanović MM, Krivokapić Z, Jovanović MM, Katić VV, Jeremić MM, Branković BR: Non-Hodgkin's lymphomas of the large bowel-clinical characteristics, prognostic factors and survival. Acta Chir Iugosl; 2008;55(3):109-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas of the large bowel-clinical characteristics, prognostic factors and survival.
  • The aims of this study were to review the clinical presentation of non-Hodgkin's lymphomas of the large bowel, to analyze the prognostic factors using univariate and multivariate methods, as well as the overall survival.
  • The following clinical information such as age, gender, symptoms, tumor localization, operation performed, histology grade, stage of disease, and adjuvant chemotherapy was obtained.
  • Overall mean survival time was 41.91 months.
  • According to the univariete analysis, the factors influencing overall survival rate was operation type (elective and emergent).
  • Tumor stage and operation type were independent prognostic factors for survival, as determined by multivariate analysis.
  • Our results showed that tumor stage and operation type should be considered as the most important prognostic factors in patients with primary non-Hodgkin's lymphomas of the large bowel.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Rectal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069702.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


16. Ryu H, Lee J, Hagerty SW, Soh BY, McAlpin SE, Cormier KA, Smith KM, Ferrante RJ: ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc Natl Acad Sci U S A; 2006 Dec 12;103(50):19176-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease.
  • It has been suggested that altered chromatin modulation and transcription dysfunction may play a role in the pathogenesis of Huntington's disease (HD).
  • We show that ESET expression is markedly increased in HD patients and in transgenic R6/2 HD mice.
  • Similarly, the protein level of trimethylated histone H3 (K9) was also elevated in HD patients and in R6/2 mice.
  • We further demonstrate that both specificity protein 1 (Sp1) and specificity protein 3 (Sp3) act as transcriptional activators of the ESET promoter in neurons and that mithramycin, a clinically approved guanosine-cytosine-rich DNA binding antitumor antibiotic, interferes with the DNA binding of these Sp family transcription factors, suppressing basal ESET promoter activity in a dose dependent manner.
  • The combined pharmacological treatment with mithramycin and cystamine down-regulates ESET gene expression and reduces hypertrimethylation of histone H3 (K9).
  • This polytherapy significantly ameliorated the behavioral and neuropathological phenotype in the R6/2 mice and extended survival over 40%, well beyond any existing reported treatment in HD mice.
  • Our data suggest that modulation of gene silencing mechanisms, through regulation of the ESET gene is important to neuronal survival and, as such, may be a promising treatment in HD patients.

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITHRAMYCIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Neurosci. 2000 Sep;23(9):387-92 [10941183.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):19489-500 [16682412.001]
  • [Cites] Science. 2001 Mar 23;291(5512):2423-8 [11264541.001]
  • [Cites] Genes Dev. 2001 Sep 15;15(18):2343-60 [11562345.001]
  • [Cites] Nature. 2001 Oct 18;413(6857):739-43 [11607033.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 15;30(2):475-81 [11788710.001]
  • [Cites] Nat Med. 2002 Feb;8(2):143-9 [11821898.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(5):1277-87 [11839795.001]
  • [Cites] Science. 2002 Jun 21;296(5576):2238-43 [11988536.001]
  • [Cites] Science. 2002 Jun 21;296(5576):2149-50 [12077389.001]
  • [Cites] J Neurosci. 2002 Oct 15;22(20):8942-50 [12388601.001]
  • [Cites] Biochem J. 2003 Feb 1;369(Pt 3):651-7 [12398767.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4281-6 [12640146.001]
  • [Cites] Nat Genet. 2003 May;34(1):75-9 [12679815.001]
  • [Cites] J Cell Sci. 2003 Jun 1;116(Pt 11):2117-24 [12730288.001]
  • [Cites] J Neurosci. 2003 May 1;23(9):3597-606 [12736330.001]
  • [Cites] Biochim Biophys Acta. 2003 Oct 1;1629(1-3):8-14 [14522075.001]
  • [Cites] J Neurosci. 2003 Oct 15;23(28):9418-27 [14561870.001]
  • [Cites] Mol Cell. 2003 Dec;12(6):1577-89 [14690609.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):4988-99 [14627700.001]
  • [Cites] Br J Cancer. 2004 Feb 23;90(4):761-9 [14970850.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(6):2478-86 [14993285.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] Adv Cancer Res. 2004;91:137-68 [15327890.001]
  • [Cites] J Neurochem. 2004 Oct;91(2):413-22 [15447674.001]
  • [Cites] J Neuropathol Exp Neurol. 1985 Nov;44(6):559-77 [2932539.001]
  • [Cites] Am J Med Sci. 1987 Nov;294(5):388-94 [2962490.001]
  • [Cites] Oncogene. 1995 Jun 15;10(12):2323-30 [7784080.001]
  • [Cites] J Med Chem. 1997 Jun 20;40(13):1969-76 [9207937.001]
  • [Cites] Hum Mol Genet. 1998 May;7(5):791-800 [9536082.001]
  • [Cites] J Neurosci. 2004 Nov 17;24(46):10335-42 [15548647.001]
  • [Cites] J Biol Chem. 2005 Jan 7;280(1):556-63 [15494404.001]
  • [Cites] Expert Opin Emerg Drugs. 2005 May;10(2):345-63 [15934871.001]
  • [Cites] J Comp Neurol. 2005 Oct 3;490(4):354-70 [16127709.001]
  • [Cites] Curr Opin Genet Dev. 2005 Oct;15(5):490-5 [16098738.001]
  • [Cites] Neurology. 2005 Dec 13;65(11):1834-6 [16344537.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1410-24 [16604191.001]
  • [Cites] Nature. 2000 Aug 10;406(6796):593-9 [10949293.001]
  • (PMID = 17142323.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / P30 AG 13846; United States / NINDS NIH HHS / NS / NS 045806; United States / NINDS NIH HHS / NS / P01 NS045242; United States / NIA NIH HHS / AG / P30 AG013846; United States / NINDS NIH HHS / NS / R01 NS052724; United States / NINDS NIH HHS / NS / NS 52724-01; United States / NINDS NIH HHS / NS / U01 NS045806; United States / NINDS NIH HHS / NS / NS 045242
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histones; 148710-94-5 / Sp3 Transcription Factor; EC 2.1.1.- / Protein Methyltransferases; EC 2.1.1.- / SETDB1 protein, human; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.1.1.43 / SETDB1 protein, mouse; NIJ123W41V / Plicamycin; R110LV8L02 / Cystamine
  • [Other-IDs] NLM/ PMC1748195
  •  go-up   go-down


17. Matković S, Jelić S, Manojlović N, Milanović N: Non-Hodgkin's lymphomas with primary localization in large bowel and rectum. Med Sci Monit; 2000 Jan-Feb;6(1):68-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas with primary localization in large bowel and rectum.
  • From 1989, at the Department of Medical Oncology of the Institute for Oncology and Radiology in Belgrade, seven patients with primary NHL of large bowel and rectum have been observed and treated, 3 males and 4 females.
  • In 3 patients an urgent laparotomy without previous diagnostic procedures was performed, while 4 patients had laparotomy only after radiographic and endoscopic diagnosis of a tumor.
  • Five patients had lymphoma localized in cecoascedental part of colon (2 centroblastic, 1 lymphoplasmocytic, 1 Burkitt and 1 Burkitt's like), 1 patient had it in the transversal part of colon (centroblastic), and one in the rectum (diffuse centrocytic).
  • They are under regular controls with 45+ and 45+ months disease free survival.
  • Out of 5 patients with localization within cecum or ascendent part of colon, in 2 cases with Burkitt/Burkitt-like histology retroperitoneal lymphadenopathy were found, one female had NHL central propagation, and the other one lymphoma generalization.
  • Both patients had early death from lymphoma.
  • The remaining three patients following chemotherapy with the ProMACE regimen (as they too had a post laparotomy stage II disease) achieved a complete response lasting for 36+, 41+ and 66+ months.
  • A long disease free survival can be obtained in these patients either with surgery only or surgery + chemotherapy, depending on disease stage and possibly initial topographic localization.
  • [MeSH-major] Colonic Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11208286.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


18. Di Giambattista M, Branckaert T, Hougardy V, Kemball-Cook G, Laub R: In silico prediction of FVIII epitopes recognised by natural autoantibodies in polyvalent immunoglobulin concentrates. Mol Immunol; 2007 Mar;44(8):1903-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inhibitory antibodies directed against blood coagulation factor VIII (FVIII) impair FVIII replacement therapy, constituting a serious complication in haemophilic and autoimmune patients.
  • Although the presence of naturally occurring anti-FVIII antibodies in healthy donors has been previously described, our methodology has allowed, for the first time, a fine mapping of several inhibitory and non-inhibitory epitopes.
  • Our observations support the hypothesis that FVIII inhibitors in haemophilia A and autoimmune disease may originate from the proliferation of natural FVIII-specific B-cell clones.
  • [MeSH-minor] Animals. Autoimmune Diseases / complications. Autoimmune Diseases / drug therapy. Autoimmune Diseases / immunology. B-Lymphocytes / immunology. Blood Coagulation Factor Inhibitors / immunology. Hemophilia A / complications. Hemophilia A / drug therapy. Hemophilia A / immunology. Humans. Models, Molecular. Protein Structure, Tertiary. Rabbits

  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17113150.001).
  • [ISSN] 0161-5890
  • [Journal-full-title] Molecular immunology
  • [ISO-abbreviation] Mol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Blood Coagulation Factor Inhibitors; 0 / Epitopes; 0 / F8 protein, human; 0 / Immunoglobulin G; 9001-27-8 / Factor VIII
  •  go-up   go-down


19. Lederer SR, Riedelsdorf G, Schiffl H: Nasal carriage of meticillin resistant Staphylococcus aureus: the prevalence, patients at risk and the effect of elimination on outcomes among outclinic haemodialysis patients. Eur J Med Res; 2007 Jul 26;12(7):284-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Haemodialysis (HD) patients with meticillin-resistant Staphylococcus aureus (MRSA) infections face high morbidity and mortality.
  • Nasal carriage of Staphylococcus aureus is known to play an important role as an endogenous source for HD-access-related infections that contribute significantly to morbidity, mortality and cost of end-stage renal disease (ESRD) management.
  • This prospective investigation in regular out-clinic haemodialysis patients was undertaken to estimate the prevalence of S.aureus nasal carriage, to define patient groups at risk and to evaluate the effect of elimination on outcomes among outclinic haemodialysis patients.
  • METHODS: 136 HD patients without signs of overt clinical infection (48 women, 88 men, age 22-88 years) were screened at least twice for the nasal carriage for meticillin-susceptible SA (MSSA) or meticillin-resistant SA (MRSA).
  • Nasal carriage of S. aureus was related to demographic (age, gender, duration on HD), comorbidity (diabetes, malignancy) and exposure to health care (dialysis staff, hospitalisation).
  • Nasal carriers for MRSA received standardized mupirocin therapy and were followed up for elimination and infections for 1 year.
  • Early diagnosis may help prevent clinically relevant infection.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Carrier State / epidemiology. Hemodialysis, Home. Methicillin Resistance. Mupirocin / therapeutic use. Nasal Cavity / microbiology. Outpatients. Staphylococcal Infections / epidemiology. Staphylococcus aureus / isolation & purification
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bacteremia / drug therapy. Female. Germany / epidemiology. Humans. Male. Middle Aged. Prevalence. Prospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17933699.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; D0GX863OA5 / Mupirocin
  •  go-up   go-down


20. Dieckmann K, Pötter R, Hofmann J, Heinzl H, Wagner W, Schellong G, Pediatric Cooperative Hodgkin Disease Study Group of the GPOH: Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90. Int J Radiat Oncol Biol Phys; 2003 Jul 1;56(3):644-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.
  • PURPOSE: The identification of risk factors is required for risk-adapted treatment strategies in the treatment of Hodgkin's disease.
  • To assess the influence of bulky disease at diagnosis as compared with other risk factors on event-free survival (EFS) in pediatric Hodgkin's disease such as stage, B-symptoms, number of involved lymph node regions, histology, and remission status after chemotherapy, we analyzed the outcome of 552 patients treated with a risk-adapted treatment strategy consisting of OPPA(OEPA)/COPP (vincristine, procarbazine, etoposide, prednisone, adriamycin, cyclophosphamide) and involved-field radiotherapy.
  • METHODS AND MATERIALS: Between 1990 and 1995, 578 patients with primary Hodgkin's disease (HD) were enrolled in the German/Austrian Pediatric Hodgkin's Disease Study Group (DAL) Multicenter Study (HD-90).
  • Patients were stratified into three treatment groups (TGs) for early, intermediate, and advanced stage.
  • All patients received induction chemotherapy (CT) with two cycles of OEPA for boys and two cycles of OPPA for girls.
  • Chemotherapy was followed by involved-field radiotherapy.
  • The radiation field, which was prescribed by the study center, was treated with a dose of 25 Gy/25 Gy/20 Gy (TG1/TG2/TG3), and in case of insufficient remission with a local boost of 5 Gy to 10 Gy.
  • The following prognostic factors were analyzed with regard to their impact on EFS: bulky disease, mediastinal tumor, number of involved lymph node regions, histology, treatment group, B-symptoms, sex, age, and remission status after chemotherapy.
  • RESULTS: Significant univariate predictive factors for the EES were: nodular sclerosis type 2 (NS2) histology (relative risk [RR] 3.43; p = 0.0002), presence of B-symptoms (RR 2.70; p = 0.0014), number of involved regions (1.55; p = 0.019), and treatment groups (RR 1.33; p = 0.017).
  • There was a higher risk (RR 1.92; p = 0.040) for patients with bulky compared with nonbulky disease (5-year EFS 89.6%/94.6%).
  • The remission status after chemotherapy did not correlate with EFS (p = 0.66).
  • CONCLUSION: Treatment strategies in Hodgkin's disease have an impact on different risk factors.
  • In the risk-adapted treatment strategy of the HD-90 study, tumor burden indicated as bulky disease or as number of involved lymph nodes loses its importance, whereas NS2 histology and B-symptoms have a major impact on treatment outcome.
  • Bulky disease at diagnosis might require higher radiation doses only in case of insufficient remission.
  • [MeSH-major] Hodgkin Disease / pathology. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Lymphatic Metastasis. Male. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / radiotherapy. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Proportional Hazards Models. Radiotherapy Dosage. Recurrence. Remission Induction. Retrospective Studies. Risk Factors. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12788169.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; COPP protocol; DVPP protocol
  •  go-up   go-down


21. Vang R, Medeiros LJ, Malpica A, Levenback C, Deavers M: Non-Hodgkin's lymphoma involving the vulva. Int J Gynecol Pathol; 2000 Jul;19(3):236-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma involving the vulva.
  • Non-Hodgkin's lymphomas (NHL) involving the vulva are rare.
  • The age of the patients ranged from 43 to 71 years (mean 60 years), and 5 presented with a vulvar mass.
  • Each tumor was classified according to the revised European-American classification of lymphoid neoplasms: four were diffuse large B-cell lymphoma, one was peripheral T-cell lymphoma, and one was mycosis fungoides/Sezary syndrome.
  • Two patients were treated with chemotherapy and radiotherapy, one patient received chemotherapy and phototherapy, one patient was treated with chemotherapy, and in two patients the treatment is unknown.
  • Clinical follow-up, available for 4 cases, ranged from 7 months to 5 years.
  • One patient with low-stage NHL responded to therapy, but relapsed and died of disease 2 years later.
  • Two patients with generalized NHL that secondarily involved the vulva died of disease 7 months and 5 years, respectively, after the diagnosis of vulvar involvement was established.
  • The patient with mycosis fungoides/Sezary syndrome is alive with disease at 4 years.
  • The three patients in this study who died and our review of the literature indicate that NHL involving the vulva is usually an aggressive disease.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Vulvar Neoplasms / pathology
  • [MeSH-minor] Aged. Antigens, CD20 / analysis. Antigens, CD3 / analysis. Female. Humans. Immunohistochemistry. Lymphoma, B-Cell / pathology. Mycosis Fungoides / pathology. Neoplasm Staging. Sezary Syndrome / pathology. Skin Neoplasms / pathology. Vulva / pathology

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10907172.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3
  •  go-up   go-down


22. Klimm B, Engert A, Diehl V: First-line treatment of Hodgkin's lymphoma. Curr Hematol Malig Rep; 2006 Mar;1(1):51-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line treatment of Hodgkin's lymphoma.
  • Substantial clinical progress over the last decades has made Hodgkin's lymphoma into one of the most curable human cancers in adults.
  • About 80% of patients in all stages and of all histologic subtypes experience long-term disease-free survival.
  • Modern treatment strategies aim to improve chemotherapy and radiotherapy, while minimizing therapy-related toxicities.
  • Ongoing trials investigate a reduction of chemotherapy doses or cycles and the application of lower radiation doses and smaller radiation field sizes.
  • For patients with a specific high-risk profile, novel approaches with more intense drug combinations are currently being investigated in clinical trials.
  • This review discusses recent approaches to the first-line treatment of early-favorable, early-unfavorable, and advanced-stage Hodgkin's lymphoma.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Alkylating Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Infertility, Female / chemically induced. Infertility, Female / prevention & control. Lymphatic Irradiation. Male. Multicenter Studies as Topic. Radiotherapy Dosage. Remission Induction. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2002;13 Suppl 1:102-6 [12078888.001]
  • [Cites] Radiother Oncol. 1986 Nov;7(3):215-21 [3544084.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):476-84 [11786577.001]
  • [Cites] J Clin Oncol. 1985 Feb;3(2):207-14 [3838188.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):560-5 [8426624.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2386-95 [12802024.001]
  • [Cites] J Clin Oncol. 1986 Sep;4(9):1295-306 [3528400.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):378-82 [1740677.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3601-8 [12913100.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2320-5 [12805333.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3440-6 [12668650.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4238-44 [11709567.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1079-85 [15205202.001]
  • [Cites] N Engl J Med. 2002 May 2;346(18):1417-8 [11986425.001]
  • [Cites] Ann Intern Med. 1986 Jun;104(6):739-46 [2422994.001]
  • [Cites] JAMA. 1993 Oct 27;270(16):1949-55 [8411552.001]
  • [Cites] Cancer Res. 1966 Jun;26(6):1221-4 [5947345.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):276-82 [14760122.001]
  • [Cites] Cancer. 1975 Jul;36(1):252-9 [54209.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2396-406 [12802025.001]
  • [Cites] Ann Oncol. 1999 Dec;10(12):1419-32 [10643532.001]
  • [Cites] Ann Oncol. 1992 Sep;3 Suppl 4:105-10 [1280463.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4285-9 [12586628.001]
  • [Cites] N Engl J Med. 1992 Nov 19;327(21):1478-84 [1383821.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):607-14 [12586796.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1638-45 [9193364.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2988-94 [12089229.001]
  • [Cites] N Engl J Med. 1991 Aug 29;325(9):599-605 [1861693.001]
  • [Cites] Eur J Cancer. 2002 Mar;38 Suppl 4:S107-13 [11858975.001]
  • [Cites] J Natl Cancer Inst. 2003 Jul 2;95(13):971-80 [12837833.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):818-29 [9508162.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1734-9 [12721249.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] J Clin Oncol. 1987 Jan;5(1):27-37 [2433409.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):830-43 [9508163.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):487-97 [10653864.001]
  • [Cites] Radiother Oncol. 1995 Sep;36(3):211-7 [8532908.001]
  • [Cites] Blood. 2003 Jan 15;101(2):420-4 [12509381.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2424-9 [15136597.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):630-7 [11821442.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4386-94 [14645429.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1989-96 [12200357.001]
  • [Cites] Eur J Cancer. 1997 May;33(6):848-53 [9291804.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:138-47 [12078896.001]
  • (PMID = 20425332.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents
  • [Number-of-references] 50
  •  go-up   go-down


23. Miyashita K, Fujii K, Yamada Y, Hattori H, Taguchi K, Yamanaka T, Yoshida MA, Okamura J, Oda S, Muta K, Nawata H, Takayanagi R, Uike N: Frequent microsatellite instability in non-Hodgkin lymphomas irresponsive to chemotherapy. Leuk Res; 2008 Aug;32(8):1183-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent microsatellite instability in non-Hodgkin lymphomas irresponsive to chemotherapy.
  • Particularly in non-Hodgkin lymphoma, the data published to date lack unity.
  • Using a unique fluorescent technique, we found MSI in eight (14%) tumours in a panel of 59 carefully selected non-Hodgkin lymphoma patients.
  • Type A and Type B.
  • Based on our previous studies using DNA mismatch repair (MMR) gene-knock out animals, we have concluded that Type A MSI is a direct consequence of defective MMR.
  • MSI observed in non-Hodgkin lymphomas was uniformly Type A, which implies that MMR deficiency occurs in this malignancy.
  • Intriguingly, in non-Hodgkin lymphoma patients treated by CHOP/VEPA-based therapies, response to chemotherapy was significantly worse in those with microsatellite-unstable tumours (p=0.027).
  • As a consequence, the patient outcomes at 1 year after treatment were significantly less favourable in this population (p=0.046), although the survival difference was not statistically confirmed in a longer term.
  • These findings suggest that in some non-Hodgkin lymphomas MMR deficiency may lead to drug resistance in tumour cells and, consequently, to poor patient outcomes.
  • In non-Hodgkin lymphoma, MSI may be a potential biomarker that predicts the tumour response against chemotherapy.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Microsatellite Instability
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA Mismatch Repair. Female. Fluorescence. Humans. Lymphoma, Non-Hodgkin / genetics. Male. Middle Aged. MutS Homolog 2 Protein / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18177936.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


24. Kudo K, Sonoda M, Sugimoto K, Koike M: [Cutaneous non-Hodgkin lymphoma of the leg occurring 11 years after renal transplantation]. Rinsho Ketsueki; 2009 Feb;50(2):107-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous non-Hodgkin lymphoma of the leg occurring 11 years after renal transplantation].
  • She received immunosuppressive therapy postoperatively.
  • Skin lesion was recognized on the left leg in April 2002 and skin biopsy demonstrated diffuse large B cell lymphoma in March 2006.
  • EBV-LMP, EBNA-2 and EBER were positive and she was diagnosed as having EBV-related posttransplant lymphoproliferative disease (PTLD).
  • Radiation therapy and rituximab therapy were administered.
  • We reduced the dose of immunosuppressive drug and performed debridement of the ulcer, which responded well to treatment.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Kidney Transplantation / adverse effects. Lymphoma, Large B-Cell, Diffuse / etiology. Lymphoproliferative Disorders / etiology. Skin Neoplasms / etiology
  • [MeSH-minor] Debridement. Female. Humans. Immunosuppressive Agents / administration & dosage. Middle Aged. Polycystic Kidney Diseases / surgery. Time Factors


25. Mentzer SJ, Perrine SP, Faller DV: Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transpl Infect Dis; 2001 Sep;3(3):177-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
  • Lymphoproliferative disorders associated with the Epstein-Barr virus (EBV) include non-Hodgkin's lymphoma, Hodgkin's lymphoma, and "post-transplant lymphoproliferative disorders" (PTLD), which occur with immunosuppression after marrow and organ transplantation.
  • PTLD is characterized by actively proliferating, latently infected EBV(+) B-lymphocytes, and often manifests a rapidly progressive fatal clinical course if the immunosuppression cannot be reversed.
  • Whereas immunologic and antiviral therapy have been moderately effective for treating EBV-associated infections in the lytic phase, they have been less useful in the more common latent phase of the disease.
  • One common treatment for herpesvirus infections has targeted the virus-specific enzyme thymidine kinase (TK).
  • The lack of viral TK expression in EBV(+) tumor cells, due to viral latency, makes anti-viral therapy alone ineffective as an anti-neoplastic therapy, however.
  • We have developed a strategy for the treatment of EBV-associated lymphomas/PTLD using pharmacologic induction of the latent viral TK gene and enzyme in the tumor cells, followed by treatment with ganciclovir.
  • A Phase I/II trial has been initiated, employing an intra-patient dose escalation of arginine butyrate combined with ganciclovir.
  • In six patients with EBV-associated lymphomas or PTLD, all of which were resistant to conventional radiation and/or chemotherapy, this combination produced complete clinical responses in four of six patients, with a partial response occurring in a fifth patient.
  • Pathologic examination in two of three patients demonstrated complete necrosis of the EBV lymphoma, with no residual disease, following a single three-week course of the combination therapy.
  • Possible side-effects of the therapy included nausea and reversible lethargy at the highest doses.
  • Additional patient accrual is sought for further evaluation of this therapy.
  • [MeSH-minor] Antiviral Agents / pharmacology. Antiviral Agents / therapeutic use. Drug Therapy, Combination. Ganciclovir / pharmacology. Ganciclovir / therapeutic use. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Viral / drug effects. Humans. Lung Neoplasms / etiology. Postoperative Complications / drug therapy. Postoperative Complications / virology. Tumor Cells, Cultured / drug effects. Virus Latency

  • Genetic Alliance. consumer health - Post-transplant lymphoproliferative disease.
  • MedlinePlus Health Information. consumer health - Lung Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11493400.001).
  • [ISSN] 1398-2273
  • [Journal-full-title] Transplant infectious disease : an official journal of the Transplantation Society
  • [ISO-abbreviation] Transpl Infect Dis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA85687
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Butyrates; 94ZLA3W45F / Arginine; IK8S1P79MU / arginine butyrate; P9G3CKZ4P5 / Ganciclovir
  • [Number-of-references] 91
  •  go-up   go-down


26. Keresztes K, Miltényi Z, András C, Illés A: [Second malignancies in patients treated for Hodgkin's disease]. Magy Onkol; 2002;46(3):247-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Second malignancies in patients treated for Hodgkin's disease].
  • [Transliterated title] Második malignus tumor gondozott Hodgkin-kóros betegeinknél.
  • THE AIM OF THE STUDY: to analyse the incidence of second malignant neoplasms (SMN) in patients treated for Hodgkin s disease.
  • PATIENTS AND METHODS: Since 1(st) January 1967, 534 patients have received primary treatment for Hodgkin s disease and 470 cases have proved to be adequate for data analysis as regards to the development of SMN.
  • RESULTS: SMN developed in 34 cases (7.2%), solid neoplasms were diagnosed in 26 cases (5.5%), lung neoplasms had the greatest incidence (11/26), hematologic malignancies were detected in 8 cases (1.7%), and non-Hodgkin s lymphoma was found in 5/8 cases.
  • The mean age of patients with solid neoplasms was 38.1 years (18-59 years) at the diagnosis of Hodgkin s disease and the length of time until the diagnosis of SMN was 13.5 years (1-33 years).
  • The therapies employed prior to the development of solid neoplasms involve: irradiation in 6 cases, chemotherapy in 8 and combined therapy in 12 cases.
  • Out of the 20 cases of chemotherapy, CV/O/PP and its variants were used in 17 cases.
  • Prior to the development of hematologic malignancies, 5 patients had received chemotherapy, 3 combined therapy and 7 patients CV/O/PP and its variants.
  • This can be explained by the less intensive therapeutic techniques employed earlier as well as by shorter survival periods.
  • As a result of better therapeutic management, the chances of long term survivals have increased and we should make every effort to avoid late complications such as SMN when planning therapeutic strategies.
  • [MeSH-major] Hodgkin Disease / therapy. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / adverse effects. Chemotherapy, Adjuvant / adverse effects. Female. Hematologic Neoplasms / epidemiology. Hematologic Neoplasms / etiology. Humans. Hungary / epidemiology. Incidence. Lung Neoplasms / epidemiology. Lung Neoplasms / etiology. Male. Middle Aged. Radiotherapy, Adjuvant / adverse effects. Time Factors

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12368920.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


27. Huang YH, Wu QL, Zong YS, Feng YF, Liang JZ, Hou JH, Shao Q, Fu J: Clinicopathologic features and Epstein-Barr virus infection status of Burkitt's lymphoma in Guangzhou district. Ai Zheng; 2009 Aug;28(8):805-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features and Epstein-Barr virus infection status of Burkitt's lymphoma in Guangzhou district.
  • BACKGROUND AND OBJECTIVE: Sporadic Burkitt's lymphoma (sBL) is uncommon and its relation to Epstein-Barr virus (EBV) is unknown in China.
  • This study was to investigate the clinical presentation, morphologic features, immunophenotype and EBV infection status of sBL in Guangzhou district, a prevalent area of EBV infection.
  • METHODS: The clinical data of 21 sBL patients were reviewed.
  • RESULTS: From January 2000 to October 2007, 21 cases(0.87%) of sBL were confirmed among 2416 cases of non-Hodgkin's lymphoma(NHL) in Sun Yat-sen University Cancer Center.
  • The 2-year survival rate of 15 patients who received chemotherapy or resection plus chemotherapy was 56.00%.
  • Most patients had lymph node(s) involvement, showing similar morphology and immunophenotype as that of endemic BL.
  • Type I EBV latent infection is associated with 28.57% of cases.
  • [MeSH-major] Burkitt Lymphoma / pathology. Burkitt Lymphoma / virology. Epstein-Barr Virus Infections / pathology. Epstein-Barr Virus Infections / virology

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664325.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Epstein-Barr virus encoded RNA 1; 0 / Interferon Regulatory Factors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Viral; 0 / interferon regulatory factor-4; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


28. Bryant ML, Worthington MA, Parsons K: Treatment of osteoporosis/osteopenia in pediatric leukemia and lymphoma. Ann Pharmacother; 2009 Apr;43(4):714-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of osteoporosis/osteopenia in pediatric leukemia and lymphoma.
  • OBJECTIVE: To evaluate the efficacy and safety of various treatment options for osteopenia and osteoporosis secondary to cancer treatment in pediatric patients undergoing cancer therapy.
  • DATA SOURCES: A systematic search of PubMed (1949-November 2008) and International Pharmaceutical Abstracts (to November 2008) was conducted using the following search terms: osteoporosis, osteopenia, pediatrics, cancer, neoplasms, chemotherapy, bisphosphonates, calcium, vitamin D, calcitonin, and physical therapy.
  • STUDY SELECTION AND DATA EXTRACTION: All prospective studies that evaluated various osteoporosis treatment options in pediatric patients undergoing chemotherapy were included.
  • Results from studies evaluating bisphosphonates and other treatments in children with osteoporosis due to other causes were also included if important safety and efficacy data were provided.
  • Most commonly reported primary efficacy endpoints included comparisons of bone density parameters measured before and after treatment.
  • DATA SYNTHESIS: Four clinical studies and 2 case reports describing treatment with bisphosphonates, specifically alendronate and pamidronate, for osteoporosis or osteopenia in pediatric cancer patients were identified.
  • Results from the trials showed that these medications were efficacious in reducing bone mineral density loss during cancer therapy and were well tolerated in this special population.
  • Four additional clinical trials involving the treatment of osteoporosis or osteopenia in children and adolescents who developed bone degeneration after chronic steroid therapy are also included.
  • In these trials, treatment options such as calcitonin, and calcium and vitamin D supplementation were also shown to be beneficial.
  • CONCLUSIONS: The clinical trials published to date are limited to only a few conducted in small populations of patients diagnosed with lymphoblastic leukemia or non-Hodgkin's lymphoma.
  • [MeSH-major] Bone Diseases, Metabolic / therapy. Leukemia / therapy. Lymphoma / therapy. Osteoporosis / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Clinical Trials as Topic / methods. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19336653.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 19
  •  go-up   go-down


29. Everett PC, Meyers JA, Makkinje A, Rabbi M, Lerner A: Preclinical assessment of curcumin as a potential therapy for B-CLL. Am J Hematol; 2007 Jan;82(1):23-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical assessment of curcumin as a potential therapy for B-CLL.
  • Curcumin, the principle component of the spice turmeric, has been used as an anti-inflammatory medication in India and China for centuries.
  • Recent studies, predominantly using actively dividing cell lines, have suggested that this compound could be used as a chemopreventative or therapeutic agent for epithelial tumors.
  • The role of PPARgamma or NF-kappaB signaling in curcumin-induced apoptosis was examined by cotreatment with a PPARgamma antagonist or EMSA of nuclear NFkappaB complexes.
  • In B-CLL cells from 14 patients, curcumin-induced apoptosis with a mean EC(50) of 5.5 microM.
  • In a 48 hr wash-out time course, curcumin-induced apoptosis was time-dependent, with a substantial reduction in apoptosis observed when curcumin was removed after 5 hr.
  • Curcumin treatment reduced basal nuclear NF-kappaB levels and 1 microM curcumin augmented both vinca alkaloid and PDE4 inhibitor-induced apoptosis in B-CLL cells.
  • Our studies suggest that curcumin may augment the efficacy of established or experimental therapies for B-CLL.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Curcumin / pharmacology. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Signal Transduction / drug effects
  • [MeSH-minor] 3',5'-Cyclic-AMP Phosphodiesterases / antagonists & inhibitors. 3',5'-Cyclic-AMP Phosphodiesterases / metabolism. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Cyclic Nucleotide Phosphodiesterases, Type 4. Dexamethasone / pharmacology. Dose-Response Relationship, Drug. Drug Evaluation, Preclinical. Female. Humans. Male. NF-kappa B / metabolism. PPAR gamma / metabolism. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Protein-Serine-Threonine Kinases / metabolism. Rolipram / pharmacology. Tumor Cells, Cultured. Vidarabine / analogs & derivatives. Vidarabine / pharmacology. Vincristine / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CURCUMIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16947318.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 106705
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / NF-kappa B; 0 / PPAR gamma; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.25 / NF-kappa B kinase; EC 3.1.4.17 / 3',5'-Cyclic-AMP Phosphodiesterases; EC 3.1.4.17 / Cyclic Nucleotide Phosphodiesterases, Type 4; FA2DM6879K / Vidarabine; IT942ZTH98 / Curcumin; K676NL63N7 / Rolipram; P2K93U8740 / fludarabine
  •  go-up   go-down


30. Cluzeau T, Mounier N: [Patients and the Web]. Bull Cancer; 2010 Oct;97(10):1133-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In recent years, Internet has become an indispensable tool for all types of information.
  • HIV infection is an infection highly publicized in recent years, we take the case of Hodgkin's disease associated with HIV to compare data from the Internet and scientific articles.
  • [MeSH-major] Information Dissemination / methods. Internet / standards. Lymphoma, AIDS-Related. Medical Informatics Applications. Patient Education as Topic / standards
  • [MeSH-minor] Anti-HIV Agents / therapeutic use. Drug Therapy, Combination / methods. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Evaluating Health Information.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20663740.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


31. Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rüdiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M: Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood; 2008 Jan 1;111(1):109-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
  • Because nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) express CD20, rituximab may be used as a nonmutagenic treatment option to avoid late toxicities in this rather indolent entity.
  • Between 1999 and 2004, the German Hodgkin Study Group (GHSG) investigated the activity of rituximab (375 mg/m(2) in 4 doses) in a phase 2 trial in 21 relapsed or refractory NLPHL patients.
  • The initial diagnosis of NLPHL was confirmed in 15 of the 21 enrolled patients by reference pathology.
  • The remaining cases were reclassified as Hodgkin lymphoma transformed to T-cell rich B-cell lymphoma (TCRBCL; n = 2) or CD20(+) classical Hodgkin lymphoma (cHL; n = 4).
  • In NLPHL patients the overall response rate was 94%, including 8 complete remission (CR) and 6 partial remission (PR).
  • With a median follow-up of 63 months (range, 3-84), the median time to progression was 33 months, with the median overall survival (OS) not reached.
  • This study is registered at http://www.klinisches-studienzentrum.de/trial/285.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Female. Germany. Humans. Kaplan-Meier Estimate. Lymphocytes / pathology. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / pathology. Male. Middle Aged. Recurrence. Remission Induction. Rituximab. T-Lymphocytes / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938252.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


32. Reinbold JB, Coetzee JF, Hollis LC, Nickell JS, Riegel C, Olson KC, Ganta RR: The efficacy of three chlortetracycline regimens in the treatment of persistent Anaplasma marginale infection. Vet Microbiol; 2010 Sep 28;145(1-2):69-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of three chlortetracycline regimens in the treatment of persistent Anaplasma marginale infection.
  • The relationship between plasma CTC drug concentration and carrier clearance has not been described.
  • Chronic carrier status was established in 21 steers with a Virginia isolate of Anaplasma marginale and confirmed by cELISA and an A. marginale-specific RT-PCR.
  • Four negative, splenectomized steers served as active disease transmission sentinels.
  • Steers were randomized to receive 4.4 mg/kg/day (LD); 11 mg/kg/day (MD); or 22 mg/kg/day (HD) of oral chlortetracycline; or placebo (CONTROL) for 80 days.
  • The LD, MD and HD treatment groups consisted of 5 infected steers and 1 splenectomized steer; CONTROL group had six infected steers and 1 splenectomized steer.
  • The daily treatments and ration were divided equally and fed twice daily.
  • Blood samples were collected semi-weekly for determining plasma drug concentration by ultrahigh performance liquid chromatography-mass spectrometry/mass spectrometry method and assessment of disease status by both cELISA and RT-PCR.
  • Mean (CV%) chlortetracycline plasma drug concentrations in the LD, MD, and HD groups were 85.3 (28%), 214.5 (32%) and 518.9 (40%)ng/mL during days 4 through 53 of treatment.
  • A negative RT-PCR assay result was confirmed in all CTC-treated groups within 49 days of treatment; however, cELISA required an additional 49 to 88 days before similar results.
  • [MeSH-major] Anaplasma marginale / drug effects. Anaplasmosis / drug therapy. Cattle Diseases / drug therapy. Chlortetracycline / therapeutic use
  • [MeSH-minor] Animals. Carrier State / drug therapy. Carrier State / microbiology. Carrier State / veterinary. Cattle. Chromatography, High Pressure Liquid / veterinary. Dose-Response Relationship, Drug. Drug Administration Schedule / veterinary. Enzyme-Linked Immunosorbent Assay / veterinary. Gas Chromatography-Mass Spectrometry / veterinary. Male. Reverse Transcriptase Polymerase Chain Reaction / veterinary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20346598.001).
  • [ISSN] 1873-2542
  • [Journal-full-title] Veterinary microbiology
  • [ISO-abbreviation] Vet. Microbiol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI070908; United States / NIAID NIH HHS / AI / AI070908
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] WCK1KIQ23Q / Chlortetracycline
  •  go-up   go-down


33. Régnier-Rosencher E, Barrou B, Marcelin AG, Jacobzone-Leveque C, Cadranel J, Leblond V, Francès C: [Primary effusion lymphoma in two kidney transplant recipients]. Ann Dermatol Venereol; 2010 Apr;137(4):285-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary effusion lymphoma in two kidney transplant recipients].
  • [Transliterated title] Lymphome des séreuses chez le transplanté rénal: deux cas.
  • BACKGROUND: Primary effusion lymphoma (PEL) is a highly malignant non-Hodgkin lymphoma associated with Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 infection (KSHV/HHV-8).
  • OBSERVATION: We describe two male kidney transplant recipients, aged 47 and 51 years, followed for Kaposi's sarcoma in skin, lymph nodes, gastrointestinal (GI) tract and lung whose disease was poorly controlled by sirolimus and chemotherapy.
  • Lymphoma cells were discovered only seven to nine months after the initial effusion despite repeated needle biopsies.
  • CONCLUSION: The contrast between a very low KHSV viral load in plasma and a very high viral load pleural effusion should alert physicians and prompt suspicion of PEL in Kaposi's sarcoma patients with recurrent serous effusion.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Epstein-Barr Virus Infections / etiology. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Immunosuppressive Agents / adverse effects. Kidney Transplantation. Lymphoma, Primary Effusion / etiology. Neoplasms, Multiple Primary / etiology. Postoperative Complications / etiology
  • [MeSH-minor] Digestive System Neoplasms / drug therapy. Digestive System Neoplasms / secondary. Digestive System Neoplasms / virology. Fatal Outcome. Giant Lymph Node Hyperplasia / complications. Giant Lymph Node Hyperplasia / virology. Humans. Immunocompromised Host. Kidney Failure, Chronic / etiology. Kidney Failure, Chronic / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / virology. Lymphatic Metastasis. Male. Middle Aged. Pleural Effusion, Malignant / cytology. Pleural Effusion, Malignant / virology. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / etiology. Sarcoma, Kaposi / virology. Skin Neoplasms / drug therapy. Skin Neoplasms / etiology. Skin Neoplasms / virology. Viral Load

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20417362.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


34. Kato H, Naganuma T, Iizawa Y, Kitagawa M, Tanaka M, Isaji S: Primary non-Hodgkin's lymphoma of the gallbladder diagnosed by laparoscopic cholecystectomy. J Hepatobiliary Pancreat Surg; 2008;15(6):659-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the gallbladder diagnosed by laparoscopic cholecystectomy.
  • Primary lymphoma of the gallbladder is an exceedingly rare disease.
  • We experienced an asymptomatic case of primary non-Hodgkin's lymphoma of the gallbladder in a 55-year-old woman in whom laparoscopic cholecystectomy made a definite diagnosis.
  • Abdominal computed tomography revealed a 4-cm gallbladder tumor with markedly enlarged lymph nodes in the retropancreatic area.
  • The discrepancy between the imaging findings and the patient's mild clinical presentation led us to suspect that the tumor was a lymphoma.
  • We examined serum markers of lymphoma, revealing slight elevations of interleukin (IL)-2 receptor and thymidine kinase.
  • Laparoscopic cholecystectomy for a total biopsy was performed successfully, and the results of intraoperative frozen-section examination led us to have a high suspicion of malignant lymphoma.
  • The final diagnosis was large diffuse B-cell lymphoma of the gallbladder with a positive CD20 antibody reaction.
  • The patient received postoperative chemotherapy with R-CHOP (rituximab, 500 mg; cyclophosphamide, 1000 mg; adriamycin, 68 mg; vincristine, 1.9 mg; and prednisone, 80 mg) starting on postoperative day 12.
  • In conclusion, gallbladder lymphoma should be added to the differential diagnosis of gallbladder tumors, especially when the imaging findings and clinical presentation are not consistent with typical signs of gallbladder carcinoma, and laparoscopic cholecystectomy is helpful for the confirmation of suspicious cases.
  • [MeSH-major] Cholecystectomy, Laparoscopic. Gallbladder Neoplasms / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Lymphatic Metastasis. Middle Aged. Prednisone / therapeutic use. Rituximab. Tomography, X-Ray Computed. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18987940.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


35. Moryl-Bujakowska A, Balwierz W, Małek A, Sztefko K: [Preliminary results of reproductive system function assessment in young men after Hodgkin's disease therapy]. Przegl Lek; 2010;67(6):382-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preliminary results of reproductive system function assessment in young men after Hodgkin's disease therapy].
  • [Transliterated title] Wstepne wyniki oceny czynności układu rozrodczego młodych mezczyzn z zakończonym leczeniem choroby Hodgkina.
  • The introduction of modern methods of combined therapy: chemotherapy and radiotherapy, allows the cure more than 90% of children and adolescents with Hodgkin's disease (HD).
  • However, the intensive treatment carries the risk of early and late complications.
  • In this report preliminary results of testicular function assessment in young men after HD therapy.
  • Testicular function was evaluated in 24 young men (age: 10.6-18.2 years, median 14.6 years at the beginning of treatment, and 18.5-24.6 years, median 21.4 years at the end of therapy) treated between January 1, 1999 and December 31, 2009. in Department of Pediatric Oncology and Hematology PAIP JU-CM in Kraków, according to PGP-HD-97 protocol.
  • Multidrug chemotherapy combined with low-dose involved-field radiotherapy (15-25 Gy) was used in treatment in 21 men, and 3 other men were treated with chemotherapy only.
  • Therapy was completed in all analyzed patients.
  • Physical examination and Tanner stages of pubic hair and genital development were recorded as well as the plasma levels of follicle stimulating hormone (FSH), luteinizing hormone (LH) and testosterone (TST) were measured in all patients.
  • All men reached Tanner stages of pubic hair and genital development appropriate for their age.
  • The most frequent abnormality was the increased level of FSH (in 15 patients, 60.5% of FSH measurements).
  • Abnormal results of measurements were found in 14/20 (70%) patients who received 6 chemotherapy cycles and in 2/4 patients treated with 3-4 cycles.
  • Initial results of reproductive system assessment indicate the impairment of testicular function depending on intensity of treatment.
  • Further observation and repeated gonadal function tests (including semen analysis) are needed in young men with completed HD treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Radiotherapy, Adjuvant / adverse effects. Testis / growth & development. Testis / radiation effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21344766.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 3XMK78S47O / Testosterone; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


36. Katsura Y, Suzukawa K, Kojima H, Yoshida C, Shimizu S, Mukai H, Hasegawa Y, Imagawa S, Mori N, Nagasawa T: Cytotoxic T-cell lymphoma arising in Behçet disease. Int J Hematol; 2003 Apr;77(3):282-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic T-cell lymphoma arising in Behçet disease.
  • The case of a 49-year-old man with peripheral T-cell lymphoma arising in Behcet disease (BD) is reported.
  • A diagnosis of incomplete BD was made, and the patient was treated with immunosuppressive agents for 9 months.
  • A left perirenal mass emerged, and a computed tomography-guided needle biopsy of the tumor revealed the infiltration of small- and medium-sized lymphoma cells.
  • A diagnosis of non-Hodgkin's lymphoma (diffuse medium, T-cell) was made.
  • Standard combination chemotherapy diminished the perirenal and orbital lesions.
  • Lymphoma cell infiltration in the esophagus was detected after chemotherapy, and the patient died of massive bleeding from the gastrointestinal tract.
  • Non-Hodgkin's lymphoma is rarely associated with BD, and only 7 cases have been reported in the literature.
  • We have summarized the published case reports of malignant lymphoma arising in BD.
  • To our knowledge, this case report is the first to describe cytotoxic T-cell lymphoma arising in Behçet disease.
  • [MeSH-major] Behcet Syndrome / complications. Lymphoma, T-Cell / etiology. T-Lymphocytes, Cytotoxic / pathology
  • [MeSH-minor] Antigens, CD / analysis. Clone Cells / immunology. Humans. Immunosuppressive Agents / therapeutic use. Kidney Neoplasms. Male. Middle Aged. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S46-55 [9894469.001]
  • [Cites] J Gastroenterol. 1997 Apr;32(2):241-5 [9085175.001]
  • [Cites] Ann Rheum Dis. 2001 Nov;60(11):996-1002 [11602462.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):317-26 [10830738.001]
  • [Cites] Arthritis Rheum. 1974 Jul-Aug;17(4):383-90 [4604718.001]
  • [Cites] No To Shinkei. 1992 Nov;44(11):1029-33 [1296716.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):296-301 [10680899.001]
  • [Cites] Int J Tissue React. 1988;10(2):59-65 [3053482.001]
  • [Cites] Ann Dermatol Venereol. 1990;117(11):885-7 [2099715.001]
  • [Cites] N Engl J Med. 1999 Oct 21;341(17):1284-91 [10528040.001]
  • [Cites] Ann Intern Med. 1976 Jan;84(1):68-76 [1106291.001]
  • [Cites] Intern Med. 1993 Aug;32(8):663-7 [8312668.001]
  • [Cites] Clin Rheumatol. 2001;20(4):239-44 [11529628.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):193-207 [10697278.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):313-23 [9578080.001]
  • [Cites] Rinsho Ketsueki. 1992 Feb;33(2):211-5 [1635171.001]
  • [Cites] Ann Rheum Dis. 1986 Sep;45(9):789 [3767471.001]
  • [Cites] Acta Pathol Jpn. 1974 Jan;24(1):141-50 [4406401.001]
  • [Cites] Arthritis Rheum. 1982 Nov;25(11):1343-51 [6215926.001]
  • [Cites] Arthritis Rheum. 1982 Sep;25(9):1130-3 [7126297.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1998 Oct;236(10):798-9 [9801898.001]
  • [Cites] Rinsho Ketsueki. 1997 Aug;38(8):657-62 [9311271.001]
  • [Cites] Nephron. 1999 Feb;81(2):239 [9933762.001]
  • [Cites] Cancer. 1995 Apr 1;75(7):1728-33 [8826934.001]
  • (PMID = 12731673.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Immunosuppressive Agents
  • [Number-of-references] 25
  •  go-up   go-down


37. Dinand V, Dawar R, Arya LS, Unni R, Mohanty B, Singh R: Hodgkin's lymphoma in Indian children: prevalence and significance of Epstein-Barr virus detection in Hodgkin's and Reed-Sternberg cells. Eur J Cancer; 2007 Jan;43(1):161-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma in Indian children: prevalence and significance of Epstein-Barr virus detection in Hodgkin's and Reed-Sternberg cells.
  • AIM: This study was done to document the prevalence of Epstein-Barr virus (EBV) in Hodgkin's lymphoma (HL) in children of North India.
  • METHODS: 145 previously untreated children diagnosed with HL from 1991 to 2003 were included.
  • Lymph node (LN) biopsies were studied and classified using World Health Organisation (WHO) classification.
  • EBV detection was done by immunohistochemistry (IHC) and in situ hybridisation (ISH) in 145 cases and 25 age- and sex-matched controls.
  • Patients were treated with chemotherapy alone.
  • EBV status had no implication on treatment response and survival.
  • CONCLUSION: EBV detection in 96.6% of childhood HL in a population with almost universal EBV seroconversion, and in none of the control lymph nodes, suggests a causative role of EBV in most cases of Indian childhood HL.
  • [MeSH-major] Epstein-Barr Virus Infections / virology. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / virology. Reed-Sternberg Cells / virology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17113770.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


38. Kalac M, Ostojić S, Gasparov S, Planinc-Peraica A, Dominis M, Jaksić B: [Microcellular lung carcinoma in patient with hepatosplenic T-cell lymphoma: a case report]. Lijec Vjesn; 2006 Mar-Apr;128(3-4):76-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Microcellular lung carcinoma in patient with hepatosplenic T-cell lymphoma: a case report].
  • Hepatosplenic T-cell lymphoma (HSTCL) is a rare form of extranodal non-Hodgkin lymphoma derived from cytotoxic T-cells, usually manifesting by sinusoidal infiltration of spleen, liver and bone marrow.
  • In 1997 World Health Organization classified malignant lymphomas and placed HSTCL among peripheral T-cell neoplasms.
  • The course of the diseases is usually very agressive with a median survival time of 8 to 16 moths despite multiagent chemotherapy.
  • We present a case of a 48-year-old male patient whose initial symptoms were fatigue, weight loss and night sweats, which were followed by splenomegaly and pancytopenia.
  • After clinical examination we suspected him to have HSTCL which was proved pathohistologically upon splenectomy and it is the first case of this lymphoma diagnosed in "Merkur" Clinical Hospital.
  • As a first line of lymphoma therapy we decided to apply FED course (fludarabine, cyclophosphamide, prednisone), being aware of the published poor results the standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisolone) yields.
  • As far as we know, the results of this chemotherapy course in the therapy of this tumor have never been published.
  • The patient underwent 6 courses of FED therapy, which he tolerated well and was in good clinical condition.
  • Upon the completion of the 6th course of therapy he was diagnosed with lung anaplastic microcellular carcinoma and was treated with 3 course of PE therapy (cisplatin, etoposide).
  • [MeSH-major] Carcinoma, Small Cell / pathology. Liver Neoplasms / pathology. Lung Neoplasms / pathology. Lymphoma, T-Cell / pathology. Neoplasms, Second Primary / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16808095.001).
  • [ISSN] 0024-3477
  • [Journal-full-title] Lijec̆nic̆ki vjesnik
  • [ISO-abbreviation] Lijec Vjesn
  • [Language] hrv
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


39. Kobe C, Dietlein M, Mauz-Körholz C, Engert A, Borchmann P, Sabri O, Schober O, Schicha H, Kluge R: [FDG-PET in Hodgkin lymphoma]. Nuklearmedizin; 2008;47(6):235-8; quiz N75-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [FDG-PET in Hodgkin lymphoma].
  • [Transliterated title] FDG-PET beim Hodgkin-Lymphom.
  • The high negative predictive value of FDG-PET in therapy control of Hodgkin lymphoma is proven by the data acquired up to now.
  • Thus, the analysis of the HD15 trial has shown that consolidation radiotherapy might be omitted in PET negative patients after effective chemotherapy.
  • Further response adapted therapy guided by PET seems to be a promising approach in reducing the toxicity for patients undergoing chemotherapy.
  • The criteria used for the PET interpretation have been standardized by the German study groups for Hodgkin lymphoma patients and will be reevaluated in the current studies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorodeoxyglucose F18. Hodgkin Disease / radionuclide imaging
  • [MeSH-minor] Humans. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19057796.001).
  • [ISSN] 0029-5566
  • [Journal-full-title] Nuklearmedizin. Nuclear medicine
  • [ISO-abbreviation] Nuklearmedizin
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


40. Dinić-Uzurov V, Lalosević V, Milosević I, Urosević I, Lalosević D, Popović S: [Current differential diagnosis of hypereosinophilic syndrome]. Med Pregl; 2007 Nov-Dec;60(11-12):581-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current differential diagnosis of hypereosinophilic syndrome].
  • HES must be distinguished from reactive eosinophilia in parasitic infections, allergic diseases, and especially from hematological diseases of clonal origin.
  • REACTIVE EOSINOPHILIA DUE TO INFECTIOUS AND PARASITIC DISEASES: Tissue helminth infections, especially toxocariasis, cause severe and long-standing hypereosinophilia.
  • Despite specific therapy, eosinophilia may persist for over a year after diagnosis, and decreases slowly.
  • HEMATOLOGIC AND OTHER NEOPLASTIC DISEASES: Numerous neoplastic diseases, like Hodgkin's and other malignant lymphomas, myeloproliferative diseases, systemic mastocytosis etc., may be associated with marked eosinophilia.
  • We had two patients with clinical and histological features resembling chronic eosinophilic leukemia, and many others with T-cell lymphoma, planocellular or adenocarcinoma etc. where eosinophilia persisted DRUG-INDUCED EOSINOPHILIA: Drugs associated with eosinophilia include penicillins, tetracyclines, especially minocycline, clarithromycin, tetrazepam, mefloquine, and many, others.
  • Toxins associated with L-tryptophan cause eosinophilia-myalgia syndrome and toxic oil syndrome, also belonging in this group.
  • Treatment includes drug discontinuation and administration of corticosteroids.
  • HYPEREOSINOPHILIA WITH ORGAN DYSFUNCTION: Many severe diseases, such as sarcoidosis, Churg-Strauss syndrome, pemphigus vulgaris, eosinophilic gastrointestinal diseases, inflammatory bowel disease and many others are associated with hypereosinophilia and target organ damage, e.g. involvement of the heart, lungs, skin, or nervous tissue.
  • If the differential diagnosis of hypereosinophilia fails to resolve the etiology succesfully, the diagnosis of idiopathic HES remains.
  • [MeSH-major] Hypereosinophilic Syndrome / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Eosinophilia / diagnosis. Eosinophilia / etiology. Humans

  • Genetic Alliance. consumer health - Hypereosinophilic syndromes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18666600.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


41. N'Golet A, N'Gouoni BG, Moukassa D, Nkoua-Mbon JB: Maxillary African histoplasmosis: unusual diagnostic problems of an unusual presentation. Pathol Res Pract; 2005;200(11-12):841-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As clinical and radiologic features are not specific, the differential diagnosis to other mandibular diseases is difficult.
  • We report on a case of African histoplasmosis that involved the right mandibula of a 17-year-old Congolese boy with a persistent and fungiform cutaneous ulceration.
  • As mycologic tests had not been carried out initially, the disease was histologically diagnosed on the basis of the presence of numerous intra-cytoplasmic large yeasts in a granulomatous lesion containing giant cells.
  • As it is impossible to confront the histologic diagnosis with mycologic tests in such a situation, the problems of the differential diagnosis to other deep fungus infections and to some yeast-like foreign body-granulomas encountered at the microscopical level underline the importance of culturing organisms from lesions to confirm the histologic diagnosis.
  • It is worth considering this pathology at least for three reasons: it usually mimicks a malignant jaw tumor; it may constitute a migrant pathology; and prognosis is commonly favorable with amphotericin B treatment.
  • [MeSH-major] Histoplasma / isolation & purification. Histoplasmosis / pathology. Maxilla / pathology. Maxillary Diseases / pathology
  • [MeSH-minor] Adolescent. Africa. Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Diagnosis, Differential. Humans. Injections, Intravenous. Jaw Neoplasms / diagnosis. Male. Skin Ulcer / drug therapy. Skin Ulcer / microbiology. Skin Ulcer / pathology

  • MedlinePlus Health Information. consumer health - Histoplasmosis.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792130.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


42. Heyns CF, Groeneveld AE, Sigarroa NB: Urologic complications of HIV and AIDS. Nat Clin Pract Urol; 2009 Jan;6(1):32-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In recent years the nature of HIV infection has been dramatically transformed from an invariably fatal disease to a chronic disorder with a relatively benign course.
  • Disease progression from HIV to AIDS and HIV-related mortality can be reduced effectively by several years of treatment with highly active antiretroviral therapy (HAART).
  • For patients who do not have access to HAART, HIV infection continues to be a lethal disorder characterized by opportunistic infection with uncommon organisms (e.g. mycobacteria, fungi, parasites and viruses), as well as lethal malignancies such as Kaposi sarcoma, non-Hodgkin lymphoma and squamous cell carcinoma of the penis or cervix.
  • In patients receiving HAART, urologic complications are likely to be caused by adverse effects of antiretroviral medication (e.g. indinavir urolithiasis) or disorders associated with aging, such as benign prostatic hyperplasia and prostate cancer.
  • Prospective clinical trials have shown that adult male circumcision can reduce the rate of female to male HIV transmission by more than 50%; however, the development of preventive or curative modalities with 100% efficacy remains elusive.
  • [MeSH-major] HIV Infections / complications. Urologic Diseases / etiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Nat Clin Pract Urol. 2010 Apr;7(4):178
  • (PMID = 19132004.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 134
  •  go-up   go-down


43. Attarbaschi A, Mann G, Dworzak M, Trebo M, Urban C, Fink FM, Horcher E, Reiter A, Riehm H, Gadner H, Austrian Cooperative Study Group: Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000. Wien Klin Wochenschr; 2002 Dec 30;114(23-24):978-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000.
  • Between 1986 and 2000 183 Austrian children and adolescents with non-Hodgkin's lymphoma (NHL) and mature B-cell acute leukemia (B-ALL) were enrolled in 3 consecutive studies of the Berlin-Frankfurt-Münster (BFM) Group.
  • In trial NHL-BFM 86, patients were stratified according to the histologic subtype and clinical stage.
  • In the succeeding studies NHL-BFM 90 and 95, treatment stratification was additionally based on the speed of tumor response to therapy and for children with B-cell NHL/B-ALL also on the pre-therapeutic serum lactic dehydrogenase level.
  • Patients with lymphoblastic lymphoma (mainly with T-cell phenotypes) had an excellent prognosis with an ALL-type chemotherapy regimen (n = 49; relapse, n = 1), whereas an intensive, short-pulse therapy delivered within a 2- to 4-month period was found to be highly efficacious in children with B-cell NHL/B-ALL (n = 114; relapse, n = 6; progression, n = 5).
  • Patients with anaplastic large cell lymphoma (ALCL) who were treated with similar alternating short courses of multi-agent chemotherapy had a less good outcome (n = 20; relapse, n = 6, progression, n = 3).
  • Children with B-cell NHL and B-ALL who failed initial therapy also had a dismal prognosis (10/11 patients died).
  • Local radiotherapy as a part of lymphoma therapy was completely abandoned in study NHL-BFM 90 and surgical interventions were confined to specific situations such as complete resection in localized B-cell NHL and ALCL, diagnostic biopsy and second-look operation.
  • In conclusion, our results showed that the BFM treatment strategy for lymphoblastic lymphoma and B-cell NHL/B-ALL was highly successful in the majority of patients; however, optimal treatment for children with ALCL has not yet been defined.
  • As a consequence, larger trials at an international level are necessary to find new prognostic markers that might define more precisely those patients who need further intensification of first-line treatment or novel therapy.
  • [MeSH-major] Burkitt Lymphoma / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Data Interpretation, Statistical. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / therapy. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Prognosis. Prospective Studies. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12635465.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


44. Nefyodov LI, Uglyanitsa KN, Nechiporenko NA, Smirnov VY, Brzosko W, Karavay NL: New biochemical mechanisms of the anticancer effect of Ukrain in the treatment of cancer of the urinary bladder. Drugs Exp Clin Res; 2000;26(5-6):195-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New biochemical mechanisms of the anticancer effect of Ukrain in the treatment of cancer of the urinary bladder.
  • The aim of this study was to elucidate the mechanisms of the anticancer effect of Ukrain by comparing the processes of formation of the pool of free amino acids and their derivatives in the blood plasma and tumor biopsy specimens and unchanged bladder tissue in 28 patients with T1N0M0 bladder cancer.
  • The examination was carried out before and after Ukrain treatment (10 mg i.v.
  • /day, for 20 days), which was combined with systemic chemotherapy for bladder cancer.
  • Twenty-eight patients served as controls and received systemic chemotherapy only.
  • In contrast to conventional chemotherapy, treatment with Ukrain eliminated the blood plasma amino acid imbalance in patients with bladder cancer, concomitantly enriching the pool of free amino acids and their derivatives in unchanged urinary bladder tissue and decreasing concentrations of Gln and leucine (Leu), regulators of malignant cell proliferation and differentiation, by 30-50%.
  • In this situation, the concentrations of Gln and Leu in tumor tissue and the surrounding healthy urinary bladder tissue correlated highly significantly and negatively (r = -0.95).
  • In conclusion, Ukrain prevents active free amino acid transport into urinary bladder tumor tissue, inhibiting the activities of protein biosynthesis, gluconeogenesis and energy production.
  • The combined decrease in Gln and Leu levels in urinary bladder tumor tissue is a specific sign of the antitumor effect of Ukrain and a mechanism of its cancerostatic action by controlling the processes of amino acid pool formation in the tumor.
  • [MeSH-major] Alkaloids / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / metabolism

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11345027.001).
  • [ISSN] 0378-6501
  • [Journal-full-title] Drugs under experimental and clinical research
  • [ISO-abbreviation] Drugs Exp Clin Res
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Amino Acids; 0 / Antineoplastic Agents, Phytogenic; 0 / Berberine Alkaloids; 0 / Phenanthridines; 6251Q9UK1S / ukrain
  •  go-up   go-down


45. Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, Badel K, Calandra G: Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant; 2009 Feb;15(2):249-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
  • We investigated the efficacy and toxicity of combining granulocyte-colony stimulating factor (G-CSF) at standard doses with plerixafor, a CXCR4 inhibitor, to mobilize stem cells in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).
  • Patients with NHL and MM underwent mobilization with G-CSF (10 microg/kg/day) for up to 9 days and plerixafor (240 microg/kg/day), which started on the evening of day 4.
  • Toxicities, increase in circulating CD34 cells/microL before and after the first dose of plerixafor, percentage of patients collecting >or= 5 x 10(6) CD34/kg, total CD34 cells/kg collected, engraftment, and exploratory efficacy analyses in heavily pretreated patients were examined.
  • Circulating CD34 cells/microL increased by 2.5-fold (1.3-6.0-fold) after the first plerixafor dose.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization / methods. Hematopoietic Stem Cells / drug effects. Heterocyclic Compounds / administration & dosage. Lymphoma, Non-Hodgkin / therapy. Multiple Myeloma / therapy
  • [MeSH-minor] Adult. Aged. Antigens, CD34. Blood Component Removal. Cell Count. Drug Therapy, Combination. Female. Graft Survival. Humans. Male. Middle Aged. Receptors, CXCR4 / antagonists & inhibitors

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19167685.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00322491
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Heterocyclic Compounds; 0 / Receptors, CXCR4; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 155148-31-5 / JM 3100
  •  go-up   go-down


46. Wedgwood A, Younes A: Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma. Clin Lymphoma Myeloma; 2007 Dec;8 Suppl 2:S63-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma.
  • ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) and BEACOPP (bleomycin/etoposide/doxorubicin/cyclophosphamide/vincristine/procarbazine/prednisone) are the most widely used regimens for the treatment of patients with advanced stage Hodgkin lymphoma.
  • Maintaining the planned dose intensity is considered an important goal to achieve when using curative therapy.
  • Therefore, prophylactic use of granulocyte colony-stimulating factor (G-CSF) is widely used to support these regimens and is mandatory to support BEACOPP-escalated and BEACOPP-14 to reduce toxicity and treatment delays.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Bleomycin / therapeutic use. Clinical Trials as Topic. Cyclophosphamide / therapeutic use. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Filgrastim. Humans. Prednisone / therapeutic use. Procarbazine / therapeutic use. Recombinant Proteins. Vinblastine / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18284718.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; PVI5M0M1GW / Filgrastim; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol
  • [Number-of-references] 26
  •  go-up   go-down


47. Olfson M, Marcus SC, Ascher-Svanum H: Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull; 2007 Nov;33(6):1379-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone.
  • OBJECTIVE: This study compares 3 cohorts of patients with schizophrenia before, during, and after initiating treatment with fluphenazine decanoate (FD), haloperidol decanoate (HD), or long-acting injectable risperidone (LAR).
  • METHODS: Administrative data are analyzed from California Medicaid (Medi-Cal) beneficiaries with schizophrenia who initiated FD, HD, or LAR treatment.
  • Patients were required to have been continuously enrolled in Medi-Cal for 180 days before and 180 days after the start of the new episode of long-acting antipsychotic therapy.
  • RESULTS: There were few demographic and clinical differences among patients initiating FD, HD, and LAR.
  • During the 180 days before starting long-acting injections, most patients initiating FD (53.5%), HD (58.5%), and LAR (61.2%) received oral antipsychotic medications for <80% of the days in this period (medication possession ratio: <0.80).
  • The mean duration of depot treatment episodes was 58.3 days (SD = 53.6) for FD, 71.7 days (SD = 56.4) for HD, and 60.6 days (SD = 48.8) for LAR (F = 18.3, df = 2, 2694, P < .0001, HD > FD).
  • Few patients who started on FD (5.4%), HD (9.7%), or LAR (2.6%) continued for at least 180 days.
  • Most patients in each group (FD [77.4%], HD [78.9%], and LAR [75.5%]) received oral antipsychotic medications during the 45 days after discontinuing long-acting injections.
  • CONCLUSIONS: Patients treated with long-acting antipsychotic injections tend to have complex pharmacological regimens and recent medication nonadherence.
  • A great majority of patients initiating long-acting antipsychotic medications discontinue use within the first few months of treatment.
  • [MeSH-major] Antipsychotic Agents / therapeutic use. Fluphenazine / therapeutic use. Haloperidol / therapeutic use. Risperidone / therapeutic use. Schizophrenia / drug therapy

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RISPERIDONE .
  • Hazardous Substances Data Bank. HALOPERIDOL .
  • Hazardous Substances Data Bank. Fluphenazine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aust N Z J Psychiatry. 1999 Dec;33(6):896-901 [10619218.001]
  • [Cites] Psychiatr Serv. 2007 Apr;58(4):482-8 [17412849.001]
  • [Cites] Br J Clin Pharmacol. 2000 Feb;49(2):158-67 [10671911.001]
  • [Cites] J Clin Psychiatry. 2000 Mar;61(3):179-84 [10817102.001]
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1248-57 [11146272.001]
  • [Cites] Schizophr Res. 2002 Jan 1;53(1-2):25-30 [11728835.001]
  • [Cites] Am J Psychiatry. 2002 Apr;159(4):554-60 [11925292.001]
  • [Cites] Am J Psychiatry. 2002 Apr;159(4):561-6 [11925293.001]
  • [Cites] Cochrane Database Syst Rev. 2002;(2):CD002305 [12076447.001]
  • [Cites] Cochrane Database Syst Rev. 2002;(3):CD001258 [12137621.001]
  • [Cites] BMJ. 2002 Aug 3;325(7358):243 [12153919.001]
  • [Cites] Med Care. 2002 Aug;40(8):630-9 [12187177.001]
  • [Cites] J Clin Psychiatry. 2002 Oct;63(10):892-909 [12416599.001]
  • [Cites] Neuropsychopharmacology. 2003 Jan;28(1):182-92 [12496955.001]
  • [Cites] Med Care. 2003 Mar;41(3):368-74 [12618640.001]
  • [Cites] Schizophr Bull. 2003;29(3):531-40 [14609246.001]
  • [Cites] J Clin Psychiatry. 2003;64 Suppl 12:5-19 [14640142.001]
  • [Cites] J Clin Psychiatry. 2003;64 Suppl 16:14-7 [14680414.001]
  • [Cites] J Clin Psychiatry. 2003;64 Suppl 16:18-23 [14680415.001]
  • [Cites] Am J Psychiatry. 2004 Apr;161(4):692-9 [15056516.001]
  • [Cites] Schizophr Res. 2004 Feb 1;66(2-3):169-75 [15061250.001]
  • [Cites] Schizophr Bull. 2004;30(2):193-217 [15279040.001]
  • [Cites] Schizophr Bull. 2004;30(2):255-64 [15279044.001]
  • [Cites] Curr Pharm Des. 2004;10(18):2219-29 [15281897.001]
  • [Cites] Psychiatr Serv. 2004 Aug;55(8):886-91 [15292538.001]
  • [Cites] J Clin Psychiatry. 2004 Aug;65(8):1076-83 [15323592.001]
  • [Cites] Psychiatr Serv. 2004 Sep;55(9):997-1005 [15345759.001]
  • [Cites] J Clin Psychiatry. 2004 Oct;65(10):1377-88 [15491242.001]
  • [Cites] Acta Psychiatr Scand. 1986 Sep;74(3):255-62 [3788652.001]
  • [Cites] Acta Psychiatr Scand. 1991 Jul;84(1):14-21 [1681680.001]
  • [Cites] Hosp Community Psychiatry. 1992 Jan;43(1):69-71 [1544654.001]
  • [Cites] J Clin Psychiatry. 1992 Dec;53(12):426-33 [1362569.001]
  • [Cites] J Chromatogr B Biomed Appl. 1994 Jun 17;656(2):373-81 [7987490.001]
  • [Cites] Psychopharmacol Bull. 1996;32(3):321-6 [8961774.001]
  • [Cites] Schizophr Bull. 1997;23(4):637-51 [9366000.001]
  • [Cites] Br J Psychiatry. 1998 Jul;173:11-53 [9850203.001]
  • [Cites] Aust N Z J Psychiatry. 1998 Dec;32(6):815-22 [10084346.001]
  • [Cites] J Clin Psychiatry. 1999 Apr;60(4):215-20 [10221280.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2005 Jan;14(1):25-30 [15508132.001]
  • [Cites] Psychiatr Serv. 2005 Mar;56(3):283-91 [15746502.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jul;29(6):972-82 [16023776.001]
  • [Cites] J Clin Psychiatry. 2005 Aug;66(8):1016-20 [16086617.001]
  • [Cites] Br J Psychiatry. 2005 Sep;187:229-34 [16135859.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1209-23 [16172203.001]
  • [Cites] Can J Psychiatry. 2006 Jul;51(8):480-91 [16933585.001]
  • [Cites] Psychiatr Serv. 2000 Feb;51(2):216-22 [10655006.001]
  • (PMID = 17470444.001).
  • [ISSN] 0586-7614
  • [Journal-full-title] Schizophrenia bulletin
  • [ISO-abbreviation] Schizophr Bull
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Delayed-Action Preparations; J6292F8L3D / Haloperidol; L6UH7ZF8HC / Risperidone; S79426A41Z / Fluphenazine
  • [Other-IDs] NLM/ PMC2779880
  •  go-up   go-down


48. Noronha V, Shafi NQ, Obando JA, Kummar S: Primary non-Hodgkin's lymphoma of the liver. Crit Rev Oncol Hematol; 2005 Mar;53(3):199-207
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the liver.
  • We review the literature on primary hepatic lymphoma (PHL).
  • PHL is a rare malignancy, and constitutes about 0.016% of all cases of non-Hodgkin's lymphoma.
  • The predominant histology is B-cell lymphoma, most commonly diffuse large cell type.
  • Most patients are treated with chemotherapy, with some physicians employing a multimodality approach incorporating surgery and radiotherapy with chemotherapy.
  • The prognosis is variable, with good response to early aggressive combination chemotherapy.
  • [MeSH-major] Liver Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] B-Lymphocytes / pathology. Combined Modality Therapy. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15718146.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 52
  •  go-up   go-down


49. Bernscherer G, Karabélyos C, Tarján Z: [The pulmonological manifestations of rheumatoid arthritis]. Orv Hetil; 2008 Jul 20;149(29):1355-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They emphasize the pulmonological complications of disease modifying antirheumatic drugs used for the pharmaceutical therapy of rheumatoid arthritis, of which they discuss the methotrexate induced pulmonary diseases.
  • Methotrexate participates nearly in all of additive double and triple--O'Dell-scheme--combined disease modifying antirheumatic drugs therapy.
  • Because of that, the early detection of drug-induced pulmonological complications is important.
  • For rheumatologists the treatment of methotrexate resistant rheumatoid arthritis is always getting a higher and higher challenge.
  • Biological therapeutical drugs act as cytokine antagonists, by blocking TNF-alpha and, compared to disease modifying antirheumatic drugs, they can more effectively inhibit the progression of the disease.
  • At 3% of patients with rheumatoid arthritis, treated with biological response modifiers, who live in Arizona, California, Nevada, pulmonary and systemic mycosis--coccidioidomycosis can appear with a 15% of mortality.
  • The authors draw attention to the fact that patients who receive biological therapy and travel to the above-mentioned endemic or earthquake-active regions, have a potential high risk, so it is indispensable that they are informed by the doctor.
  • Testing and use of newer and newer groups of biological response modifiers are expected in the near future in the therapy of rheumatoid arthritis.
  • Nowadays--in patients, who are non-reactive for TNF-alpha inhibitor treatment--the use of B-lymphocyte inhibitor rituximab, characteristic in non-Hodgkin lymphoma therapy is possible.
  • The pulmonary complications of rheumatoid arthritis therapy of that cytokine are not known yet.
  • Today, antirheumatic therapy results in a significant improvement of patients' life-quality, whilst the more and more modern therapeutical methods cause more complications.
  • [MeSH-major] Antirheumatic Agents / adverse effects. Arthritis, Rheumatoid / complications. Arthritis, Rheumatoid / drug therapy. Immunologic Factors / adverse effects. Immunosuppressive Agents / adverse effects. Lung Diseases / etiology. Respiratory Tract Infections / etiology

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. Etanercept .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18617467.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antirheumatic Agents; 0 / Immunoglobulin G; 0 / Immunologic Factors; 0 / Immunosuppressive Agents; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab; FYS6T7F842 / Adalimumab; OP401G7OJC / Etanercept; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 14
  •  go-up   go-down


50. Perez SA, Karamouzis MV, Skarlos DV, Ardavanis A, Sotiriadou NN, Iliopoulou EG, Salagianni ML, Orphanos G, Baxevanis CN, Rigatos G, Papamichail M: CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res; 2007 May 1;13(9):2714-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: CD4(+)CD25(bright) regulatory T cells (Tregs) are increased in patients with several malignancies and correlate with disease stage and prognosis.
  • Breast cancer patients represent a heterogeneous population with unpredictable disease progression even at advanced stages.
  • Circulating Tregs in correlation with HER-2/neu (HER) status and treatment with chemotherapy, either alone or in combination with trastuzumab therapy, were monitored in advanced-stage breast cancer patients.
  • EXPERIMENTAL DESIGN: Circulating Treg frequency and absolute counts of 46 HER(+) and 28 HER(-), stage III and IV, breast cancer patients before therapy and during trastuzumab therapy and/or chemotherapy have been compared with 24 healthy donors and correlated with plasma HER extracellular domain concentration and clinical outcome.
  • Trastuzumab therapy, with or without combined chemotherapy, resulted in a progressive decrease of circulating Tregs.
  • Furthermore, decrease in Tregs correlated with either objective clinical response or stable disease, whereas increased Treg frequency during trastuzumab therapy coincided with disease progression.
  • No statistically significant change in Treg frequency following chemotherapy was observed in HER(-) patients.
  • CONCLUSIONS: Treg cell frequency does not directly correlate with clinical stage in breast cancer, as stage III and IV HER(+) and HER(-) patients exhibit significantly different Treg profiles.
  • Trastuzumab therapy, either alone or combined with chemotherapy, results in decreased Treg frequency in HER(+) advanced patients with an objective clinical response.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / immunology. Receptor, ErbB-2 / analysis. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antigens, CD4 / analysis. Female. Humans. Interleukin-2 Receptor alpha Subunit / analysis. Lymphocyte Count. Neoplasm Staging. Prognosis. Trastuzumab. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17473204.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD4; 0 / Antineoplastic Agents; 0 / Interleukin-2 Receptor alpha Subunit; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


51. Toubai T, Tanaka J, Ota S, Fukuhara T, Hashino S, Kondo T, Shono Y, Morioka M, Kawamura T, Masauzi N, Kakinoki Y, Kobayashi H, Kunieda Y, Kasai M, Kurosawa M, Asaka M, Imamura M: Effect of granulocyte colony-stimulating factor on IL-12 p40 production during chemotherapy for B-cell lineage non-Hodgkin's lymphoma patients. Eur J Haematol; 2006 Nov;77(5):403-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of granulocyte colony-stimulating factor on IL-12 p40 production during chemotherapy for B-cell lineage non-Hodgkin's lymphoma patients.
  • We investigated the serum IL-12 p40 and IL-12 Mix (p40 and p70) production in 28 patients with B-cell lineage non-Hodgkin's lymphoma (NHL) treated with chemotherapy (e.g., CHOP regimen) with or without G-CSF administration and eight healthy volunteers.
  • We found that serum levels of IL-12 p40 (191.2 +/- 150.0 pg/mL) and IL-12 Mix (277.4 +/- 274.5 pg/mL) in the patients before chemotherapy were higher than those in the healthy volunteers (IL-12 p40: 76.4 +/- 25.3 pg/mL, IL-12 Mix: 48.5 +/- 33.4 pg/mL) (P = 0.04 and 0.02, respectively).
  • Next, we examined the serum IL-12 p40 and IL-12 Mix levels in nine patients receiving chemotherapy with administration of G-CSF (CG group, n = 9) and without G-CSF (C group, n = 9).
  • Serum IL-12 p40 and IL-12 Mix levels were decreased on 10 d after chemotherapy in both groups, and those in CG groups were significantly lower than those in C group.
  • These results indicated that administration of G-CSF decreased serum IL-12 p40 and IL-12 Mix levels.
  • However, the survival rate of patients at clinical stages III and IV in CG group (n = 6, 66.0%) was significantly better than that of patients in C group (n = 4, 25.0%) (P = 0.02).
  • Long-term administration of G-CSF appears to influence the survival rate by reducing immunosuppressive IL-12 p40 production.
  • [MeSH-major] Biomarkers, Tumor / blood. Down-Regulation / drug effects. Gene Expression Regulation, Leukemic / drug effects. Granulocyte Colony-Stimulating Factor / administration & dosage. Interleukin-12 Subunit p40 / blood. Lymphoma, B-Cell / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prednisone / administration & dosage. Recombinant Proteins. Survival Rate. Time Factors. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16930137.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IL12B protein, human; 0 / Interleukin-12 Subunit p40; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


52. Alshayeb H, Wall BM: Non-Hodgkin's lymphoma associated membranoproliferative glomerulonephritis: rare case of long term remission with chemotherapy: a case report. Cases J; 2009;2:7201
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma associated membranoproliferative glomerulonephritis: rare case of long term remission with chemotherapy: a case report.
  • INTRODUCTION: Although membranoproliferative glomerulonephritis has been reported to occur in association with non-Hodgkin's lymphoma, information concerning the long term effects of treatment of non-Hodgkin's lymphoma on the associated membranoproliferative glomerulonephritis is limited.
  • Kidney biopsy was consistent with membranoproliferative glomerulonephritis, type 1.
  • Bone marrow biopsy performed in the evaluation of periaortic lymphadenopathy, hepatosplenomegaly, and thrombocytopenia confirmed the diagnosis of low grade B-cell non-Hodgkin's lymphoma.
  • The patient's renal function improved and proteinuria resolved after initial treatment of non-Hodgkin's lymphoma with chemotherapy.
  • During eleven years of follow up, membranoproliferative glomerulonephritis has remained in remission, as confirmed by repeatedly negative urinalyses, normal blood pressure and absence of clinical signs and symptoms suggestive of nephritic/nephrotic syndrome.
  • CONCLUSION: Membranoproliferative glomerulonephritis has been known to be associated with both chronic lymphocytic leukemia and non-Hodgkin's lymphoma, particularly with B cell lymphocytic type non-Hodgkin's lymphoma.
  • There is limited information available concerning the effects of treatment of non-Hodgkin's lymphoma on the progression of non-Hodgkin's lymphoma associated membranoproliferative glomerulonephritis.
  • This report presented a rare case of non-Hodgkin's lymphoma associated membranoproliferative glomerulonephritis, that continued to be in remission during eleven years of follow up after initial chemotherapy treatment of lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kidney Int. 1992 Jul;42(1):127-35 [1635342.001]
  • [Cites] Am J Kidney Dis. 1991 Mar;17(3):247-57 [1996564.001]
  • [Cites] Kidney Int. 1987 Mar;31(3):781-9 [3106698.001]
  • [Cites] Am J Med. 1986 Jan;80(1):63-70 [3510541.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2005 Jul;14(4):396-403 [15931011.001]
  • [Cites] Am J Nephrol. 1999;19(5):599-604 [10575191.001]
  • [Cites] Eur J Haematol. 2001 Sep;67(3):158-64 [11737248.001]
  • [Cites] Clin Nephrol. 2002 Apr;57(4):303-9 [12005247.001]
  • [Cites] Kidney Int. 2004 Jan;65(1):85-96 [14675039.001]
  • [Cites] Kidney Int. 1999 Jul;56(1):355-77 [10411717.001]
  • (PMID = 20181193.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2827065
  •  go-up   go-down


53. Briani C, Zambello R, Cavallaro T, Ferrari S, Lucchetta M, Pollanz S, Grisold W: Improvement of peripheral nervous system manifestations of B-cell non-Hodgkin's lymphoma after rituximab therapy. J Peripher Nerv Syst; 2009 Jun;14(2):146-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement of peripheral nervous system manifestations of B-cell non-Hodgkin's lymphoma after rituximab therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / drug therapy. Peripheral Nervous System Diseases / drug therapy. Peripheral Nervous System Diseases / etiology
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived. Demyelinating Diseases / drug therapy. Demyelinating Diseases / etiology. Demyelinating Diseases / pathology. Female. Humans. Male. Middle Aged. Rituximab. Sural Nerve / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19691537.001).
  • [ISSN] 1529-8027
  • [Journal-full-title] Journal of the peripheral nervous system : JPNS
  • [ISO-abbreviation] J. Peripher. Nerv. Syst.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


54. Karnak I, Emin Senocak M, Kutluk T, Tanyel FC, Büyükpamukçu N: Pulmonary metastases in children: an analysis of surgical spectrum. Eur J Pediatr Surg; 2002 Jun;12(3):151-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary surgery is frequently used for the treatment of metastasis or nodules in children with various types of malignancies.
  • The primaries were osteosarcoma (n = 2), synovial sarcoma (n = 1), fibrosarcoma (n = 1), Ewing's sarcoma (n = 2), mesenchymal chondrosarcoma (n = 1), Wilms' tumour (n = 4), clear-cell sarcoma (n = 1), Hodgkin lymphoma (n = 3), hepatoblastoma (n = 1), hepatocellular carcinoma (n = 1) and haemangioendotheliosarcoma (n = 1).
  • Pulmonary metastases were encountered either at the time of initial diagnosis (22 %) or occurred within 6 months to 5 years.
  • They were frequently nodular (94 %), unilateral (94 %) and located in the right lung (70 %).
  • The nodules contained tumour cells in most cases (n = 14) (78 %), mature nephrogenic elements (6 %) and no tumour tissue (16 %) in the remaining cases.
  • However, synovial sarcoma was encountered in metastasis in one case with fibrosarcoma primary.
  • Overall disease-free survival rate was 56 % during the follow-up period (mean, 36.4 +/- 31.8 months).
  • Therefore combined therapies such as chemotherapy and/or radiotherapy should be continued in the postoperative period.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Pneumonectomy. Retrospective Studies. Thoracotomy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12101495.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


55. Asaoku H: [Hematopoietic stem cell transplantation for malignant lymphoma]. Nihon Rinsho; 2000 Mar;58(3):704-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hematopoietic stem cell transplantation for malignant lymphoma].
  • The clinical results and indications for hematopoietic stem cell transplantation (HSCT) including malignant lymphoma(ML) will be reviewed in this paper.
  • In aggressive non-Hodgkin's lymphoma, patients with chemosensitive relapses and induction failures are appropriate candidates for HSCT.
  • Purged HSCT may improve outcome of patients with relapses in follicular lymphoma and mantle cell lymphoma.
  • High dose therapy with HSCT is proposed as a potentially curative treatment for ML that is not curable with conventional chemotherapy such as induction failure, relapse, poor-risk and indolent lymphoma.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow Purging. Combined Modality Therapy. Humans. Lymphoma, Follicular / therapy. Lymphoma, Mantle-Cell / therapy. Neoplasm Recurrence, Local / therapy. Prognosis. Randomized Controlled Trials as Topic. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10741150.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Number-of-references] 15
  •  go-up   go-down


56. Silverman GJ: Anti-CD20 therapy and autoimmune disease: therapeutic opportunities and evolving insights. Front Biosci; 2007;12:2194-206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-CD20 therapy and autoimmune disease: therapeutic opportunities and evolving insights.
  • Based on the successful clinical experience with the anti-CD20 antibody, rituximab, for the treatment of B-cell non-Hodgkins lymphoma, there is a rapidly growing literature on the treatment of patients with autoimmune diseases with this therapeutic agent.
  • However, the pathogenetic mechanisms responsible for these diseases may differ greatly from those in B cell malignancies.
  • Herein, I provide an overview on recently published clinical experience, and discuss immunobiologic perspectives that are most relevant to understanding the special opportunities and challenges posed by these diseases.
  • Of special importance, there is emerging evidence that the same inherited genetic variations and acquired immunodefects that underlie autoimmune disease pathogenesis may in some patients also interfere with the efficacy of anti-CD20 antibody-based therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Autoimmune Diseases / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / metabolism. Arthritis, Rheumatoid / drug therapy. Arthritis, Rheumatoid / immunology. B-Lymphocytes / drug effects. B-Lymphocytes / immunology. Cell Lineage. Humans. Lupus Erythematosus, Systemic / drug therapy. Lupus Erythematosus, Systemic / immunology. Purpura, Thrombocytopenic, Idiopathic / drug therapy. Purpura, Thrombocytopenic, Idiopathic / immunology. Rituximab. Self Tolerance

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17127456.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 76
  •  go-up   go-down


57. Bonelli RM, Niederwieser G, Lahousen T, Hofmann P: Zotepine in Huntington's disease. Hum Psychopharmacol; 2003 Apr;18(3):227-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zotepine in Huntington's disease.
  • The authors report a patient with Huntington's disease (HD) presenting with severe chorea.
  • The motor scale of the unified HD rating scale (UHDRS-I) revealed 81 points.
  • Motor function clearly improved with zotepine, until she reached an UHDRS-I of 34 points on day 7 of treatment.
  • This is the first description of zotepine in HD.
  • Our findings suggest that zotepine is useful in the treatment of HD chorea.
  • Controlled trials of its use in HD would be welcome.
  • [MeSH-major] Antipsychotic Agents / therapeutic use. Dibenzothiepins / therapeutic use. Huntington Disease / drug therapy
  • [MeSH-minor] Adult. Chorea / drug therapy. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 John Wiley & Sons, Ltd.
  • (PMID = 12672176.001).
  • [ISSN] 0885-6222
  • [Journal-full-title] Human psychopharmacology
  • [ISO-abbreviation] Hum Psychopharmacol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Dibenzothiepins; U29O83JAZW / zotepine
  •  go-up   go-down


58. Efrosă I, Miron I, Tansanu I: [Clinical features and therapeutics in Hodgkin disease of children]. Rev Med Chir Soc Med Nat Iasi; 2009 Jan-Mar;113(1):93-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and therapeutics in Hodgkin disease of children].
  • [Transliterated title] Particularităţi evolutive şi terapeutice ale bolii Hodgkin la copilul mic.
  • AIM: To investigate the incidence and evolution of Hodgkin disease to children under 5 years age.
  • MATERIAL AND METHOD: The patients have been investigate to Pediatric Hemato-Oncologic Department from Clinical and Emergencies Hospital for Children "Sf.
  • In this period 129 patients with Hogkin disease have been hospitalised, and among these 48 patients was under 5 years age (37.20%).
  • Anatomopathologic examination of samples from affected ganglions indicate: 7 patients with lymphocyte prevalence (14.58%), 6 with nodular sclerosis (12.50%), 31 with mixed cellularity (64.58%) and 4 patients with lymphoid depletion (8.34%).
  • Ann-Arbor classification of disease indicate a high incidence of stage II (27 cases--56.25%) in the beginning period than stage I (15 cases--31.25%), III (3 cases--6.25%) and IV (3 cases--6.25%).
  • Radiotherapy (35 cases--72.91%) and chemotherapy (27.09%) have been used.
  • [MeSH-major] Hodgkin Disease / pathology. Hodgkin Disease / therapy. Lymphocytes / pathology. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Chemotherapy, Adjuvant. Child, Preschool. Combined Modality Therapy / methods. Female. Humans. Incidence. Infant. Male. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Romania / epidemiology. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21495304.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


59. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F, CESAME Study Group: Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet; 2009 Nov 7;374(9701):1617-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.
  • BACKGROUND: Reports of an increased risk of lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease are controversial.
  • METHODS: 19,486 patients with inflammatory bowel disease, of whom 11,759 (60.3%) had Crohn's disease and 7727 (39.7%) had ulcerative colitis or unclassified inflammatory bowel disease, were enrolled in a nationwide French cohort by 680 gastroenterologists, who reported details of immunosuppressive therapy during the observation period, cases of cancer, and deaths.
  • The risk of lymphoproliferative disorder was assessed according to thiopurine exposure.
  • 23 new cases of lymphoproliferative disorder were diagnosed, consisting of one case of Hodgkin's lymphoma and 22 cases of non-Hodgkin lymphoproliferative disorder.
  • The incidence rates of lymphoproliferative disorder were 0.90 per 1000 (95% CI 0.50-1.49) patient-years in those receiving, 0.20/1000 (0.02-0.72) patient-years in those who had discontinued, and 0.26/1000 (0.10-0.57) patient-years in those who had never received thiopurines (p=0.0054).
  • The multivariate-adjusted hazard ratio of lymphoproliferative disorder between patients receiving thiopurines and those who had never received the drugs was 5.28 (2.01-13.9, p=0.0007).
  • Most cases associated with thiopurine exposure matched the pathological range of post-transplant disease.
  • INTERPRETATION: Patients receiving thiopurines for inflammatory bowel disease have an increased risk of developing lymphoproliferative disorders.
  • FUNDING: Programme Hospitalier de Recherche Clinique National (AOM05157), Association François Aupetit, Délégation Inter-régionale de la Recherche clinique Ile de France-Assistance Publique Hôpitaux de Paris (AP-HP), Ligue contre le Cancer, and Fonds de Recherche de la Société Nationale Française de Gastro-entérologie.
  • [MeSH-major] Colitis, Ulcerative / drug therapy. Crohn Disease / drug therapy. Immunosuppressive Agents / adverse effects. Lymphoproliferative Disorders. Purines / adverse effects
  • [MeSH-minor] Adult. Age Distribution. Aged. Drug Therapy, Combination. Female. France / epidemiology. Humans. Incidence. Male. Middle Aged. Multivariate Analysis. Proportional Hazards Models. Prospective Studies. Risk Factors. Sex Distribution. Time Factors. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet. 2009 Nov 7;374(9701):1572-3 [19837454.001]
  • [CommentIn] Med Klin (Munich). 2010 Jun;105(6):442-3 [20593573.001]
  • [CommentIn] Gastroenterology. 2010 Apr;138(4):1618-20 [20178840.001]
  • (PMID = 19837455.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Purines; 0 / Tumor Necrosis Factor-alpha
  • [Investigator] Dupas JL; Godeberge P; Hugot JP; Nahon S; Sabaté JM; Tucat G; Colombel JF; Cosnes J; Gendre JP; Lémann M; Hébuterne X; Cortot A; Bouhnik Y; Laharie D; Flourié B; Lerebours E; Beaugerie L; Peyrin-Biroulet L; Allez M; Messing B; Cadiot G; Marteau P; Soulé JC; Gornet JM; Veyrac M; Duclos B; Beau P; Bourreille A; Baumer P; Carbonnel F; Heresbach D; Metman EH; Florent C; Blain A; Faucheron JL; Potier P; Boehm C; Kurtz T; Lamouliatte H; Nion-Larmurier I; Delchier JC; Chaussade S; Weiss AM; Cézard JP; Siproudhis L; Sondag D; Jian R; Souquet JC; Bord P; Coffin B; D'almagne H; Delasalle P; Fournier R; Cavicchi M; Souffran MH; Vandromme L; Guedon C; Seksik P; Michiels C; Renard P; Rogier P; Gouilloud S; Rotenberg A; Savoye G; Thevenin A; Mallet L; Brazier F; Jean F; Justum AM; Latrive JP; Gerbal JL; Pierrugues R; Chardonnal G; Picon L; Reix N; Drouët D'aubigny N; Uettwiller H; Courillon Mallet A; Palacci A; Bensaude RJ; Bonniaud P; Empinet O; Nisard A; Rudelli A; Tubiana B; Capelle P; Dabadie A; Evard D; Julien PE; Picon-Coste M; Schneider S; Goldfain D; Bellanger J; Blondelot JP; Lamy P; Lemière S; Mockly JF; Pellat B; Gatineau-Sailliant G; Nalet B; Nancey S; Kusielewicz D; Loison P; Popot JM; Merite F; Roux JP; Afchain P; Blanquart A; Heyries L; Reville M; Viron D; Zerbib F; Claviere C; Léostic D; Pouderoux P; Moitry A; Hagège H; Humeau B; Lederman E; Lescut D; Luneau F; Mesnard B; Smadja L; Steinberg M; Brun M; Macaigne G; Marchal JL; Ollivier S; Ouvry D; Perche JP; Rambaud S; Benamouzig R; Cazenave JL; Coffin JC; Blazquez M; Lagneau M; Person B; Wittersheim C; Napoleon B; Cemachovic I; Iglicki F; Howaizi M; Leprince E; Leurent B; Morin T; Darsouni R; Attar A; Baron P; Breton A; Gillion JM; Guemene JM; Jouffre C; Moreau X; Claude P; Quinton A; Abitbol V; Brichard JM; Desaint B; Bouygues M; Chatrenet P; Salmeron M; Silvie J; Waldner B; Emery Y; Moraillon A; Kunkel D; Dubois P; Faure P; L'Hirondel C; Labérenne JE; Moreau P; Pereira A; Plihon G; Wolff T; Ngo Y; Boruchowicz A; Jost B; Gotlib JP; Danne O; Raoux P; Ramond-Bouhali MJ; Baetz A; Veyres B; Chapoutot C; Le Dréau G; Filippi J; Mudry J; Kalt P; Minault S; Bounin PA; Andréani T; Charneau J; Reijasse D; Bolze JL; Thaunat JL; Le Couteulx C; Maurage C; Bader R; Codjovi P; Migairou JL; Morali A; Rey P; Molard BR; Petit R; Koch S; Cassan P; Deschamps JP; Meicler Caby C; Meurisse JJ; Prades P; Boulant J; Diacono M; Monsch JM; Dupuy JF; Bellaiche G; Guegan M; Comte JM; Cayla JM; Le Tallec F; Meurisse F; Desurmont P; Roget L; Bouyssou P; Le Gall B; Bloch F; Larvol L; Jullien M; Moreau J; Rebouissoux L; Decroix B; Dib N; Dieterling P; Lenormand F; Lagier E; Fallourd P; Charpin S; Bertrand H; Bommelaer G; Battistelli D; Delon B; Dentant L; Dorval E; Dumortier J; Gaye-Bareyt E; Gerosa Y; Guez C; Mornet M; Benfredj P; Piperaud R; Stremsdoerfer N; Verdier E; Grinholtz A; Barjonet G; See A; Arotçarena R; Baudet A; Broyer J; Charachon A; Blondon H; Mouton P; Claudez H; Labat-Labourdette J; Haëm J; Estable P; Levy P; Rosenbaum A; Balavoine Y; Blanchi A; Coutarel P; Delaperriere N; Dervichian M; Marois F; Seroka J; Michaud L; Leroy O; Meyran E; Poilroux B; Tensaouti A; Paupard T; Agard D; Beaulieu S; Benfiguig K; Capony P; Cottereau J; Desreumaux P; Dramard JM; Duché M; Mamou P; Etienney I; D'Abrigeon G; Godeberge B; Puech J; Roger J; Lapalus MG; Bauret P; Houcke P; Pornin B; Champigneulle B; Cuissard L; David XR; Lombard F; Granveau A; Hamon JF; Ink O; Blondel F; Namias A; Pillon D; Reignier A; Tordjman G; Christidis C; Zirabe S; Audebert M; Bion E; Bourgeaux C; Poupardin C; Deplaix P; Fratini G; Garnier T; Desseaux G; Magois H; Lochum S; Vergier JF; Texereau P; Rat C; Uzzan F; Vidal A; Vinante N; Watrin B; Wurtz-Huckert C; Barre B; Chaslin Ferbus D; Contou JF; Coupier D; David B; Gargot D; Huc D; Barraya R; Faroux R; Fourgeaud JL; Grimprel H; Auroux J; Rey JF; Arnoux JP; Lentini F; Tardy L; Mouterde O; Spyckerelle C; Vacherot B; Weissman A; Alpérine M; Le Sidaner A; Bonnet-Eymard PO; Colson JL; Pellet D; Deltombe B; Edouard A; Maechel H; Jaillet JC; Genes J; Leveque AM; Lucidarme D; Maignan P; Mallier Gehrke N; Sanchez J; Tusseau F; Casteur A; Bottlaender J; Constantini D; Coton T; Even P; Druart F; Riot F; Gauchet JM; Hecquet G; Henry G; Hochain P; Arpurt JP; Medini A; Dartois-Hoguin M; Moindrot H; Emery P; Periac P; Prunier A; Renkes P; Tawil-Longreen C; Vincent E; Vitte RL; Loeb C; Carwana A; Barbereau D; Bohon P; Corrieri-Baizeau C; Sahy D; Derreveaux P; David D; Desbazeille F; Fontenelle P; Slama JL; Le Mercier Y; Certin M; Reig JJ; Rosa I; Helbert T; Tounian P; Turner L; Perot V; Aillet L; Pauwels A; Barré P; Nury B; Cazalbou C; Devulder F; Durget A; Dubroca J; Gaudy D; Greff M; Jacques C; Lafarge J; Kezachian G; Le Gall R; Pariente A; Pinault T; Bismuth M; Boyer-Darrigrand N; Bretagnolle P; Carpentier S; Cholet F; Theodore C; Combes R; Combet F; Delanoe C; De Montigny S; Soudan D; Fourdan O; Minier G; Languepin J; Roche J; Ginies JL; Nouel O; Petitgars P; Robin E; Hamm R; Roques JF; Roussin-Bretagne S; Sénéjoux A; Muron S; Bardoux N; Berthelemy P; Madonia P; Carles B; Reynier C; Cuillerier E; Dadamessi I; Danis J; Debenes B; Dubuc-Rey N; Lesur G; Jouet P; Lenaerts C; Garret M; Mineur A; Chabry B; Pigot F; Rossi V; Tennenbaum R; Salloum J; Slaoui MH; Mathieu S; Papapietro V; Viola S; Bezet A; Altman C; Audan A; Calabet J; Masliah C; Fayemendy L; Duruy M; Gauffeny B; Helie L; Imani K; Janin-Manificat R; Galmiche JP; Kerlirzin A; Bedenne L; Locher C; Michaudel G; Missonnier G; Rinaldi-Dovio M; Rouillon JM; Ecuer S; Patenotte A; Bronstein JA; Baty V; Bougnol M; Bourbon P; Cerbelaud P; Chavaillon A; Boiffin F; Dubern B; Duval De Laguierce I; Greco F; Bouhot F; Grandmaison B; Gros P; Targues G; Corallo J; Boutin J; Guillan J; Barbieux JP; Loury Lariviere I; Le Genissel H; Leroi H; Bellaiche M; Elie-Legrand MC; Dapoigny M; Denoyel P; Pienkowski P; Pouche P; Saurfelt MM; Thorel JM; Piche T; Travers B; Tuvignon P; Zalcberg M; Boulay G; Zamora C; Samama J; Ricotie E; De Fleury P; Maille F; Mougenel JL; Gonot O; Menat JP; Kaassis M; Lang F; Abramowitz L; Ganne N; Pecriaux O; Seyrig JA; Sobhani I; Parmentier T; Van Nieuwenhuyse A; Weber FX; Glibert A; Bineau C; Canet B; Collin C; Cordet F; Parlier DD; Carre D; Peytier A; Fein F; Barouk J; Dewannieux J; Hartwig J; Jouve JL; Laplane B; Lascar G; Legrand C; Le Marchand P; Liebaert MP; Terdiman-Pire M; Abdelli N; Neveu D; De La Lande P; De Saint Louvent P; Pelatan C; Petit A; Richecoeur M; Texier F; Cazals JB; Tissot B; Mourrut C; Doubremelle M; Foltz M; Gautier-Jubé F; Martin J; Khouri E; Lons T; Carlier-Bandu M; Monnin JL; Roche H; Willemin B; Houard X; Fatisse A; Algard M; Arab K; Borel I; Lagarrigue C; Chryssostalis A; Boutroux D; Dupuychaffray JP; Khaddari S; Mion F; Puy-Montbrun T; Girardet JP; Gury B; Landau A; Le Bihan M; Nieuviarts S; Ollivry J; Le Bourgeois P; Piquet MA; Escartin MP; Systchenko R; Venezia F; Wantiez M; Lesage X; Zrihen E; Aygalenq P; Dieumegard B; Savarieau B; Bulois P; Cattan S; Diez JL; Fauchot O; Durous E; Gazut V; Guilleminet C; Bories JM; Joly Le Floch I; Vove JP; Lelouch S; Lévy P; Lhopital F; Marcato N; Mozer-Bernardeau M; Nousbaum JB; Cattan P; Plane A; Raymond JM; Roseau G; Rozental G; Boustière C; Bonny C; Cordier-Collet M; Courat L; Croguennec B; Delaunay-Tardy K; Labarriere D; Geagea E; Gottrand F; Gelsi E; Thiefin G; Wohlschies E; Miguet M; Ponsot P; Suzanne J; Teste Y; Dupont Gossart AC; Baroni JL; Benchaa B; Blanc G; Maroy B; Bonjean P; Brézault C; Bridoux-Henno L; Chayette C; Auby D; Fiorucci R; Galindo G; Hubert G; Bonneau G; Marinier E; Pouteau M; Alamdari A; Delbende B; Chamouard P; D'Abravanel P; Dall'Osto H; Hervé S; Lefebvre J; Levoir D; Lillo P; Rouch M; Mathonnet M; De Lustrac M; Ramond FJ; Roupret B; Soupison A; Ait-Ouadda D; Barbaza Y; Bayart B; Bottini T; Cochet F; Goderel I; Maury O; Mbonyingo L; Pourtau V; Romain-Huttin L; Sallé AV; Trang J; Admane H; Drouet E
  •  go-up   go-down


60. Pawlak K, Pawlak D, Mysliwiec M: Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients. Am J Nephrol; 2007;27(3):221-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients.
  • BACKGROUND: Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) play an important role in the atherosclerosis.
  • Recombinant human erythropoietin (EPO) has become widely used to treat anemic hemodialyzed (HD) patients; however, an increased mortality has been reported for HD patients with cardiovascular disease when randomly assigned to normal hematocrit by EPO.
  • METHODS: Assessment of MMP-2, MMP-9, TIMP-1 and TIMP-2 were performed in 20 stable HD patients and 15 healthy controls.
  • Of the 20 patients, 10 were receiving EPO therapy [HD-EPO(+)] for 12 months or more and 10 were not receiving EPO therapy [HD-EPO(-)].
  • RESULTS: All parameters, with the exception of MMP-9, were lower in the healthy subjects compared with the HD subjects, irrespective of EPO administration.
  • There was no difference in MMPs/TIMPs system, MDA and C-reactive levels between HD-EPO(+) and HD-EPO(-) patients.
  • CONCLUSION: Erythropoietin therapy did not influence MMPs/TIMPs system, inflammation, or SOX in a low-risk HD patient population, in the absence of concomitant iron supplementation and mean Hg levels within target.
  • [MeSH-major] C-Reactive Protein / metabolism. Erythropoietin / adverse effects. Metalloproteases / drug effects. Oxidative Stress / drug effects. Renal Dialysis / adverse effects. Tissue Inhibitor of Metalloproteinases / drug effects
  • [MeSH-minor] Adult. Aged. Anemia / drug therapy. Case-Control Studies. Female. Humans. Male. Malondialdehyde / blood. Middle Aged. Uremia / therapy

  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 S. Karger AG, Basel
  • (PMID = 17384500.001).
  • [ISSN] 1421-9670
  • [Journal-full-title] American journal of nephrology
  • [ISO-abbreviation] Am. J. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Tissue Inhibitor of Metalloproteinases; 11096-26-7 / Erythropoietin; 4Y8F71G49Q / Malondialdehyde; 9007-41-4 / C-Reactive Protein; EC 3.4.- / Metalloproteases
  •  go-up   go-down


61. Blumenfeld Z, Dann E, Avivi I, Epelbaum R, Rowe JM: Fertility after treatment for Hodgkin's disease. Ann Oncol; 2002;13 Suppl 1:138-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility after treatment for Hodgkin's disease.
  • BACKGROUND: The investigational endeavors of ovarian cryopreservation await the clinical experience of auto- or xenotransplantation, in vitro maturation of thawed primordial follicles, their in vitro fertilization and embryo transfer.
  • Moreover, the risk of possible reimplantation of malignant stem cells with the thawed cryoperserved ovary has been raised following experimental animal observations.
  • Therefore, until these innovative endeavors prove successful, we have attempted to minimize the gonadotoxic effect of chemotherapy by the co-treatment with a gonadotropin-releasing hormone agonistic analog (GnRH-a) to induce a temporary prepubertal milieu.
  • The immunoreactive inhibin-A and -B in these patients was measured before, during and following the gonadotoxic chemotherapy.
  • METHODS: A prospective clinical protocol was undertaken in 60 women aged 15-40 years with lymphoma, 10 with leukemia and 10 undergoing chemotherapeutic treatments for non-malignant diseases such as systemic lupus erythematosus or other autoimmune diseases.
  • A monthly injection of depot D-TRP(6)-GnRH-a was administered from before starting the chemotherapy until its conclusion, up to a maximum of 6 months.
  • Hormonal profile [follicle-stimulating hormone (FSH), luteinizing hormone (LH), E2, T, P4, insulin-like growth factor (IGF)-1, IGF-BP3 and prolactin) was taken before starting the GnRH-a/chemotherapy co-treatment, and monthly thereafter until resumtion of spontaneous ovulation.
  • This group was compared with a control group of 60 women who have been treated with similar chemotherapy.
  • RESULTS: Whereas all but three (40, 36 and 34 year old) of the surviving patients within the GnRH-a/ chemotherapy co-treatment group resumed spontaneous ovulation and menses within 12 months, less than half of the patients in the 'control' group (chemotherapy without GnRH-a co-treatment) resumed ovarian function and regular cyclic activity (P <0.05).
  • Inhibin-A and -B decreased during the GnRH-a/ chemotherapy co-treatment but increased to normal levels in patients who resumed regular ovarian cyclicity, and/or spontaneously conceived, as compared with low levels in those who developed POF.
  • CONCLUSIONS: If these preliminary data are consisent in a larger group of patients, GnRH-a co-treatment should be considered in every woman of reproductive age receiving chemotherapy, in addition to assisted reproductive technologies and the investigation into ovarian cryopreservation for future in vitro maturation, autotransplantation or xenotransplantation.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Premature Ovarian Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2003 Mar;14(3):499; author reply 499-500 [12598361.001]
  • (PMID = 12078896.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / inhibin A; 0 / inhibin B; 57285-09-3 / Inhibins; 57773-63-4 / Triptorelin Pamoate
  • [Number-of-references] 104
  •  go-up   go-down


62. Zhang R, Wang D, Li Q, Sun T, Hao X: [Primary lymphoma of the spleen: clinical analysis of 23 cases]. Zhonghua Wai Ke Za Zhi; 2002 Mar;40(3):208-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary lymphoma of the spleen: clinical analysis of 23 cases].
  • OBJECTIVE: To investigate the best diagnostic and therapeutic method for primary lymphoma of the spleen.
  • They accepted chemotherapy after operation.
  • B-cell type non-Hodgkin's lymphoma was noted in 21 patients and T-cell letion in 2.
  • CONCLUSIONS: The diagnosis of splenic lymphoma is dependent mainly on B-ultrasound examination and CT scanning.
  • Splenectomy combined with chemotherapy may provide optimum therapy for patients with splenic lymphoma.
  • [MeSH-major] Lymphoma / surgery. Splenic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Drug Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Splenectomy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11955418.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


63. Beaumont M, Sanz M, Carli PM, Maloisel F, Thomas X, Detourmignies L, Guerci A, Gratecos N, Rayon C, San Miguel J, Odriozola J, Cahn JY, Huguet F, Vekhof A, Stamatoulas A, Dombret H, Capote F, Esteve J, Stoppa AM, Fenaux P: Therapy-related acute promyelocytic leukemia. J Clin Oncol; 2003 Jun 1;21(11):2123-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute promyelocytic leukemia.
  • PURPOSE: To analyze patient cases of therapy-related acute promyelocytic leukemia (tAPL), occurring after chemotherapy (CT), radiotherapy (RT) or both for a prior disorder, diagnosed during the last 20 years in three European countries.
  • PATIENTS AND METHODS: The primary disorder and its treatment, interval from primary disorder to tAPL, characteristics of tAPL, and its outcome were analyzed in 106 patients.
  • Primary disorders were predominantly breast carcinoma (60 patients), non-Hodgkin's lymphoma (15 patients), and other solid tumors (25 patients).
  • Median interval from primary disorder to tAPL diagnosis was 25 months (range, 4 to 276 months).
  • Characteristics of tAPL were generally similar to those of de novo APL.
  • With treatment using anthracycline-cytarabine-based CT or all-trans-retinoic acid combined with CT, actuarial survival was 59% at 8 years.
  • CONCLUSION: tAPL is not exceptional, and develops usually less than 3 years after a primary neoplasm (especially breast carcinoma) treated in particular with topoisomerase II-targeted drugs (anthracyclines or mitoxantrone and less often etoposide).
  • Characteristics and outcome of tAPL seem similar to those of de novo APL.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Belgium / epidemiology. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Child. DNA Topoisomerases, Type II. Female. France / epidemiology. Humans. Lymphoma / drug therapy. Lymphoma / radiotherapy. Male. Middle Aged. Retrospective Studies. Spain / epidemiology. Treatment Outcome. Tretinoin / administration & dosage

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12775738.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


64. Dave S: Gene expression profiling and outcome prediction in non-Hodgkin lymphoma. Biol Blood Marrow Transplant; 2006 Jan;12(1 Suppl 1):50-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling and outcome prediction in non-Hodgkin lymphoma.
  • Gene expression profiling with microarrays has provided new insights into the molecular biology of tumors can that underlie differences in responses to therapy and patient outcomes.
  • In diffuse large B-cell lymphoma, gene expression profiling has revealed at least 2 diseases that are strikingly different in their response to chemotherapy and the inhibition of critical oncogenic pathways.
  • In follicular lymphoma, gene expression profiling showed that the host immune response to tumors is an important determinant of outcome and can strongly predict survival at the time of diagnosis.
  • The application of immunologic therapies that modify the host immune response could have a major effect on survival in patients with follicular lymphoma.
  • Thus, the application of gene expression profiling in non-Hodgkin lymphoma provides important prognostic information at the time of diagnosis and can be translated into therapeutic options that improve patient outcomes.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Leukemic. Lymphoma, Non-Hodgkin / genetics. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Disease-Free Survival. Humans. Predictive Value of Tests. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399585.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 6
  •  go-up   go-down


65. Makis W, Lisbona R, Derbekyan V: Hodgkin lymphoma post-transplant lymphoproliferative disorder following pediatric renal transplant: serial imaging with F-18 FDG PET/CT. Clin Nucl Med; 2010 Sep;35(9):704-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma post-transplant lymphoproliferative disorder following pediatric renal transplant: serial imaging with F-18 FDG PET/CT.
  • Post-transplant lymphoproliferative disorder (PTLD) occurs in 1.2% of pediatric renal transplant patients, and is frequently Epstein-Barr Virus mediated.
  • Hodgkin Lymphoma PTLD is the rarest of the 4 types of PTLDs recognized by the World Health Organization, with an incidence of <4% of all PTLD patients.
  • It has a distinct clinical course and treatment from all other types of PTLD.
  • This is a case of a 16-year-old girl who had a renal transplant in 2000 due to Moya Moya disease.
  • Her first F-18 FDG PET/CT done in 2006 showed mildly FDG-avid mediastinal adenopathy (histologically nonspecific reactive nodes), however in 2009, after presenting with fevers, a repeat PET/CT showed extensive intensely FDG-avid disease.
  • Biopsy of a supraclavicular node identified Hodgkin Lymphoma PTLD.
  • The patient was treated with chemotherapy and reimaged, showing excellent response to therapy.
  • In contrast, classic PTLD is treated by withdrawal of immunosuppression and administration of Rituximab.
  • F-18 FDG PET/CT is known to be very useful in the staging and monitoring of response to therapy in the setting of classic PTLD.
  • In this case, serial F-18 FDG PET/CT scans proved very useful in the evaluation and follow-up of the rare and distinct Hodgkin Lymphoma PTLD subtype.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / etiology. Hodgkin Disease / radionuclide imaging. Kidney Transplantation / adverse effects. Positron-Emission Tomography. Tomography, X-Ray Computed


66. Zafranskaya M, Oschmann P, Engel R, Weishaupt A, van Noort JM, Jomaa H, Eberl M: Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis. Immunology; 2007 May;121(1):29-39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis.
  • Therapy with interferon-beta (IFN-beta) has well-established clinical effects in multiple sclerosis (MS), albeit the immunomodulatory mechanisms are not fully understood.
  • The proportion of CD45RO+ memory T cells was higher in MS patients than in healthy donors, but returned to normal values upon therapy with IFN-beta.
  • While CD45RO+ CD4+ T cells from all three groups responded to MOG in vitro, untreated patients showed augmented proliferative responses compared to healthy individuals and IFN-beta treatment reduced this elevated reactivity back to the values observed in healthy donors.
  • Compared with healthy individuals, responding CD4+ and CD8+ cells were skewed towards a type 1 cytokine phenotype in untreated patients, but towards a type 2 phenotype under IFN-beta therapy.
  • Assessment of T-cell subsets and their reactivity to MOG may represent an important diagnostic tool for monitoring successful immunotherapy in MS.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Immunosuppressive Agents / therapeutic use. Interferon-beta / therapeutic use. Multiple Sclerosis, Relapsing-Remitting / therapy
  • [MeSH-minor] Adult. Antigens, CD45 / blood. Cell Proliferation. Cells, Cultured. Cytokines / biosynthesis. Disease Progression. Flow Cytometry. Humans. Immunologic Memory. Immunophenotyping. Lymphocyte Activation / immunology. Middle Aged. Myelin Proteins. Myelin-Associated Glycoprotein / immunology. Myelin-Oligodendrocyte Glycoprotein. Protein Tyrosine Phosphatase, Non-Receptor Type 1. T-Lymphocyte Subsets / immunology

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mult Scler. 2004 Dec;10(6):630-5 [15584487.001]
  • [Cites] J Neurol. 2004 Nov;251(11):1329-39 [15592728.001]
  • [Cites] Clin Neuropharmacol. 2004 Nov-Dec;27(6):258-69 [15613929.001]
  • [Cites] J Clin Immunol. 2004 Nov;24(6):653-63 [15622450.001]
  • [Cites] J Neuroimmunol. 2005 Feb;159(1-2):155-64 [15652415.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):83-8 [15744304.001]
  • [Cites] Annu Rev Immunol. 2005;23:307-36 [15771573.001]
  • [Cites] Annu Rev Immunol. 2005;23:683-747 [15771584.001]
  • [Cites] Immunol Rev. 2005 Apr;204:208-31 [15790361.001]
  • [Cites] Ann Neurol. 2005 Apr;57(4):526-34 [15786444.001]
  • [Cites] Eur J Immunol. 2005 Apr;35(4):1311-9 [15761848.001]
  • [Cites] J Immunol. 2005 May 1;174(9):5233-42 [15843519.001]
  • [Cites] Curr Drug Targets Inflamm Allergy. 2005 Apr;4(2):239-45 [15853746.001]
  • [Cites] Int J Immunopathol Pharmacol. 2005 Apr-Jun;18(2):377-83 [15888259.001]
  • [Cites] Curr Opin Neurol. 2005 Jun;18(3):211-20 [15891402.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):7497-505 [15944248.001]
  • [Cites] Science. 2005 Jul 8;309(5732):264-8 [15933162.001]
  • [Cites] Brain. 2005 Aug;128(Pt 8):1747-63 [15975943.001]
  • [Cites] J Neurol Sci. 2005 Aug 15;235(1-2):11-7 [15972217.001]
  • [Cites] J Interferon Cytokine Res. 2005 Aug;25(8):485-9 [16108731.001]
  • [Cites] Cytokine. 2005 Oct 21;32(2):111-6 [16246570.001]
  • [Cites] J Immunol. 2006 Jun 15;176(12):7288-300 [16751372.001]
  • [Cites] Brain. 1999 Nov;122 ( Pt 11):2089-100 [10545394.001]
  • [Cites] Immunol Cell Biol. 1999 Dec;77(6):559-64 [10571678.001]
  • [Cites] J Neuroimmunol. 2000 Jun 1;105(1):46-57 [10713363.001]
  • [Cites] J Immunol. 2000 Aug 1;165(3):1641-51 [10903775.001]
  • [Cites] J Exp Med. 2000 Aug 7;192(3):393-404 [10934227.001]
  • [Cites] J Neuroimmunol. 2000 Nov 1;111(1-2):86-92 [11063825.001]
  • [Cites] J Neurosci Res. 2001 Feb 1;63(3):290-302 [11170179.001]
  • [Cites] Glia. 2001 Nov;36(2):220-34 [11596130.001]
  • [Cites] Brain. 2002 Mar;125(Pt 3):538-50 [11872611.001]
  • [Cites] J Clin Invest. 2002 Mar;109(5):581-4 [11877465.001]
  • [Cites] Nat Rev Neurosci. 2002 Apr;3(4):291-301 [11967559.001]
  • [Cites] J Immunol. 2002 Jun 1;168(11):5920-7 [12023398.001]
  • [Cites] Cell Immunol. 2002 Jul-Aug;218(1-2):1-6 [12470608.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Jan;74(1):123-6 [12486283.001]
  • [Cites] Acta Neurol Scand. 2003 Jan;107(1):7-11 [12542507.001]
  • [Cites] J Neuroimmunol. 2003 Apr;137(1-2):164-76 [12667661.001]
  • [Cites] J Neuroimmunol. 2003 Apr;137(1-2):187-96 [12667663.001]
  • [Cites] J Neuroimmunol. 2003 Apr;137(1-2):197-209 [12667664.001]
  • [Cites] J Neurol Sci. 2003 May 15;209(1-2):93-9 [12686409.001]
  • [Cites] J Interferon Cytokine Res. 2003 Mar;23(3):127-33 [12716484.001]
  • [Cites] J Immunol. 2003 Sep 1;171(5):2187-91 [12928361.001]
  • [Cites] J Immunol Methods. 2003 Dec;283(1-2):173-83 [14659909.001]
  • [Cites] Immunol Res. 2003;28(3):201-21 [14713715.001]
  • [Cites] J Immunol. 2004 Mar 15;172(6):3893-904 [15004197.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):971-9 [15067033.001]
  • [Cites] J Immunol. 2004 Apr 15;172(8):5120-7 [15067096.001]
  • [Cites] J Immunol. 2004 May 15;172(10):5967-72 [15128778.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4222-31 [14976054.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):678-84 [15224093.001]
  • [Cites] Immunol Rev. 2004 Jun;199:9-26 [15233723.001]
  • [Cites] Ann Neurol. 2004 Aug;56(2):192-205 [15293271.001]
  • [Cites] J Neuroimmunol. 2004 Oct;155(1-2):172-82 [15342209.001]
  • [Cites] Ann Neurol. 1983 Mar;13(3):227-31 [6847134.001]
  • [Cites] Cell. 1990 Aug 10;62(3):563-7 [2199065.001]
  • [Cites] Neurology. 1993 Apr;43(4):655-61 [8469318.001]
  • [Cites] Neurology. 1993 Apr;43(4):662-7 [8469319.001]
  • [Cites] J Neuroimmunol. 1993 Jul;46(1-2):145-53 [8360326.001]
  • [Cites] Neurology. 1993 Oct;43(10):2080-7 [8105424.001]
  • [Cites] J Clin Invest. 1993 Dec;92(6):2602-8 [7504688.001]
  • [Cites] J Clin Invest. 1993 Dec;92(6):2633-43 [7504690.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10859-63 [7526383.001]
  • [Cites] J Neurosci Res. 1996 Sep 15;45(6):852-62 [8892097.001]
  • [Cites] Neurology. 1997 Aug;49(2):385-92 [9270566.001]
  • [Cites] Mult Scler. 1997 Jun;3(3):180-3 [9310963.001]
  • [Cites] J Clin Invest. 1998 Feb 15;101(4):725-30 [9466965.001]
  • [Cites] J Clin Immunol. 1999 May;19(3):179-85 [10404403.001]
  • [Cites] J Neurol. 1999 Jul;246(7):569-73 [10463358.001]
  • [Cites] J Neurol. 2004 Sep;251 Suppl 5:v12-v29 [15549350.001]
  • (PMID = 17239199.001).
  • [ISSN] 0019-2805
  • [Journal-full-title] Immunology
  • [ISO-abbreviation] Immunology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Immunosuppressive Agents; 0 / MOG protein, human; 0 / Myelin Proteins; 0 / Myelin-Associated Glycoprotein; 0 / Myelin-Oligodendrocyte Glycoprotein; 77238-31-4 / Interferon-beta; EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 1
  • [Other-IDs] NLM/ PMC2265917
  •  go-up   go-down


67. Balwierz W, Moryl-Bujakowska A, Depowska T, Klekawka T, Stanuch H, Matysiak M, Sopyło B, Kołakowska-Mrozowska B, Krenke K, Chybicka A, Raś M, Sońta-Jakimczyk D, Moszant A, Wachowiak J, Kaczmarek-Kanold M, Kowalczyk J, Odój T, Balcerska A, Drozyńska E, Wysocki M, Kołtan A, Krawczuk-Rybak M, Stolarska M: [Over 30-year experience of Polish Pediatric Leukemia/Lymphoma Study Group for treatment of Hodgkin's disease in children and adolescents: improvement curability and decrease of serious complications]. Przegl Lek; 2004;61 Suppl 2:33-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Over 30-year experience of Polish Pediatric Leukemia/Lymphoma Study Group for treatment of Hodgkin's disease in children and adolescents: improvement curability and decrease of serious complications].
  • [Transliterated title] Ponad 30-letnie doświadczenie Polskiej Grupy ds. Leczenia Białaczek i Chłoniaków w leczeniu choroby Hodgkina u dzieci i młodziezy: poprawa wyleczalności i zmniejszenie powaznych powikłań.
  • Currently over 90% of children with HD can be cured thanks to use of chemotherapy (CT) combined with involved field radiotherapy (IF-RT).
  • From 1971 to 2001, 1062 children and adolescents with HD (stage I to IV) were treated in 10 oncological centers PPLLSG.
  • Year by year the intensity of therapy (CT and RT) was gradually adjusted to the risk-factor groups, and invasive methods of staging were also gradually limited.
  • Supportive care was improved at the same time.
  • Along with the modified therapy protocol, five consecutive periods of time (I: 1971-82; II: 1983-87; IIII: 1988-93; IV: 1994-96; V: 1997-2001) were analyzed.
  • In order to decrease the incidence of late complications, the dose of IF-RT from 45 Gy to 15-30 Gy was reduced in the next periods.
  • Intensity of therapy should be tailored to the stage of disease, and to other significant prognostic factors.
  • The current strategy of diagnosing and treatment of HD is aimed at balancing between the highest possible cure rates and risk of late complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Bleomycin / administration & dosage. Chemotherapy, Adjuvant / adverse effects. Child. Child, Preschool. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Mechlorethamine / administration & dosage. Multicenter Studies as Topic. Poland. Prednisolone / administration & dosage. Prednisone / administration & dosage. Procarbazine / administration & dosage. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Recurrence. Remission Induction. Retrospective Studies. Survival Analysis. Time Factors. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15688474.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; B-DOPA protocol; MVPP protocol
  •  go-up   go-down


68. Shiratori S, Tsutsumi Y, Kawamura T, Kudo K, Shimoyama N, Masauzi N, Tanaka J, Asaka M, Imamura M: HCV non-structural protein 3 and HCV RNA genome in non-Hodgkin lymphoma and transition of the serum HCV RNA level: a retrospective analysis in one institution. Int J Hematol; 2008 Apr;87(3):298-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HCV non-structural protein 3 and HCV RNA genome in non-Hodgkin lymphoma and transition of the serum HCV RNA level: a retrospective analysis in one institution.
  • There have been various reports on the association of hepatitis C virus (HCV) infection with B lymphocyte proliferative disorders, such as non-Hodgkin lymphoma (NHL).
  • We experienced a case (Case 1) of anti-HCV antibody (HCV-Ab)-positive NHL in which HCV nonstructural protein 3 (NS3) expression was observed in lymphoma tissue at the time of recurrence and in which the serum HCV RNA level exhibited a transient increase prior to recurrence.
  • We investigated the HCV RNA genome in lymphoma tissue in Case 1, and it could be detected at recurrence.
  • We also investigated HCV NS3 protein expression in lymphoma tissue and changes in serum HCV RNA level during the clinical course in four other cases of HCV-Ab-positive NHL treated in our hospital.
  • We examined lymphoma tissues for HCV NS3 protein expression in four of the five cases, but it was not identified except for in Case 1 at recurrence.
  • In three cases with no recurrence, serum HCV RNA levels showed a tendency to decrease after completion of chemotherapy and became stable thereafter.
  • [MeSH-major] Hepacivirus. Lymphoma, Large B-Cell, Diffuse / virology. Neoplasm Recurrence, Local / virology. RNA, Viral / blood. Viral Nonstructural Proteins / metabolism

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol J. 2004;5(6):530-3 [15570298.001]
  • [Cites] Ann Oncol. 2003 Sep;14(9):1341-5 [12954572.001]
  • [Cites] Am J Med. 1999 May;106(5):556-60 [10335728.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23 (3):468-73 [15659492.001]
  • [Cites] Am J Gastroenterol. 2002 Jul;97(7):1802-6 [12135039.001]
  • [Cites] Am J Hematol. 2001 Jul;67(3):168-71 [11391713.001]
  • [Cites] Hum Pathol. 2005 Aug;36(8):878-85 [16112004.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):81-5 [15185347.001]
  • [Cites] Int J Cancer. 2004 Jun 20;110(3):380-5 [15095303.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1113-20 [12916862.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • [Cites] Am J Hematol. 2000 Jun;64(2):95-100 [10814987.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1711-6 [15284859.001]
  • [Cites] Blood. 2003 Aug 1;102(3):996-9 [12714514.001]
  • [Cites] Am J Clin Pathol. 2000 Mar;113(3):391-8 [10705820.001]
  • [Cites] Gastroenterology. 1999 Mar;116(3):636-42 [10029622.001]
  • [Cites] Histopathology. 2006 Jan;48(2):189-98 [16405668.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3745-9 [11739181.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):76-80 [15185346.001]
  • [Cites] Am J Hematol. 2004 Jul;76(3):252-7 [15224361.001]
  • [Cites] Med Oncol. 2003;20(2):165-8 [12835519.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18544-9 [16339892.001]
  • (PMID = 18320139.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Hepatitis C Antibodies; 0 / NS3 protein, hepatitis C virus; 0 / RNA, Viral; 0 / Viral Nonstructural Proteins
  •  go-up   go-down


69. Tobinai K: Proteasome inhibitor, bortezomib, for myeloma and lymphoma. Int J Clin Oncol; 2007 Oct;12(5):318-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteasome inhibitor, bortezomib, for myeloma and lymphoma.
  • Multiple myeloma is one of the incurable B-cell malignancies that continues to relapse with current treatment modalities, and the duration to progression becomes shorter in patients who repeatedly receive chemotherapy.
  • There are no available treatment options in which durable efficacy can be expected after relapse; therefore, an effective therapy with a novel mechanism of action has been desired.
  • In this review article, the results of clinical trials of bortezomib for multiple myeloma, including a Japanese phase I/II and pharmacokinetic/pharmacodynamic study, and those for non-Hodgkin lymphoma, especially for mantle cell lymphoma, are summarized.
  • [MeSH-major] Boronic Acids / therapeutic use. Lymphoma / drug therapy. Multiple Myeloma / drug therapy. Protease Inhibitors / therapeutic use. Proteasome Inhibitors. Pyrazines / therapeutic use
  • [MeSH-minor] Animals. Bortezomib. Clinical Trials as Topic. Humans

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Int J Hematol. 2004 Feb;79(2):165-73 [15005346.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1530-4 [12393500.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3412-20 [15809451.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1083-6 [11861386.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):776-83 [15953004.001]
  • [Cites] Mayo Clin Proc. 1994 Aug;69(8):781-6 [8035637.001]
  • [Cites] Br J Haematol. 2007 Aug;138(3):330-7 [17614819.001]
  • [Cites] Int J Hematol. 2006 Dec;84(5):406-12 [17189220.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4420-7 [12431963.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Sep;7(2):131-4 [17026824.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3071-6 [11306489.001]
  • [Cites] Invest New Drugs. 2000 May;18(2):109-21 [10857991.001]
  • [Cites] Science. 1995 Aug 4;269(5224):682-5 [7624798.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9 [12391322.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2105-12 [16606971.001]
  • [Cites] Cancer Control. 1998 May;5(3):218-225 [10761055.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):929-36 [16432076.001]
  • [Cites] Oncogene. 1998 Nov 12;17(19):2437-44 [9824154.001]
  • [Cites] Cancer. 1991 Sep 1;68(5):975-80 [1913491.001]
  • [Cites] Blood. 2005 Nov 1;106(9):2977-81 [16020506.001]
  • [Cites] Genes Dev. 1996 Aug 15;10(16):1979-90 [8769642.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3058-65 [15626743.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2505-11 [12171876.001]
  • [Cites] N Engl J Med. 2003 May 8;348(19):1875-83 [12736280.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):937-44 [16418495.001]
  • [Cites] Ann Oncol. 2007 Jan;18(1):116-21 [16971665.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):667-75 [15613697.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2649-54 [8653711.001]
  • [Cites] J Clin Oncol. 1988 May;6(5):889-905 [2452861.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):165-72 [15461622.001]
  • [Cites] Curr Biol. 2000 Nov 2;10(21):1329-38 [11084332.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):676-84 [15613699.001]
  • [Cites] Oncogene. 2001 Jul 27;20(33):4519-27 [11494147.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):630-9 [15659509.001]
  • [Cites] Br J Haematol. 2007 Jun;137(5):429-35 [17451408.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1357-63 [15190257.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3832-42 [9850028.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2615-22 [10363983.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2495-502 [14695409.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):2955-60 [16707588.001]
  • [Cites] Blood. 2006 May 1;107(9):3492-4 [16410442.001]
  • [Cites] Chem Biol. 2001 Aug;8(8):739-58 [11514224.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3777-84 [16099887.001]
  • [Cites] N Engl J Med. 1996 Jul 11;335(2):91-7 [8649495.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] N Engl J Med. 1984 May 24;310(21):1353-6 [6546971.001]
  • [Cites] Br J Haematol. 1998 Sep;102(5):1115-23 [9753033.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4867-74 [17001068.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1195-200 [15690325.001]
  • (PMID = 17929113.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  • [Number-of-references] 63
  •  go-up   go-down


70. Amezyane T, Lecoules S, Bordier L, Blade JS, Desramé J, Bechade D, Coutant G, Algayres JP: [Humoral hypercalcemia revealing a malignant non hodgkin lymphoma]. Ann Endocrinol (Paris); 2008 Feb;69(1):58-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Humoral hypercalcemia revealing a malignant non hodgkin lymphoma].
  • [Transliterated title] Hypercalcémie humorale révélant un lymphome malin non hodgkinien.
  • INTRODUCTION: Hypercalcemia is a rare complication of non-Hodgkin lymphoma.
  • Usually, hypercalcemia occurs late in the disease course, except for high-grade lymphoma.
  • EXEGESIS: We report the case of a 82-year-old man who presented with abdominal pain and weight loss, leading to the diagnosis of diffuse large-B-cell lymphoma (high-grade lymphoma) associated with symptomatic hypercalcemia (3.21mmol/l).
  • Calcium concentration was normalized with glucocorticoids and sequential chemotherapy.
  • CONCLUSION: This case report confirms that hypercalcemia, as consequence of excessive plasmatic level of PTH-rP secreted by tumoral cells, can occur early in the course of high-grade lymphoma.
  • Glucocorticoids and chemotherapy are the best treatment options.
  • [MeSH-major] Hypercalcemia / etiology. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Aged, 80 and over. Antineoplastic Agents / therapeutic use. Humans. Male. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164274.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


71. Seidemann K, Henze G, Beck JD, Sauerbrey A, Kühl J, Mann G, Reiter A: Non-Hodgkin's lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials. Ann Oncol; 2000;11 Suppl 1:141-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials.
  • BACKGROUND: Lymphoma and leukemia are the commonest malignant diseases in patients with chromosomal breakage syndromes and immunodeficiency (Ataxia teleangiectasia (AT) and Nijmegen breakage syndrome (NBS)).
  • With improved management of infections, malignant disease is more frequently diagnosed and has become one of the commonest causes of death in pediatric AT and NBS.
  • PATIENTS AND METHODS: In three consecutive multicenter therapy trials for pediatric non-Hodgkin's lymphoma (NHL) (NHL-BFM), 1569 patients with newly diagnosed NHL have been registered between 1986 and 1997.
  • RESULTS: Median age of patients with AT and NBS at diagnosis of NHL was nine years.
  • NHL-entities differed from non-AT/NBS-patients: diffuse large B-cell lymphomas, n = 7 (78%); ALCL, n = 1; lymphoblastic T-cell lymphoma, n = 1.
  • Dose reductions according to individual tolerance concerned mainly ethotrexate, alkylating agents and epipodophyllotoxines.
  • Curative treatment is possible and should be attempted.
  • Intensity of therapy should be adjusted to individual risk factors and tolerance.
  • Alkylating agents, epipodophyllotoxines should be omitted, dose of MTX should be limited to 1 g/m2.

  • MedlinePlus Health Information. consumer health - Ataxia Telangiectasia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10707797.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


72. Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ, Koeffler HP: Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia; 2007 Feb;21(2):333-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma.
  • Mantle cell lymphoma (MCL) is an aggressive form of B-cell non-Hodgkin's lymphoma, with a mean survival of only 3-5 years and suboptimal therapeutic options.
  • MCL is characterized by a balanced translocation t(11;14)(q13;q32), resulting in overexpression of cyclin D1, a G(1) cyclin regulated by the PI3K/Akt/mammalian target of rapamycin (mTOR) signaling pathway.
  • As improved therapy for MCL is required and the mTOR pathway may be involved in its pathophysiology, the antiproliferative effects of RAD001 (everolimus), an mTOR inhibitor, against three MCL cell lines were investigated.
  • As a single agent, RAD001 inhibited proliferation in MCL cell lines (Jeko1, SP49 and NCEB1) approximately 40-65% compared to diluent control cells.
  • This was associated with G(1) cell-cycle arrest and reduced phosphorylation of the mTOR downstream target, 4E-BP1.
  • Furthermore, combination drug studies revealed predominantly synergistic cytotoxicity with RAD001 and several secondary agents, including doxorubicin, vincristine or rituximab (components of the standard MCL regimen), as well as paclitaxel, vorinostat and bortezomib.
  • Thus, these findings support future clinical studies of RAD001 in the treatment of MCL.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Lymphoma, Mantle-Cell / pathology. Sirolimus / analogs & derivatives
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Cell Division / drug effects. Cell Line, Tumor. Dimethyl Sulfoxide / pharmacology. Everolimus. Humans


73. Lopez M: [Success in chemotherapy of cancer. The curing of Hodgkin's disease. II]. Clin Ter; 2000 Sep-Oct;151(5):375-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Success in chemotherapy of cancer. The curing of Hodgkin's disease. II].
  • [Transliterated title] I successi della chemioterapia del cancro. La guarigione della malattia di Hodgkin. II.
  • [MeSH-major] Hodgkin Disease
  • [MeSH-minor] Antigens, CD / analysis. Antigens, Neoplasm / analysis. History, 20th Century. Humans. Lymphoma, Non-Hodgkin / pathology. Reed-Sternberg Cells / pathology. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11141723.001).
  • [ISSN] 0009-9074
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] ita
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm
  •  go-up   go-down


74. Krol V, Cunha BA, Schoch PE, Klein NC: Appropriateness of empiric gentamicin and vancomycin therapy for bacteremias in chronic dialysis outpatient units in the era of antibiotic resistance. J Chemother; 2006 Oct;18(5):490-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appropriateness of empiric gentamicin and vancomycin therapy for bacteremias in chronic dialysis outpatient units in the era of antibiotic resistance.
  • Bacteremias in inpatient chronic HD units have been described, but there is little information on bacteremias in ambulatory HD units.
  • To determine the frequency of bacteremia and pathogen distribution in ambulatory chronic HD units, we retrospectively reviewed our experience with 107 bacteremias in 5 chronic ambulatory HD units over a 3 year period.
  • The first objective was to determine if bacteremias in ambulatory HD setting were substantially different in frequency or type than in the inpatient HD setting.
  • Secondly, febrile patients suspected of having bacteremia in chronic HD patients are often empirically treated with vancomycin and gentamicin.
  • Chronic HD patients require repeated and frequent venous access for HD.
  • Bacteremias are common in chronic HD patients and may be primary or secondary and are often related to venous access site infections.
  • The distributions of bacteremia pathogens in chronic HD patients are predominantly reflective of skin flora, i.e., staphylococci and to lesser extent aerobic Gram-negative bacilli.
  • After S. aureus (MSRA/MSSA) and coagulase-negative staphylococcus (CoNS), enterococci are the next most important Gram-positive pathogens in bacteremic HD patients.
  • Most strains of E. faecalis are sensitive to vancomycin and for practical purposes should be considered as vancomycin sensitive enterococci (VSE).
  • In contrast, most strains of E. faecium are resistant to vancomycin and should be considered as vancomycin resistant enterococci (VRE).
  • We retrospectively reviewed 107 patients on chronic ambulatory HD to determine the adequacy of empiric vancomycin and gentamicin prophylaxis.
  • We found amikacin is preferred to gentamicin and that meropenem is an effective alternate substitution for gentamicin and vancomycin combination therapy.
  • [MeSH-major] Antibiotic Prophylaxis / methods. Bacteremia / drug therapy. Drug Resistance, Multiple, Bacterial / physiology. Gentamicins / therapeutic use. Renal Dialysis / adverse effects. Vancomycin / therapeutic use
  • [MeSH-minor] Drug Therapy, Combination. Enterococcus / drug effects. Enterococcus / isolation & purification. Hemodialysis Units, Hospital / organization & administration. Humans. Outpatients. Retrospective Studies. Staphylococcaceae / drug effects. Staphylococcaceae / isolation & purification

  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. Vancomycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17127225.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Gentamicins; 6Q205EH1VU / Vancomycin
  •  go-up   go-down


75. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM: Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol; 2009 Jul 10;27(20):3346-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.
  • PURPOSE: This is a multicenter phase I/II dose-finding study in relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL) evaluating veltuzumab, a humanized anti-CD20 antibody with structure-function differences from chimeric rituximab.
  • PATIENTS AND METHODS: Eighty-two patients (median age, 64 years; 79% stage III/IV, one to nine prior treatments) received four once-weekly doses of 80 to 750 mg/m(2) of veltuzumab and were assessed for safety, efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity.
  • RESULTS: Veltuzumab was well tolerated, with no grade 3 to 4 drug-related adverse events despite short infusion times (typically 2 hours initially, 1 hour subsequently at doses < 375 mg/m(2)).
  • In follicular lymphoma, 24 (44%) of 55 patients had objective responses (OR), with 15 (27%) complete responses (CRs) or CRs unconfirmed (CRus) by International Working Group criteria, and with some responses occurring despite two to five prior rituximab-containing regimens, less favorable prognosis (elevated lactate dehydrogenase, tumors > 5 cm, and Follicular Lymphoma International Prognostic Index > or = 2), and at all dose levels.
  • In marginal zone lymphoma, five (83%) of six patients had ORs, with two CRs/CRus (33%), and in diffuse large B-cell lymphoma, three (43%) of seven patients achieved partial responses.
  • At all dose levels studied, B cells were depleted after the first infusion, veltuzumab serum half-lives were similar after the fourth infusion, and mean antibody serum levels exceeded values considered important for anti-CD20 therapy (ie, 25 microg/mL).
  • CONCLUSION: Veltuzumab appeared safe and active at all tested doses, encouraging further study, including dose levels less than those typically used with rituximab.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. B-Lymphocytes / drug effects. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Fatigue / chemically induced. Female. Fever / chemically induced. Headache / chemically induced. Humans. Kaplan-Meier Estimate. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Male. Middle Aged. Pruritus / chemically induced. Recurrence. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19451441.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00285428/ NCT00596804
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / veltuzumab
  •  go-up   go-down


76. Lucetti C, Gambaccini G, Bernardini S, Dell'Agnello G, Petrozzi L, Rossi G, Bonuccelli U: Amantadine in Huntington's disease: open-label video-blinded study. Neurol Sci; 2002 Sep;23 Suppl 2:S83-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amantadine in Huntington's disease: open-label video-blinded study.
  • Huntington's disease (HD) is characterized by chorea, cognitive and behavioral changes.
  • Amantadine, a non-competitive NMDA receptor antagonist, has shown an antidyskinetic effect on levodopa-induced dyskinesias, which are known to have strict pathogenetic analogies with choreic hyperkinesias.
  • Eight HD patients received oral amantadine (100 mg tid) unblinded for a 1-year period.
  • No changes were observed in neuropsychologic and psychiatric assessments after 6 and 12 months of therapy.
  • These data may have relevance to the treatment of HD with amantadine.
  • [MeSH-major] Amantadine / pharmacology. Dyskinesia, Drug-Induced / drug therapy. Excitatory Amino Acid Antagonists / pharmacology. Huntington Disease / drug therapy
  • [MeSH-minor] Aged. Female. Humans. Hyperkinesis / chemically induced. Levodopa / adverse effects. Male. Receptors, N-Methyl-D-Aspartate / metabolism. Time Factors

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • Hazardous Substances Data Bank. AMANTADINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12548355.001).
  • [ISSN] 1590-1874
  • [Journal-full-title] Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  • [ISO-abbreviation] Neurol. Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Excitatory Amino Acid Antagonists; 0 / Receptors, N-Methyl-D-Aspartate; 46627O600J / Levodopa; BF4C9Z1J53 / Amantadine
  •  go-up   go-down


77. Villani F, Busia A, Villani M, Vismara C, Viviani S, Bonfante V: Serum cytokine in response to chemo-radiotherapy for Hodgkin's disease. Tumori; 2008 Nov-Dec;94(6):803-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum cytokine in response to chemo-radiotherapy for Hodgkin's disease.
  • AIMS AND BACKGROUND: Mediastinal radiotherapy and multiple-drug chemotherapy, including bleomycin employed in the treatment of Hodgkin's disease, can produce lung toxicity leading to fibrosis.
  • MATERIAL AND METHODS: In a pilot study, we evaluated lung function in 20 patients suffering from Hodgkin's disease, mainly in stage II A, submitted to multiple-drug chemotherapy including bleomycin (ABVD) and mediastinal radiotherapy and correlated its modifications with serum concentration of the cytokines determined by immunoenzymatic assay.
  • Spirometry and transfer lung function for carbon monoxide (DLCO) were performed before, at the end of chemotherapy, at the end of radiotherapy and after a follow-up of 6 and 12 months.
  • RESULTS: DLCO decreased at the end of the combined treatment and then remained constantly decreased.
  • TNF-alfa, TGF-beta and PDGF-alfa concentrations did not change, whereas IL-1 beta significantly increased after the completion of the combined treatment and after a follow-up of 6-months and then declined to normal values after 12 months.
  • The serum concentration of the cytokine was significantly higher in patients who had a DLCO < 75% of predicted after 1 year than in patients with a DLCO > 75%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytokines / blood. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adult. Bleomycin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Interleukin-1beta / blood. Male. Mediastinal Neoplasms / blood. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / radiotherapy. Middle Aged. Pilot Projects. Platelet-Derived Growth Factor / metabolism. Prednisone / therapeutic use. Procarbazine / therapeutic use. Prognosis. Respiratory Function Tests. Transforming Growth Factor beta / blood. Tumor Necrosis Factor-alpha / blood. Vinblastine / therapeutic use. Vincristine / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19267096.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-1beta; 0 / Platelet-Derived Growth Factor; 0 / Transforming Growth Factor beta; 0 / Tumor Necrosis Factor-alpha; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol
  •  go-up   go-down


78. Costello RT, Zerazhi H, Charbonnier A, de Colella JM, Alzieu C, Poizot-Martin I, Cohen R, Bardou VJ, Xerri L, Olive D, Nezri M, Lepeu G, Gastaut JA: Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus. Cancer; 2004 Feb 15;100(4):667-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus.
  • BACKGROUND: Optimal treatment of human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma (NHL) has yet to be defined, because chemotherapy could exacerbate immunodeficiency, with subsequent adverse effects for patients.
  • METHODS: The authors investigated the feasibility of an intensive chemotherapy regimen for HIV-associated NHL.
  • Thirty-eight patients were treated with a first course of cyclophosphamide (Cy), vincristine, and prednisone; followed by 3 courses of high-dose Cy (2000 mg/m2), doxorubicin (Doxo; 50 mg/m2), vincristine, and prednisone (modified high-dose CHOP); 1 course of high-dose methotrexate (MTX; 8000 mg/m2); and 1 course of high-dose cytarabine (8000 mg/m2).
  • Radiotherapy was added to the treatment regimen for patients with bulky disease or residual tumor.
  • Chemotherapy was administered in conjunction with granulocyte-colony-stimulating factor and antiretroviral therapy.
  • RESULTS: Patients received 91.5%, 93%, 66%, and 63% of the scheduled doses of Cy, Doxo, MTX, and cytarabine, respectively.
  • The complete response rate was 60.5%, with a total response rate of 79%.
  • The 40-month overall survival rate was 43%, the disease-free survival rate was 65%, and the recurrence-free survival rate was 39%.
  • Both an International Prognostic Index score of 0 or 1 and Burkitt-type histology had positive effects on survival, whereas CD4-positive lymphocyte counts, viral burden, and previous highly active antiretroviral therapy did not.
  • CD4-positive T lymphocyte levels decreased from 0.197 +/- 0.156 x10(9)/L before treatment to 0.152 +/- 0.1 x10(9)/L at 6 months after the end of treatment.
  • A decrease in viral load, from 380,000 +/- 785,000 copies/mL before treatment to 25,000 +/- 43,000 copies/mL at 6 months after the end of treatment, also was observed.
  • CONCLUSIONS: The results of the current study indicate that intensive chemotherapy is effective and tolerable for patients with HIV-associated NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / administration & dosage. HIV Infections / complications. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adult. Anti-HIV Agents / therapeutic use. CD4 Lymphocyte Count. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Injections, Intravenous. Male. Methotrexate / administration & dosage. Middle Aged. Prednisone / administration & dosage. Prognosis. Radiotherapy, Adjuvant. Treatment Outcome. Vincristine / administration & dosage. Viral Load

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 14770420.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol
  •  go-up   go-down


79. Piekarczyk A, Zimak J, Taljański W: [Pharmacokinetics of methotrexate and therapeutic drug monitoring in children with osteosarcoma. Computer simulation using a pharmacokinetic model]. Med Wieku Rozwoj; 2000 Apr-Jun;4(2 Suppl 2):27-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pharmacokinetics of methotrexate and therapeutic drug monitoring in children with osteosarcoma. Computer simulation using a pharmacokinetic model].
  • The pharmacokinetics of methotrexate (MTX) and the therapeutic drug monitoring (TDM) in children treated-with high-dose of MTX (HD MTX) have been discussed.
  • The pharmacokinetics of MTX was studied in 15 children (54 courses) with osteosarcoma, treated with HD MTX (8, 10 and 12 g/m2; 4 h i.v. infusion).
  • Pharmacokinetic analysis was performed by standard non-compartmental methods and using two-compartment nonlinear model with coexistence of additional, parallel linear route of elimination from the central compartment.
  • This proposed model can be used for computer simulation and prognosis of the serum-level curve course depending on the simulated dosage, enhanced diuresis and simulated kidney or liver insufficiency during the dose individualisation.
  • The usage of the pharmacokinetic model for computer simulations may improve the understanding of MTX kinetics and can optimalise dosage regimens for the next cycles of chemotherapy.
  • [MeSH-major] Bone Neoplasms / drug therapy. Methotrexate / pharmacokinetics. Nonlinear Dynamics. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Area Under Curve. Child. Computer Simulation. Drug Monitoring. Humans. Infusions, Intravenous. Models, Biological

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11178326.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


80. Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M: High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res; 2006 Sep 1;12(17):5190-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
  • PURPOSE: Angiogenesis is increased in aggressive histology non-Hodgkin's lymphoma and may be a target with selective cyclooxygenase-2 inhibition and metronomic chemotherapy.
  • EXPERIMENTAL DESIGN: We assessed response, toxicity, and biomarkers of angiogenesis to low-dose cyclophosphamide (50 mg p.o. o.d.) and high-dose celecoxib (400 mg p.o. b.i.d.) in adult patients with relapsed or refractory aggressive non-Hodgkin's lymphoma in a multicenter phase II prospective study.
  • Patients had primarily relapsed diffuse large B-cell lymphoma (63%) were heavily pretreated (median of three regimens) and high risk (79% international prognostic index, >or=2) and 34% were relapsed after autologous stem cell transplant.
  • With a median follow-up of 8.4 months, the overall best response rate is 37% (2 complete clinical response/complete clinical response unconfirmed and 9 partial response), with 22% achieving stable disease.
  • Three patients developed deep vein thromboses and two heavily pretreated patients developed treatment-related acute myelogenous leukemia or myelodysplasia after 3.7 and 12 months of therapy.
  • CONCLUSIONS: Low-dose cyclophosphamide and high-dose celecoxib is well tolerated and active in pretreated aggressive non-Hodgkin's lymphoma.
  • [MeSH-major] Cyclophosphamide / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Pyrazoles / administration & dosage. Sulfonamides / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Celecoxib. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Maximum Tolerated Dose. Middle Aged. Prospective Studies. Recurrence. Risk Factors. Survival Rate. Treatment Outcome. Vascular Endothelial Growth Factor A / blood

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16951238.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Sulfonamides; 0 / Vascular Endothelial Growth Factor A; 8N3DW7272P / Cyclophosphamide; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


81. Ambulkar I, Nair R: Primary ovarian lymphoma: report of cases and review of literature. Leuk Lymphoma; 2003 May;44(5):825-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian lymphoma: report of cases and review of literature.
  • Primary female reproductive system lymphomas are distinctly uncommon.
  • We report two cases with primary ovarian non Hodgkin's lymphoma (NHL) having unilateral involvement in one case while the other had bilateral ovarian involvement.
  • Histologically, by using the WHO classification, one lesion was classified as diffuse small B cell phenotype of intermediate grade and the other as diffuse high grade, B cell phenotype.
  • On the basis of staging studies and clinical follow up, we conclude that both of the neoplasms in the report arose in the ovary.
  • Both of the patients are disease free at 24 months and 6 months of follow up respectively, following excision and chemotherapy.
  • We conclude that that the complete remission and failure free survival of patients with ovarian NHL treated with appropriate treatment appear to be similar to that of patients with extranodal NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / surgery. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / surgery. Remission Induction / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for ovarian lymphoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12802921.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 21
  •  go-up   go-down


82. Gebert C, Hardes J, Ahrens H, Buerger H, Winkelmann W, Gosheger G: Primary multifocal osseous Hodgkin disease: a case report and review of the literature. J Cancer Res Clin Oncol; 2005 Mar;131(3):163-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary multifocal osseous Hodgkin disease: a case report and review of the literature.
  • PURPOSE: Hodgkin disease (HD) typically involves the lymphatic system at one or more sites.
  • Rarely, Hodgkin disease presents as an osseous lesion without involvement of lymph nodes.
  • Therefore, the histologic diagnosis of osseous HD can be problematic.
  • We present a rare case of multifocal osseous HD and a review the literature with special emphasis on treatment and prognosis.
  • METHODS: Osteomyelitis and lymphoma are the main differential diagnoses and can only be excluded histologically by the presence of Sternberg Reed cells or by immunohistochemical examinations.
  • This case reports a 21-year old man with a Hodgkin lymphoma located at the proximal femur and the proximal tibia.
  • Regarding the Ann Arbor classification, the presented case should be a stage IV disease.
  • The patient is without evidence of disease 4 years after curettage, local radiation therapy, and systemic chemotherapy despite the poor prognosis considering the Ann Arbor classification.
  • CONCLUSION: Reviewing the few reported cases, osseous HD must be distinguished from systemic HD with diffuse bone marrow involvement and from osseous metastases in advanced stage of disease because it seems to have a better prognosis.
  • [MeSH-major] Bone Neoplasms / diagnosis. Hodgkin Disease / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Femur / diagnostic imaging. Femur / pathology. Humans. Immunohistochemistry. Lymphoma / diagnosis. Male. Osteomyelitis / diagnosis. Radiography. Tibia / diagnostic imaging. Tibia / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 1992 Oct;(283):276-80 [1395259.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):536-44 [9469338.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2386-95 [12802024.001]
  • [Cites] Ann Hematol. 1992 Aug;65(2):61-5 [1324741.001]
  • [Cites] Cancer. 1982 Jan 15;49(2):338-42 [7053832.001]
  • [Cites] CMAJ. 1989 May 1;140(9):1059-60 [2706592.001]
  • [Cites] Br J Surg. 1969 Apr;56(4):277-81 [4952475.001]
  • [Cites] Semin Oncol. 1990 Dec;17(6):683-95 [2251515.001]
  • [Cites] Skeletal Radiol. 1995 Jan;24(1):61-3 [7709257.001]
  • [Cites] Radiology. 1961 Jul;77:53-60 [13702399.001]
  • [Cites] Semin Oncol. 1980 Jun;7(2):174-83 [7444471.001]
  • [Cites] Cancer Treat Rev. 1986 Jun;13(2):77-111 [3527412.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1079-85 [15205202.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):476-83 [10507773.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):79-88 [8630944.001]
  • [Cites] Cancer. 1998 Sep 1;83(5):1041-7 [9731909.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1166-78 [10091803.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2234-6 [6488141.001]
  • [Cites] Radiol Clin North Am. 1990 Jul;28(4):841-64 [2190273.001]
  • [Cites] J Clin Oncol. 1985 Feb;3(2):215-21 [2981984.001]
  • [Cites] Cancer Treat Rep. 1982 Apr;66(4):1035-44 [6951632.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1509-17 [7417953.001]
  • [Cites] Rontgenpraxis. 2003;55(3):114-24 [15119314.001]
  • [Cites] Am J Hematol. 1989 Mar;30(3):115-20 [2644822.001]
  • [Cites] Br J Radiol. 1967 Dec;40(480):939-48 [4952885.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1052-5 [4016696.001]
  • [Cites] Ann Intern Med. 1985 Jan;102(1):37-41 [3966743.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:98-101 [12078913.001]
  • [Cites] Cancer. 1984 Jan 15;53(2):232-6 [6360333.001]
  • [Cites] N Engl J Med. 1964 Mar 5;270:508-14 CONTD [14089119.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1965 Mar;93:568-72 [14259982.001]
  • [Cites] Oncology. 2001;60(2):101-9 [11244323.001]
  • [Cites] Skeletal Radiol. 1979;4(4):233-5 [531588.001]
  • [Cites] Med Pediatr Oncol. 1995 Mar;24(3):204-7 [7530802.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1972 Mar;114(3):559-63 [4110941.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1786-93 [5121683.001]
  • [Cites] Australas Radiol. 1993 Feb;37(1):63-6 [8323514.001]
  • (PMID = 15605165.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  •  go-up   go-down


83. Emir S, Kutluk MT, Göğüş S, Büyükpamukçu M: Paraneoplastic cerebellar degeneration and Horner syndrome: association of two uncommon findings in a child with Hodgkin disease. J Pediatr Hematol Oncol; 2000 Mar-Apr;22(2):158-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic cerebellar degeneration and Horner syndrome: association of two uncommon findings in a child with Hodgkin disease.
  • An 11-year-old boy admitted with a right cervical mass was found to have Hodgkin disease.
  • He was treated with chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), in addition to radiotherapy.
  • Three months after initiation of therapy, he had a partial remission of tumor.
  • Neurologic symptoms improved dramatically after chemotherapy started.
  • Hodgkin disease should be included in the differential diagnosis of children with cerebellar findings and Horner syndrome.
  • [MeSH-major] Hodgkin Disease / complications. Horner Syndrome / etiology. Paraneoplastic Cerebellar Degeneration / complications


84. Simonelli C, Zanussi S, Cinelli R, Dal Maso L, Di Gennaro G, D'Andrea M, Nasti G, Spina M, Vaccher E, De Paoli P, Tirelli U: Virological efficacy in HIV-infected patients affected by non-Hodgkin lymphoma, treated with antiblastic chemotherapy and highly active antiretroviral therapy. Scand J Infect Dis Suppl; 2003;106:49-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Virological efficacy in HIV-infected patients affected by non-Hodgkin lymphoma, treated with antiblastic chemotherapy and highly active antiretroviral therapy.
  • This study evaluated replication of human immunodeficiency virus (HIV) and the genotypic resistance pattern in 26 HIV-infected patients affected by non-Hodgkin lymphoma who were treated with at least 3 cycles of chemotherapy (CT; rituximab and CDE) and highly active antiretroviral therapy (HAART).
  • The data show that a combination therapy consisting of CT and HAART is feasible and that the virological response can be maintained in the majority of such patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antiretroviral Therapy, Highly Active / methods. Drug Resistance, Viral / genetics. HIV Infections / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Virus Replication / drug effects
  • [MeSH-minor] Adult. Drug Interactions. Drug Therapy, Combination. Female. Genotype. Humans. Male. Middle Aged. Prognosis. Prospective Studies. RNA, Viral / analysis. Risk Assessment. Sampling Studies. Survival Analysis. Treatment Outcome. Viral Load


85. Grisariu S, Avni B, Batchelor TT, van den Bent MJ, Bokstein F, Schiff D, Kuittinen O, Chamberlain MC, Roth P, Nemets A, Shalom E, Ben-Yehuda D, Siegal T, International Primary CNS Lymphoma Collaborative Group: Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood; 2010 Jun 17;115(24):5005-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report.
  • Neurolymphomatosis (NL) is a rare clinical entity.
  • The International Primary CNS Lymphoma Collaborative Group retrospectively analyzed 50 patients assembled from 12 centers in 5 countries over a 16-year period.
  • NL was related to non-Hodgkin lymphoma in 90% and to acute leukemia in 10%.
  • The affected neural structures included peripheral nerves (60%), spinal nerve roots (48%), cranial nerves (46%), and plexus (40%) with multiple site involvement in 58%.
  • Imaging studies often suggested the diagnosis with 77% positive magnetic resonance imaging, and 84% (16 of 19) positive computed tomography-positron emission tomography studies.
  • Cerebrospinal fluid cytology was positive in 40%, and nerve biopsy confirmed the diagnosis in 23 of 26 (88%).
  • Treatment in 47 patients included systemic chemotherapy (70%), intra-cerebrospinal fluid chemotherapy (49%), and radiotherapy (34%).
  • Response to treatment was observed in 46%.
  • NL is a challenging diagnosis, but contemporary imaging techniques frequently detect the relevant neural invasion.
  • An aggressive multimodality therapy can prevent neurologic deterioration and is associated with a prolonged survival in a subset of patients.
  • [MeSH-major] Leukemia. Leukemic Infiltration. Lymphoma, Non-Hodgkin. Nervous System Neoplasms
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Cerebrospinal Fluid / cytology. Cooperative Behavior. Female. Humans. International Cooperation. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2006 Nov;80(2):209-10 [16645712.001]
  • [Cites] J Neurooncol. 2006 Sep;79(2):153-7 [16855865.001]
  • [Cites] Intern Med. 2007;46(8):533-4 [17443052.001]
  • [Cites] Intern Med. 2007;46(13):1029-32 [17603246.001]
  • [Cites] Clin Nucl Med. 2007 Aug;32(8):646-8 [17667443.001]
  • [Cites] Clin Nucl Med. 2008 Jan;33(1):30-1 [18097253.001]
  • [Cites] J Neurol. 2008 Jan;255(1):135-7 [17994311.001]
  • [Cites] Hematol Oncol. 2008 Mar;26(1):43-5 [17957824.001]
  • [Cites] Ophthalmology. 2008 May;115(5):e1-6 [18321583.001]
  • [Cites] Intern Med. 2008;47(12):1159-60 [18552480.001]
  • [Cites] J Neurooncol. 2008 Oct;90(1):77-83 [18592137.001]
  • [Cites] Muscle Nerve. 2008 Sep;38(3):1196-200 [18642385.001]
  • [Cites] Spine (Phila Pa 1976). 2008 Oct 1;33(21):E807-11 [18827688.001]
  • [Cites] Neurology. 2009 Jan 6;72(1):98 [19122040.001]
  • [Cites] Arch Dermatol. 2009 Mar;145(3):294-6 [19289760.001]
  • [Cites] J Neurosurg. 2009 Aug;111(2):247-51 [19216652.001]
  • [Cites] Neurology. 2001 Aug 28;57(4):740-2 [11524499.001]
  • [Cites] Neurol Sci. 2000 Aug;21(4):241-5 [11214664.001]
  • [Cites] Muscle Nerve. 2001 Aug;24(8):1068-70 [11439382.001]
  • [Cites] J Peripher Nerv Syst. 2001 Dec;6(4):197-203 [11800041.001]
  • [Cites] Ann Oncol. 2002 May;13(5):802-5 [12075752.001]
  • [Cites] Ann Nucl Med. 2002 Jun;16(4):297-8 [12126101.001]
  • [Cites] Eur J Radiol. 2002 Oct;44(1):16-8 [12350404.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):104-15 [12672282.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):343-8; discussion 348 [14505860.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2403-7 [15160344.001]
  • [Cites] Eur Neurol. 2004;52(1):57-8 [15240984.001]
  • [Cites] J Neurooncol. 2004 Jul;68(3):243-4 [15332327.001]
  • [Cites] Neurology. 1989 Jan;39(1):144-6 [2535894.001]
  • [Cites] Clin Neuropathol. 1990 Sep-Oct;9(5):224-30 [2272142.001]
  • [Cites] Neurology. 2004 Nov 9;63(9):1751 [15534276.001]
  • [Cites] Eur J Haematol. 2005 Jan;74(1):66-9 [15613109.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):163-7 [15925997.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):279-80 [15980982.001]
  • [Cites] J Neurosurg. 2005 Jun;102(6):1166 [16028783.001]
  • [Cites] J Neuroimaging. 2006 Apr;16(2):167-9 [16629741.001]
  • [Cites] Br J Neurosurg. 2006 Apr;20(2):103-5 [16753628.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Aug;33(8):975-6 [16703365.001]
  • [Cites] Neurology. 2006 Aug 22;67(4):722-3 [16924037.001]
  • [Cites] J Peripher Nerv Syst. 2007 Mar;12(1):58-60 [17374105.001]
  • (PMID = 20368468.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R13 CA124293
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3710441
  •  go-up   go-down


86. Labanauskiene J, Gehl J, Didziapetriene J: Evaluation of cytotoxic effect of photodynamic therapy in combination with electroporation in vitro. Bioelectrochemistry; 2007 Jan;70(1):78-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of cytotoxic effect of photodynamic therapy in combination with electroporation in vitro.
  • EP is applied in oncology as a method to enhance delivery of anticancer drugs.
  • For that reason it was essential to combine photodynamic tumor therapy (PDT)--the cancer treatment method based on the use of photosensitizers that localize selectively in malignant tumors and become cytotoxic when exposed to light, and EP, with the aim to enhance the delivery of photosensitizers into the tumor and therefore to increase the efficacy of PDT.
  • A Chinese hamster lung fibroblast cell line (DC-3F) was used.
  • The cells were affected by photosensitizers chlorin e(6) (C e(6)) at the dose of 10 mug/ml and aluminium phthalocyanine tetrasulfonate (AlPcS4) at the dose of 50 microg/ml.
  • [MeSH-minor] Animals. Cell Line. Cell Survival / drug effects. Cricetinae. Indoles / toxicity. Neoplasms / drug therapy. Neoplasms / pathology. Porphyrins / toxicity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698325.001).
  • [ISSN] 1567-5394
  • [Journal-full-title] Bioelectrochemistry (Amsterdam, Netherlands)
  • [ISO-abbreviation] Bioelectrochemistry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Indoles; 0 / Porphyrins; 19660-77-6 / chlorin e6; 2683-84-3 / chlorin; 33308-41-7 / tetrasulfophthalocyanine
  •  go-up   go-down


87. Bartlett NL: The present: optimizing therapy--too much or too little? Hematology Am Soc Hematol Educ Program; 2010;2010:108-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The present: optimizing therapy--too much or too little?
  • Despite the use of less toxic chemotherapy and more limited doses and fields of radiation, the prognosis for patients with all stages of classical Hodgkin lymphoma (HL) has continued to improve over the last 20 years.
  • The challenge today is better identification of prognostic markers that will allow even further reduction of therapy in the most favorable subsets and new approaches for those who have a high risk of failure with current approaches.
  • Most ongoing clinical trials for newly diagnosed HL base therapy decisions on the result of an interim restaging PET/CT, de-escalating for early responders and escalating for patients with a suboptimal response.
  • While awaiting the results of these important trials, the debates rage on regarding the use of consolidative radiotherapy in early stage HL and the use of escalated BEACOPP in advanced stage disease.
  • Unfortunately, we still face the very difficult decision with nearly every patient with HL of "too much," risking long-term consequences, or "too little," risking relapse and the need for additional toxic therapy.
  • At present, we need to make these very difficult initial treatment decisions with inadequate data, but reassured by the excellent outcomes for most patients and encouraged by the new agents available for those who fail first-line therapy.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21239779.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


88. Kamar N, Kany M, Bories P, Ribes D, Izopet J, Durand D, Rostaing L: Reversible posterior leukoencephalopathy syndrome in hepatitis C virus-positive long-term hemodialysis patients. Am J Kidney Dis; 2001 Apr;37(4):E29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic hepatitis C virus (HCV) infection is quite prevalent in long-term hemodialysis (HD) patients.
  • Among 39 HCV-positive long-term HD patients treated with IFN-alpha, we observed three cases of reversible posterior leukoencephalopathy syndrome (PLES).
  • The three patients were receiving IFN-alpha and recombinant erythropoietin therapies simultaneously for de novo anemia.
  • Contrast-enhanced computed tomography scan or magnetic resonance imaging showed low-density areas in the occipital lobes (in three patients), frontal lobes (in one patient), and temporal lobes (in one patient).
  • After withdrawal of IFN-alpha and recombinant erythropoietin therapies, hemodiafiltration, and symptomatic treatment of seizures and hypertension, PLES was reversible within 1 week in one patient, 10 days in one patient, and 2 months in the third patient.
  • Our case reports show the occurrence of reversible PLES in HCV-positive long-term HD patients treated with IFN-alpha.
  • Physicians caring for HCV-positive long-term HD patients treated with IFN-alpha need to be particularly cautious when these patients receive simultaneously recombinant erythropoietin and when IFN-alpha therapy induces a weight loss, which indicates a reduction in dry weight.
  • [MeSH-major] Brain Diseases / etiology. Hepatitis C / drug therapy. Interleukin-1 / therapeutic use. Kidney Diseases / therapy. Renal Dialysis
  • [MeSH-minor] Adult. Anemia / drug therapy. Anemia / epidemiology. Anemia / etiology. Comorbidity. Erythropoietin / adverse effects. Erythropoietin / therapeutic use. Humans. Hypertension / chemically induced. Hypertension / complications. Hypertension / epidemiology. Male. Middle Aged. Recombinant Proteins. Syndrome


89. Hartmann P, Rehwald U, Salzberger B, Franzen C, Sieber M, Wöhrmann A, Diehl V: BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann Oncol; 2003 Oct;14(10):1562-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection.
  • BACKGROUND: Hodgkin's disease (HD) is the most common non-AIDS-defining tumor diagnosed in HIV-infected patients.
  • Antineoplastic treatment is difficult considering the underlying immunodeficiency caused by HIV itself and may increase the risk of opportunistic infections.
  • The purpose of this study was to evaluate the efficacy and safety of the chemotherapeutic regimen bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone (BEACOPP) in HIV-infected patients with HD (HIV-HD).
  • PATIENTS AND METHODS: Twelve patients with HIV-HD were scheduled to receive six cycles of BEACOPP.
  • Five patients received concomitant antiretroviral therapy.
  • Restaging was carried out after three and six cycles of chemotherapy.
  • CD4 counts and HIV RNA levels were regularly monitored during the course of chemotherapy.
  • Two patients died of opportunistic infections within the treatment period, one patient died of a relapse after 26 months.
  • The mean decline of CD4+ lymphocytes was 238 +/- 230/ micro l, with a mean recovery of 272 +/- 329/ micro l 6 months after the last cycle.
  • Plasma levels of HIV RNA increased moderately or even declined under chemotherapy if highly active anti-retroviral therapy was given concomitantly with BEACOPP.
  • CONCLUSIONS: The BEACOPP regimen is feasible and highly effective in HIV-HD patients.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14504059.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 63231-63-0 / RNA; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


90. Hainsworth JD: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial. Semin Oncol; 2002 Feb;29(1 Suppl 2):25-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial.
  • The purpose of this study is to evaluate the activity of rituximab (Rituxan; Genentech, Inc, South San Francisco, CA, and IDEC Pharmaceuticals, San Diego, CA) in the first-line treatment of patients with indolent non-Hodgkin's lymphoma, and to evaluate the role of scheduled maintenance courses of rituximab in prolonging duration of remission.
  • Sixty-two patients with stages II to IV indolent non-Hodgkin's lymphoma (follicular or small lymphocytic) who had received no previous systemic therapy entered this multicenter, community-based trial.
  • Patients who had an objective response or stable disease continued treatment every 6 months with repeat 4-week courses of rituximab for a total of four treatment courses.
  • When evaluated at week 6, 28 of 60 evaluable patients (47%) had objective response and 27 patients (45%) had minor response or stable disease.
  • Response rates were similar in patients with follicular lymphoma and small lymphocytic lymphoma (63% and 66%, respectively).
  • Rituximab is highly effective as a first-line single agent for the treatment of indolent non-Hodgkin's lymphoma.
  • Final information regarding duration of response and time to progression awaits further follow-up.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy. Male. Middle Aged. Rituximab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 by W.B. Saunders Company.
  • (PMID = 11842385.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


91. Ducreux M, Bouche O, Pignon JP, Mousseau M, Raoul JL, Cassan P, Leduc B, Berger C, Dunant A, Fournet J, Bedenne L, FFCD 9601 Collaborative Group: Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial. Oncology; 2006;70(3):222-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.
  • LV5FU2 with high-dose leucovorin (LV), weekly infusional 5-fluorouracil (5FU) (AIO schedule) and raltitrexed have been demonstrated to be active agents in first-line treatment of colorectal cancer.
  • We performed a 4-arm randomised trial to compare (1) a low-dose intravenous bolus of LV (20 mg/m2), followed by an intravenous bolus of 5FU (400 mg/m2), followed by a 22-hour continuous infusion of 5FU (600 mg/m2) on day 1 and day 2/2 weeks (ldLV5FU2 arm), (2) a weekly continuous infusion of high-dose 5FU (2.6 g/m2/week) for 6 weeks followed by a rest week (HD-FU arm) and (3) raltitrexed (Tomudex arm; 3 mg/m2/3 weeks) to standard LV5FU2.
  • The 4 arms were well balanced for sex ratio, age, WHO performance status, the primary tumour site and prior adjuvant chemotherapy.
  • Treatment was stopped due to low accrual.
  • The treatments gave rise to different rates of grade 3-4 neutropenia (3, 4, 11 and 14% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively, p = 0.028), leucopenia and vomiting.
  • At least one episode of grade 3-4 toxicity was observed in 27, 25, 38 and 47% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.016).
  • An objective response was observed in 28, 21, 22 and 10% of the patients in the LV5FU2, ldLV5FU2, HD-FU and Tomudex arms, respectively (p = 0.04).
  • Despite the early closure of the study and the lack of power of the comparison, it seems that ldLV5FU2 could be considered as an active, easier and less expensive option for the treatment of metastatic colorectal cancer compared to classic LV5FU2 or weekly HD-FU.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. France. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Staging. Quality of Life. Quinazolines / administration & dosage. Quinazolines / adverse effects. Thiophenes / administration & dosage. Thiophenes / adverse effects. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16816536.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Quinazolines; 0 / Thiophenes; FCB9EGG971 / raltitrexed; U3P01618RT / Fluorouracil
  •  go-up   go-down


92. Makita K, Ohta K, Mugitani A, Hagihara K, Ohta T, Yamane T, Hino M: Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant; 2004 Mar;33(6):661-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In spite of successful engraftment, the recipient died from a disease relapse.
  • Her leukemia cells were positive for CD13, CD33, and G-CSF receptor without chromosomal abnormality and responded to G-CSF in vitro.
  • During chemotherapy, she died of progressive pneumonia.
  • However, efforts towards an international long-term study, or at least to report every case similar to ours, would be required to be conclusive.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / therapeutic use. Hematopoietic Stem Cell Mobilization / adverse effects. Leukemia, Myeloid, Acute / diagnosis. Tissue Donors
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Multiple Myeloma / therapy. Recombinant Proteins. Tissue and Organ Harvesting


93. Lichtner M, Rossi R, Mengoni F, Vignoli S, Colacchia B, Massetti AP, Kamga I, Hosmalin A, Vullo V, Mastroianni CM: Circulating dendritic cells and interferon-alpha production in patients with tuberculosis: correlation with clinical outcome and treatment response. Clin Exp Immunol; 2006 Feb;143(2):329-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating dendritic cells and interferon-alpha production in patients with tuberculosis: correlation with clinical outcome and treatment response.
  • Little is known about the enumeration and functional evaluation of circulating DC in patients with tuberculosis and their correlation with clinical outcome during the course of anti-tuberculous treatment.
  • We assessed circulating mDC and pDC counts measured by a newly developed single-platform flow cytometric assay based on TruCOUNT, as well as the production of interferon (IFN)-alpha after in vitro stimulation by herpes simplex virus (HSV-1) in 24 patients with active tuberculosis (TB) and 37 healthy donors.
  • In 13 patients these parameters were assessed longitudinally, before and after the specific anti-microbial treatment.
  • Most interestingly, in all nine patients with successful anti-tuberculous therapy there was a significant and marked increase of pDC counts and IFN-alpha production.
  • In contrast, no significant longitudinal variations in DC counts and IFN-alpha production were observed in four patients with lack of response to specific treatment.
  • In conclusion, active TB is associated with a defect in blood DC numbers and IFN-alpha production that is restored after bacterial clearance and clinical improvement, as a result of effective anti-tuberculous treatment.
  • [MeSH-minor] Adolescent. Adult. Aged. Antitubercular Agents / therapeutic use. Cell Count / methods. Female. Flow Cytometry / methods. Humans. Leukocytes, Mononuclear / immunology. Male. Middle Aged. Simplexvirus / immunology. Treatment Outcome. Tuberculosis, Pulmonary / drug therapy. Tuberculosis, Pulmonary / immunology

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Tuberculosis.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2002 Feb 18;195(4):517-28 [11854364.001]
  • [Cites] JAMA. 1999 Aug 18;282(7):677-86 [10517722.001]
  • [Cites] Nat Rev Immunol. 2002 Mar;2(3):151-61 [11913066.001]
  • [Cites] Clin Microbiol Rev. 2002 Apr;15(2):294-309 [11932234.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4796-801 [11971031.001]
  • [Cites] Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii54-8 [12379623.001]
  • [Cites] Curr Mol Med. 2002 Dec;2(8):739-56 [12462394.001]
  • [Cites] Clin Immunol. 2002 Dec;105(3):296-303 [12498811.001]
  • [Cites] J Infect Dis. 2003 Jan 1;187(1):26-37 [12508143.001]
  • [Cites] J Exp Med. 2003 Jan 6;197(1):7-17 [12515809.001]
  • [Cites] J Exp Med. 2003 Jan 6;197(1):121-7 [12515819.001]
  • [Cites] J Immunol. 2003 Feb 1;170(3):1174-82 [12538673.001]
  • [Cites] Infect Immun. 2003 May;71(5):2487-97 [12704120.001]
  • [Cites] Tuberculosis (Edinb). 2003;83(1-3):98-106 [12758197.001]
  • [Cites] Lancet Infect Dis. 2003 Sep;3(9):578-90 [12954564.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2513-21 [12829599.001]
  • [Cites] FEMS Immunol Med Microbiol. 2003 Oct 15;38(3):249-56 [14522460.001]
  • [Cites] J Immunol. 2003 Nov 15;171(10):5571-8 [14607965.001]
  • [Cites] J Immunol Methods. 2004 Jan;284(1-2):73-87 [14736418.001]
  • [Cites] Clin Infect Dis. 2004 Mar 1;38(5):754-6 [14986262.001]
  • [Cites] Curr Opin Microbiol. 2004 Feb;7(1):58-61 [15036141.001]
  • [Cites] J Theor Biol. 2004 Apr 21;227(4):463-86 [15038983.001]
  • [Cites] J Immunol. 2004 Apr 15;172(8):4907-16 [15067070.001]
  • [Cites] Curr Opin Immunol. 2000 Feb;12(1):114-21 [10679408.001]
  • [Cites] Annu Rev Immunol. 2000;18:767-811 [10837075.001]
  • [Cites] Br J Haematol. 2004 Jul;126(1):77-80 [15198735.001]
  • [Cites] Vet Immunol Immunopathol. 2004 Aug;100(3-4):187-95 [15207456.001]
  • [Cites] J Infect Dis. 1983 Dec;148(6):962-6 [6606691.001]
  • [Cites] J Clin Invest. 1986 Jul;78(1):115-23 [3088039.001]
  • [Cites] J Immunol. 2001 Jun 15;166(12):7033-41 [11390447.001]
  • [Cites] Blood. 2001 Jul 1;98(1):140-5 [11418473.001]
  • [Cites] Blood. 2001 Aug 15;98(4):906-12 [11493432.001]
  • [Cites] Cell. 2001 Aug 10;106(3):259-62 [11509173.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2574-6 [11588058.001]
  • [Cites] Blood. 2001 Nov 15;98(10):3016-21 [11698285.001]
  • [Cites] J Immunol. 2002 Feb 1;168(3):1294-301 [11801668.001]
  • [Cites] J Immunol. 1997 Jul 15;159(2):635-43 [9218578.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):245-52 [9521319.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Oct;158(4):1156-62 [9769275.001]
  • [Cites] Int J Tuberc Lung Dis. 1999 Mar;3(3):214-8 [10094322.001]
  • [Cites] AIDS. 1999 May 7;13(7):759-66 [10357374.001]
  • [Cites] Science. 1999 Jun 11;284(5421):1835-7 [10364556.001]
  • [Cites] Immunol Today. 1999 Jul;20(7):307-12 [10379048.001]
  • [Cites] Nat Med. 1999 Aug;5(8):919-23 [10426316.001]
  • [Cites] J Infect Dis. 2004 Dec 1;190(11):1919-26 [15529255.001]
  • [Cites] Lancet Infect Dis. 2004 Dec;4(12):761-76 [15567126.001]
  • [Cites] J Clin Immunol. 2004 Nov;24(6):647-52 [15622449.001]
  • [Cites] J Immunol. 2005 Apr 1;174(7):4203-9 [15778382.001]
  • [Cites] Mol Immunol. 2005 May;42(8):869-77 [15829276.001]
  • [Cites] J Infect Dis. 2005 Jul 15;192(2):303-10 [15962225.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):3268-72 [16116218.001]
  • [Cites] Annu Rev Immunol. 2002;20:581-620 [11861613.001]
  • (PMID = 16412058.001).
  • [ISSN] 0009-9104
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antitubercular Agents; 0 / Interferon-alpha
  • [Other-IDs] NLM/ PMC1809593
  •  go-up   go-down


94. Reece DE: Hematopoietic stem cell transplantation in Hodgkin disease. Curr Opin Oncol; 2002 Mar;14(2):165-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation in Hodgkin disease.
  • Intensive therapy and autologous stem cell transplantation represent the standard of care in most patients whose Hodgkin disease has not been cured with conventional chemotherapy.
  • In particular, recurrent disease and late transplant-related complications limit the effectiveness of this approach.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11880706.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


95. Fermé C, Mounier N, Casasnovas O, Brice P, Divine M, Sonet A, Bouafia F, Bastard-Stamatoullas A, Bordessoule D, Voillat L, Reman O, Blanc M, Gisselbrecht C, Groupe d'Etude des Lymphomes de l'Adulte: Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood; 2006 Jun 15;107(12):4636-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
  • From 1989 to 1996, 533 eligible patients with stage IIIB/IV Hodgkin lymphoma (HL) were randomly assigned to receive 6 cycles of hybrid MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/Adriamycin [doxorubicin], bleomycin, vinblastine; n = 266) or ABVPP (doxorubicin, bleomycin, vinblastine, procarbazine, prednisone; n = 267).
  • Patients in complete remission (CR) or partial response of at least 75% after 6 cycles received 2 cycles of consolidation chemotherapy (CT) (n = 208) or subtotal nodal irradiation (RT) (n = 210).
  • A better survival probability was observed after ABVPP alone: the 10-year overall survival (OS) estimates were 90% for ABVPP x 8, 78% for MOPP/ABV x 8, 82% for MOPP/ABV with RT, and 77% for ABVPP x 6 with RT (P = .03); and the 10-year disease-free survival (DFS) estimates were 70%, 76%, 79%, and 76%, respectively (P = .09).
  • These results showed that RT was not superior to consolidation CT after a doxorubicin-induced CR in patients with advanced HL.
  • Prospective evaluation of late adverse events may improve the management of patients with HL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Evaluation Studies as Topic. Female. Humans. Longitudinal Studies. Lymphatic Irradiation / adverse effects. Male. Mechlorethamine / administration & dosage. Mechlorethamine / adverse effects. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / mortality. Prednisolone / administration & dosage. Prednisolone / adverse effects. Prednisone / administration & dosage. Prednisone / adverse effects. Procarbazine / administration & dosage. Procarbazine / adverse effects. Recurrence. Retrospective Studies. Risk Factors. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16478882.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; BOAP protocol; MOPP protocol; VBA protocol
  •  go-up   go-down


96. Alacacioglu I, Kargi A, Ozcan MA, Piskin O, Solak C, Secil M, Unlu M, Demirkan F, Ozsan GH, Undar B: Fatal disseminated mucormycosis in a patient with mantle cell non-Hodgkin's lymphoma: an autopsy case. Braz J Infect Dis; 2009 Jun;13(3):238-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal disseminated mucormycosis in a patient with mantle cell non-Hodgkin's lymphoma: an autopsy case.
  • A patient with mantle cell non-Hodgkin's lymphoma presented herself with fever, nausea, right upper quadrant pain on the 7th day of R-CHOP chemotherapy.
  • After hospitalization with the suspicion of acute cholecystitis, she received antibiotherapy with G-CSF because of emerging neutropenia at the 10th day of chemotherapy.
  • Abdominal computed tomography revealed small infarcts in the spleen and kidneys.
  • The ecchymotic lesion which developed on her right lateral malleolus, became bullous in the following days and treated as ecthyma gangrenosum.
  • Although the patient was afebrile with a normal neutrophil count on the third day of antibiotherapy, she developed acute renal failure and deteriorated rapidly.
  • [MeSH-major] Lymphoma, Mantle-Cell / pathology. Mucormycosis / pathology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20191205.001).
  • [ISSN] 1678-4391
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


97. Hough RE, Lorigan PC, Poynton C, Newland A, Gupta RK, Foran J, Hancock BW: A phase II protection study of BB-10010 in patients with high grade non-Hodgkin's lymphoma undergoing intensive chemotherapy. Int J Oncol; 2003 Feb;22(2):421-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II protection study of BB-10010 in patients with high grade non-Hodgkin's lymphoma undergoing intensive chemotherapy.
  • The aim of this study was to determine whether administration of BB-10010, a synthetic stem cell inhibitor, would allow more intensive chemotherapy to be administered to patients with newly diagnosed high grade NHL.
  • Thirteen patients were randomised to receive BB-10010 concurrently with dose-intensified BEMOP/CA chemotherapy (7 patients) or chemotherapy alone (6 patients).
  • Although the mean neutrophil count of BB-10010 treated patients was higher following cycles 1, 2 and 3 of chemotherapy compared with those receiving chemotherapy alone, there was no difference in the mean number of cycles tolerated, blood component usage and hospital admissions due to infections.
  • Whilst BB-10010 can be administered safely, it does not improve the ability of patients to tolerate intensive chemotherapy for high grade NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Growth Inhibitors / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Macrophage Inflammatory Proteins / therapeutic use
  • [MeSH-minor] Adult. Aged. Cell Division / drug effects. Chemokine CCL3. Chemokine CCL4. Female. Hematopoietic Stem Cells / drug effects. Humans. Lymphoma, T-Cell / drug therapy. Male. Middle Aged. Neutropenia / chemically induced. Neutropenia / prevention & control. Safety. Thrombocytopenia / chemically induced. Thrombocytopenia / prevention & control. Treatment Failure

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12527943.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Chemokine CCL3; 0 / Chemokine CCL4; 0 / Growth Inhibitors; 0 / Macrophage Inflammatory Proteins
  •  go-up   go-down


98. Lim ST, Levine AM: Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma. CA Cancer J Clin; 2005 Jul-Aug;55(4):229-41; 260-1, 264
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma.
  • Human immunodeficiency virus-infected patients are at an increased risk for developing both Hodgkin and non-Hodgkin lymphoma when compared with the general population.
  • With the remarkable decrease in the incidence of opportunistic infections since the availability of highly active antiretroviral therapy (HAART), acquired immune deficiency syndrome-related lymphoma (ARL) is now the second most common cancer associated with human immunodeficiency virus after Kaposi sarcoma.
  • Over the last few years, advances in our understanding of the molecular biology of this heterogeneous group of lymphomas have led to the adoption of new classification systems.
  • Apart from the contribution of HAART, this improvement in prognosis can also be attributed to new initiatives in treatment of these patients, such as the use of effective infusional regimens, the feasibility of high-dose therapy with peripheral stem cell rescue for relapsed or refractory disease, and better supportive care.
  • Nonetheless, several controversial issues persist, including the optimal timing of HAART with combination chemotherapy, the role of rituximab when incorporated into treatment regimens, and the optimal therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / physiopathology
  • [MeSH-minor] AIDS-Related Opportunistic Infections. Drug Administration Schedule. Humans. Incidence. Peripheral Blood Stem Cell Transplantation. Prevalence. Prognosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020424.001).
  • [ISSN] 0007-9235
  • [Journal-full-title] CA: a cancer journal for clinicians
  • [ISO-abbreviation] CA Cancer J Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


99. Wun T, Kwon DS, Tuscano JM: Radioimmunotherapy: potential as a therapeutic strategy in non-Hodgkin's lymphoma. BioDrugs; 2001;15(3):151-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy: potential as a therapeutic strategy in non-Hodgkin's lymphoma.
  • Lymphomas are the fifth most common malignancy in the United States and are increasing in incidence.
  • Despite being among the most responsive malignancies to radiation and chemotherapy, the majority of patients relapse or have progressive disease.
  • Monoclonal antibodies (MAbs) directed at cell-specific surface antigens have been useful in the diagnosis of lymphomas and, more recently, the therapeutic mouse-human chimeric MAb rituximab has demonstrated effectiveness in B cell lymphomas.
  • Conjugating MAbs to radionuclides is a strategy for improving the efficacy of MAb lymphoma therapy by delivering radiation in close proximity to the tumour (radioimmunotherapy or RIT).
  • In addition, the low dose rate of the delivered radiation may exert a greater antitumour activity than an equivalent dose of conventional external beam radiation.
  • The antigenic targets for MAb therapy have included CD20, CD22, HLA-DR, and B cell idiotype.
  • Clinical studies to date have focused on relapsed and refractory patients with both indolent and aggressive lymphomas, although more recent studies have included previously untreated patients with indolent lymphoma.
  • Radioimmunoconjugate has been delivered as either single or multiple doses.
  • Neutropenia and thrombocytopenia are the dose-limiting toxicities and have prompted the incorporation of autologous stem cell support as a means of achieving dose escalation.
  • The combination of RIT with chemotherapy at conventional or high dose, or with biological agents is a fertile area for investigation.
  • The potential of RIT in the treatment for lymphomas will be defined only by well designed comparative prospective clinical studies.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Radioimmunotherapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Humans. Radiopharmaceuticals / therapeutic use

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11437681.001).
  • [ISSN] 1173-8804
  • [Journal-full-title] BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • [ISO-abbreviation] BioDrugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Radiopharmaceuticals
  • [Number-of-references] 36
  •  go-up   go-down


100. Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, McDermott D, Levine J, Warren D, McCauley M, Wheeler C, Frei E 3rd: A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies. Bone Marrow Transplant; 2001 Sep;28(5):447-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies.
  • Two cycles of high-dose chemotherapy with stem cell support (HDC) may increase the total dose delivered and dose intensity.
  • A brief induction phase and different non-cross-resistant agents for each HDC cycle were used to avoid drug resistance.
  • Patients with stable disease or better after induction received HD CTCb followed by HD melphalan and dose-escalated paclitaxel.
  • At 475 mg/m(2) of paclitaxel by 24-h infusion, dose-limiting transient peripheral sensory neuropathy was encountered.
  • Complete and near complete response after completion of therapy was achieved in 22 (85%) of 26 patients.
  • Whilst selection biases may in part contribute to favorable EFS and OS, a randomized comparison of standard therapy vs double transplant in both metastatic and locally advanced breast cancer is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Hematopoietic Stem Cell Transplantation
  • [MeSH-minor] Adult. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Melphalan / administration & dosage. Melphalan / adverse effects. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Remission Induction / methods. Survival Rate. Treatment Failure. Treatment Outcome